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Introduction: Cardiomyopathies are disorders of the myocardium that can lead to heart failure, 
arrhythmias and sudden death. Heritable forms include dilated, hypertrophic and arrhythmogenic 
cardiomyopathy (DCM, HCM and ACM respectively). As heterogeneous disorders, over 50 genes 
have been implicated in these cardiomyopathies to date. However, the yield of genetic testing 
ranges from less than 40% in idiopathic DCM to over 50% in ACM and HCM, indicating that many 
causal genes are yet to be identified. This is particularly true in African populations, where the 
genetics of cardiomyopathy is underexplored. In a review of the role of next-generation 
sequencing in gene discovery, over 20 new cardiomyopathy genes were found to have been 
identified through exome sequencing of cardiomyopathy patients. The literature review also 
highlighted the need for functional validation of newly identified disease genes. Therefore, the 
aims of this investigation were to utilise exome sequencing to identify disease-causing mutations 
in South African families with heritable cardiomyopathy, and to establish methods of variant 
validation through functional modelling in zebrafish. 
 
Methods: Five probands and 34 relatives were included in this investigation. The probands and 
their relatives were clinically examined and diagnosed with DCM, HCM or ACM at Groote Schuur 
Hospital, Cape Town. Exome sequencing was performed on each of the five probands as well as 
at least one other family member. Variants of interest were identified by filtering the exome 
sequencing data by allele frequency, variant quality, variant consequence, predicted 
deleteriousness, and the potential inheritance patterns as determined by family history analysis. 
Variants occurring in known cardiomyopathy genes were prioritised, but genes outside the cardiac 
panel were considered based on literature mining, expression in the heart, and results of prior 
animal models. Candidate variants were validated by Sanger sequencing and assessed using 
international criteria for pathogenicity. The candidate ACM gene POLG was investigated in 
zebrafish larvae using two genetic manipulations. Firstly, zebrafish polg was disrupted using 
CRISPR/Cas9 in single-cell embryos and, at three days post-fertilisation, the phenotypic effects 
were compared to uninjected control larvae, as well as larvae in which other known 
cardiomyopathy genes were disrupted. Secondly, human POLG cDNA was cloned, and the 
c.2492A>G variant introduced using site-directed mutagenesis; this construct was used to 
generate variant POLG mRNA that was injected into zebrafish embryos. Larvae were 
phenotypically examined at four days post-fertilisation and compared to three control groups 
(unmutated POLG-injected, water-injected, and uninjected embryos). 
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Results: In three families, genotype-phenotype correlations were identified that have not yet been 
reported in South Africa, although this genetic overlap between cardiomyopathies has been 
described elsewhere. Family 1: the mutation MYH7 c.4394C>T (p.S1465L) was identified in three 
siblings with DCM. Although MHY7 is typically associated with HCM, mutations in this region have 
been reported in DCM patients in other populations. Family 2: the mutation GLA c.774_775del 
(p.R259Rfs*5) was found in a mother and her son, both of whom had been diagnosed with HCM. 
The finding of a pathogenic truncating GLA mutation in this family resulted in the genetic re-
diagnosis of those individuals with Fabry disease, an HCM phenocopy. Family 3: in this large 
DCM family consisting of three affected brothers and their nephew, no pathogenic variants were 
identified, but two variants of uncertain significance (VUSs) were found in the genes DSC2 and 
PKP2. Both variants fulfilled some criteria for pathogenicity, but have not been associated with 
DCM in South African patients before. In Families 4 and 5, no mutations in known 
cardiomyopathy-causing genes were identified. Family 4: exome sequencing revealed the variant 
POLG c.2492A>G (p.Y831C) in this ACM family, with a clinical phenotype consisting of arrhythmia 
and left ventricular fibrosis. This was a VUS, but in vivo modelling using CRISPR/Cas9 in 
zebrafish larvae demonstrated that disruption of the gene may impair cardiac development, while 
expression of the c.2492A>G variant in zebrafish larvae resulted in a significant reduction in heart 
rate, ventricle size and cardiac output. These results indicate that POLG variation may underly 
the arrythmia observed in the family, while prior mouse models reported that POLG mutations 
can induce cardiac fibrosis. Family 5: rare, compound heterozygous missense mutations in ITGB5 
were identified as the candidate causative variants in this small family with severe paediatric 
DCM, possibly affecting adhesion of cardiomyocytes to the extracellular membrane. 
 
Conclusion: In total, pathogenic or likely pathogenic mutations were identified in two out of five 
families studied, while three VUSs with moderate or strong pathogenic potential were identified in 
two other families. The potential role of POLG in human cardiomyopathy and arrhythmic 
phenotypes is a finding that should be explored further, as should the putative role of ITGB5 in 
paediatric cardiomyopathy. This study indicates how exome sequencing, combined with in vivo 
functional analysis, can identify variants that are likely to contribute to disease in human patients. 






The work presented in this thesis addresses the genetics of familial cardiomyopathy. Although a 
genetic aetiology is often suspected in cardiomyopathy, with over 50 cardiomyopathy genes 
described to date, many causal genes have not yet been identified. In particular, the genetics of 
cardiomyopathy in Africa remains largely unexplored. 
 
In Chapter 1, heritable cardiomyopathies are introduced, and the rationale and aims of the study 
are presented. Chapter 1 also contains a literature review titled “Next-generation sequencing in 
cardiomyopathy” in which modern sequencing techniques are explained and the new 
cardiomyopathy genes that have been identified using these techniques are discussed. This 
chapter also gives an overview of functional models of cardiomyopathy. 
 
Chapter 2 describes the methods used to investigate the genetics of cardiomyopathy in selected 
patients from a South African cohort. Included is the study design as well as an overview of the 
molecular process from DNA extraction to variant identification and functional validation using 
zebrafish genetic manipulations.  
 
Subsequently, Chapters 3 and 4 present the results of these genetic investigations. In Chapter 
3, families are described in which mutations in known cardiomyopathy genes were found as the 
causes of dilated and hypertrophic cardiomyopathy, giving rise to genotype-phenotype 
correlations which have not been characterised in South African patients to date. Chapter 4 
focusses on potential new cardiomyopathy genes, POLG and ITGB5, identified in two families 
with arrhythmogenic and paediatric cardiomyopathy, respectively, in which the genetic analysis 
did not identify disease-causing mutations in established cardiomyopathy genes.  
 
Chapter 5 explores the zebrafish model as a functional model for validating genetic findings in 
African cardiomyopathy patients, using two different genetic techniques and one of the genes 
from Chapter 4 (POLG) as a candidate.  
 
Chapter 6 summarises the principal findings of the study and considers its practical implications 




Chapter 1 Introduction 
 
1.1 Cardiovascular disease and cardiomyopathy 
 
Cardiovascular disease (CVD) is the leading cause of mortality in the world as evidenced by the 
latest release from the Global Burden of Disease study (Global Burden of Disease Collaborators 
2018, Lopez and Adair 2019). Non-communicable diseases (NCDs) such as those of the 
cardiovascular system are typically chronic and progressive in nature; consequently, they are 
becoming an increasing healthcare burden in low- and middle-income countries (LMICs) due to 
social and economic factors, as well as the high prevalence of communicable diseases in these 
populations (Mayosi et al. 2009). Indeed, according to the World Health Organisation (WHO) up 
to 80% of NCD-related deaths, and 90% of those before the age of 60 years, are reported to occur 
in the developing world (WHO 2018). It has been estimated that over 75% of deaths due to CVD, 
similarly, are in LMICs, where the sufficient detection and treatment of CVD may not be possible 
(WHO 2017). Although many instances of CVD can be predisposed by lifestyle choices, with risk 
factors including physical inactivity, obesity and tobacco use (Perk et al. 2012, Yusuf et al. 2004), 
some forms of CVD such as cardiomyopathy cannot be influenced in this way, and may be 
heritable (Lahrouchi, Behr, and Bezzina 2016, McNally and Puckelwartz 2015). 
 
Cardiomyopathies are disorders of the myocardium, the muscle layer of the heart. When this layer 
is compromised structurally and/or functionally, the heart’s ability to contract and pump blood may 
be affected. An impairment in myocardial function may progress to cardiac dysfunction and heart 
failure; furthermore, patients with cardiomyopathy are at risk of arrhythmias and sudden cardiac 
death (SCD) (Towbin 2014). Although few studies of the incidence of the disease in African 
populations have been conducted (Figure 1.1), it is recognised as a prevalent healthcare burden 
with considerably greater incidences of, for example, dilated cardiomyopathy (DCM) and 
peripartum cardiomyopathy (PPCM), when compared to European and American populations 
(Sliwa, Damasceno, and Mayosi 2005). Out of 1,006 patients presenting with acute heart failure 
in 12 countries in Africa, cardiomyopathy was identified as the cause of heart failure in 26.5% of 






Figure 1.1: Comparison of cardiomyopathy studies over the last decade by region. Shown is the 
number of publications that were found to report on the incidence or prevalence of cardiomyopathy in Africa, 
Asia, Europe and North America, between 2011 and 2021. The numbers were determined by a search of 
PubMed using the Medical Subject Heading terms “incidence” OR “prevalence” AND “cardiomyopathy”, 
followed by manual refinement of the 2,140 results by excluding papers that were unrelated or did not report 
on the frequency of cardiomyopathy. Publications from Australia, Middle East and South America were not 
included in this analysis. 
 
 
There are many types of cardiomyopathy, some of which are part of a systemic disorder while 
others affect only the heart. These conditions can be divided into several morphological 
phenotypes, although the basis for these classifications is not always clear (Elliott et al. 2008). 
Nevertheless, a group of heritable cardiomyopathies is evident; these are caused by mutations in 
genes expressed in myocardial tissues, tend to present in younger individuals and are usually 
more progressive in nature than acquired forms of the disease (McNally, Golbus, and Puckelwartz 
2013). Cardiomyopathies with documented genetic influences include DCM, as well as 
arrhythmogenic, hypertrophic and restrictive cardiomyopathy (ACM, HCM and RCM, respectively) 
and left ventricular noncompaction (LVNC), where up to 50% of cases may have a familial origin 
(Baig et al. 1998, Corrado, Basso, and Thiene 2009). The work in this thesis is primarily 
concerning ACM, DCM and HCM (Figure 1.2); these and other forms of heritable cardiomyopathy 







Figure 1.2: Illustration of DCM, ACM and HCM phenotypes. Also indicated are the myocardial cell 
components that inherited mutations typically affect. HCM is traditionally caused by mutations in genes 
encoding the sarcomere, the contractile unit of the heart. ACM is usually caused by mutations in genes 
encoding the desmosome, which is involved in cell adhesion. DCM is the most heterogeneous form of 
cardiomyopathy and may be caused by mutations in cytoskeletal, sarcomeric, nuclear or transcription co-
activator genes. Adapted from McCauley MD and Wehrens XH. 2009. Dis Model Mech, 2(11-12):565. ACM, 
arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy 
 
 
1.2 Clinical genetic description of the heritable cardiomyopathies 
 
1.2.1 Clinical genetic description of dilated cardiomyopathy 
 
The most common form of cardiomyopathy, DCM, is also the most genetically heterogeneous. 
The exact prevalence of DCM is unclear but may be as high as 1/250 (Hershberger, Hedges, and 
Morales 2013). DCM is also the most common form of cardiomyopathy in Africa where it is 






hypertension (Adebayo et al. 2009, Damasceno et al. 2012, Falase and Ogah 2012, Makubi et 
al. 2014, Sliwa et al. 2008). 
 
According to the European Society of Cardiology (ESC) guidelines, DCM is defined as the 
presence of left ventricular dilation and left ventricular systolic dysfunction. Characterised by 
enlargement of the left ventricle and systolic dysfunction (Elliott et al. 2008), the left ventricular 
dilatation with impaired contraction typical of DCM may result from many insults, both genetic and 
environmental. Familial DCM, if defined as the presence of two or more family members 
manifesting DCM, constitutes around half of all DCM cases. Familial DCM has been attributed to 
mutations in genes encoding various components of the cardiac myocyte. These include 
cytoskeletal, sarcomeric and nuclear envelope proteins, as well as transcription factors and ion 
channels (McNally and Mestroni 2017). Candidate gene screening has identified over 50 genes 
associated with DCM, although few of these have been shown to be common causes of the 
disease. The most frequently mutated gene in DCM is the giant sarcomeric protein-coding gene 
TTN, truncating mutations in which can cause DCM through impaired force generation or 
transmission in the myocardium (McNally and Mestroni 2017). However, TTN and other genes 
only account for approximately 40% of patients with familial DCM (Sturm and Hershberger 2013, 
Sweet, Taylor, and Mestroni 2015), indicating that there are yet more causative genes to be 
discovered. 
 
1.2.2 Clinical genetic description of hypertrophic cardiomyopathy 
 
Defined as cardiac hypertrophy in the absence of loading conditions, HCM is typically 
characterised by hypertrophy most severely involving the interventricular septum, the presence 
of a dynamic left ventricular outflow tract obstruction, and a propensity to SCD due to ventricular 
arrhythmias (Elliott et al. 2006, 2008). The increased stiffness of the ventricular walls can also 
lead to diastolic dysfunction, and some patients enter a “burned out” phase of left ventricular 
dilatation and systolic dysfunction mimicking primary DCM. It is a fairly common disease, with a 
reported prevalence of up to 1/500 (Maron et al. 1995, Zou et al. 2004). The prevalence of the 
disease in Africa is unclear, but between 0.07% and 5.75% of African patients referred for 
echocardiography were diagnosed with HCM (Abegaz 1990, Jingi et al. 2013, Maro, Janabi, and 
Kaushik 2006, Ogah et al. 2008, Raphael et al. 2018). In contrast to DCM, the genetics of HCM 
are less diverse, and up to 50% of HCM cases carry mutations in known cardiomyopathy genes 
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(Gruner et al. 2013, Jensen et al. 2013). The genes that are primarily implicated in HCM are those 
involved in structure and function of the cardiac sarcomere (Marian and Braunwald 2017).  
 
1.2.3 Clinical genetic description of arrhythmogenic cardiomyopathy 
 
ACM is a form of cardiomyopathy in which the ventricular myocardium is progressively infiltrated 
by fibrofatty tissue (Marcus et al. 2010). ACM is an inclusive term that refers to an arrhythmogenic 
disease of the myocardium characterised by ventricular arrhythmias and underlying structural 
abnormalities, not caused by loading conditions such as valvular heart disease, hypertensive 
heart disease, or ischaemia (Towbin et al. 2019). ACM includes, but is not limited to, ARVC and 
may overlap with other cardiomyopathy phenotypes, in particular DCM (Towbin et al. 2019). Many 
have advocated for the use of the term ACM, rather than ARVC, due to the frequent involvement 
of structural and functional abnormalities of the left ventricle (Corrado, Basso, and Judge 2017), 
a recommendation that is adhered to in this thesis. Often exacerbated by exercise, ACM is an 
important cause of arrhythmia and SCD amongst the young and athletic. The prevalence of ACM 
ranges from 1/5000 to 1/2000 in European populations (Pilichou et al. 2016), but the prevalence 
of ACM in Africa is largely unknown (Watkins et al. 2009). It has been reported that between 
0.25% and 0.43% of African patients referred for echocardiography are subsequently diagnosed 
with ACM (James et al. 2012, Raphael et al. 2018).  
 
Most of the implicated genes in ACM encode components of the cardiac desmosome: mutations 
in DSC2, DSG2, DSP, JUP and PKP2 have been associated with impaired electrical and 
mechanical stability of the myocardial tissue, leading to ACM phenotypes (Haugaa et al. 2016, 
Ohno 2016). However, other cardiomyopathy genes such as CTNNA3, DES, RYR2, TGFB3, 
TMEM43 and TTN have been associated with ACM as well (Ohno 2016). The genetic cause of 
the disease has not been identified in up to 50% of cases (Quarta et al. 2011). 
 
1.2.4 Clinical genetic description of left ventricular noncompaction 
 
LVNC is a form of cardiomyopathy in which the left ventricular walls develop prominent 
trabeculations (spongy collections of muscle fibres caused by failure of compaction during cardiac 
development) which can lead to heart failure, arrhythmias and SCD (Captur and Nihoyannopoulos 
2010). The prevalence of the disease is largely unknown and may be due to indistinct diagnostic 
criteria. In a prospective study of 700 patients referred for cardiac magnetic resonance in New 
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York, the LVNC diagnosis rate ranged from 3% to 39% when using different imaging criteria 
(Ivanov et al. 2017). Although the incidence of the disease in Africa is unclear, approximately 7% 
of 780 sub-Saharan Africans referred to a cardiomyopathy clinic were diagnosed with LVNC 
(Peters et al. 2012). 
 
Similar to DCM, LVNC has a heterogeneous genetic basis, with candidate mutations identified in 
cytoskeletal, ion channel, sarcomeric and nuclear membrane genes (Dong et al. 2017). The 
pathogenesis of LVNC and the process of noncompaction are unclear at this stage, and a greater 
understanding of the genetics of the condition may help clarify how it occurs. 
 
1.2.5 Clinical genetic description of restrictive cardiomyopathy 
 
RCM is a disorder characterised by stiffening of the myocardium, while chamber size and systolic 
function remain normal. Impaired filling of the ventricles can lead to arrhythmias and symptoms 
of heart failure (Elliott et al. 2008). It is thought to be the least common form of cardiomyopathy, 
although the exact prevalence is unclear (Muchtar, Blauwet, and Gertz 2017). Limited data on the 
incidence in Africa is available; however, when investigating 6,275 Ethiopian and 3,908 Malawian 
CVD patients, RCM was reported in 0.11% and 0.08% of cases, respectively (Jingi et al. 2013, 
Yadeta et al. 2017). RCM can be caused by mutations in the genes ACTC1, MYH7, TNNT2 and 
TNNI3 (Muchtar, Blauwet, and Gertz 2017). 
 
1.3 The genetics of familial cardiomyopathy  
 
In excess of 50 genes have been associated with cardiomyopathy to date (McNally, Golbus, and 
Puckelwartz 2013). Although the different cardiomyopathies are clinically distinct, there is a 
degree of genetic overlap between them, as mutations within some genes have been reported to 
induce more than one type of cardiomyopathy (Kalyva et al. 2014). The mutations which cause 
cardiomyopathies usually occur within genes involved in cardiac muscle contraction, cytoskeletal 
organisation and cell adhesion (Bao et al. 2013, Zhao et al. 2016); however, the known 
cardiomyopathy-related genes cannot explain all familial cases of the disease, with as many as 
40-60% of patients lacking a conclusive genetic diagnosis (Gruner et al. 2013, Quarta et al. 2011, 
Sturm and Hershberger 2013, Sweet, Taylor, and Mestroni 2015). This is particularly true in 
African populations, where relatively few genetic studies have been conducted to date and the 
genetics of cardiomyopathy is largely unknown (Shaboodien et al. 2020). 
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In previous work conducted in South African populations, a founder mutation within the gene 
PKP2 was described in several Afrikaner families with ACM (Watkins et al. 2009), while similar 
founder mutations have been described in MYBPC3 and MYH7 in South African HCM families 
(Moolman-Smook et al. 1999). Additional disease-causing variants were described in South 
African cardiomyopathy patients in the known cardiomyopathy genes DSP (Fish 2010), MYBPC3 
(Moolman-Smook et al. 1998, 1999, Ntusi et al. 2016), MYH7 (Moolman, Brink, and Corfield 1993, 
1995, Ntusi et al. 2016, Posen et al. 1995), PLN (Fish 2016, Fish et al. 2016), TNNI3 (Mouton et 
al. 2015) and TNNT2 (Moolman et al. 1997). The novel ACM gene CDH2 was first identified in a 
large South African family (Fish 2016, Mayosi et al. 2017). Outside South Africa, limited 
investigations have been performed on African cohorts, in which mutations were reported in 
known cardiomyopathy genes in Egyptian and Tunisian HCM patients (Jaafar et al. 2016, Kassem 
et al. 2013), a large Moroccan family with DCM (Adadi et al. 2018), and a single patient from East 
Africa (Choung et al. 2017). 
 
Familial cases of cardiomyopathy are typically observed to have an autosomal dominant (AD) 
pattern of inheritance, in which a single copy of the mutated gene is sufficient to cause disease 
(Towbin 2014). However, autosomal recessive (AR), X-linked, mitochondrial and syndromic forms 
of cardiomyopathy have also been described (Csányi et al. 2016, Theis et al. 2011, Towbin 2014). 
Identifying the causative mutations in families is of importance, both to family members who may 
be at risk of developing the disease, and also in the elucidation of disease pathways in the heart. 
The study of inherited cardiomyopathy, however, can be complicated by the genetic heterogeneity 
of the disease, as well as factors such as incomplete penetrance, phenotypic diversity and the 
presence of genetic modifiers. 
 
1.4 Review: Next-generation sequencing in cardiomyopathy 
 
Due to the large number of known cardiomyopathy genes, as well as the need to consider 
previously unreported genes for their role in cardiomyopathy, techniques such as candidate gene 
screens are not suitable for uncovering the genetic basis of the disease. While several 
cardiomyopathy-causing variants have been identified using traditional Sanger-based DNA 
sequencing of candidate genes, next-generation sequencing (NGS) is likely the technique that 
will enable the elucidation of additional cardiomyopathy genes (McNally and Puckelwartz 2015). 
NGS refers to massively parallel non-Sanger-based high-throughput DNA sequencing 
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technologies that include, amongst others, exome sequencing, whole genome sequencing and 





Figure 1.3: An overview of the next-generation sequencing techniques, their advantages and 
limitations. NGS, next-generation sequencing 
 
 
NGS has allowed the identification of novel variants and genes for cardiomyopathy, although the 
detection of variants of uncertain clinical significance is a diagnostic challenge. One of the early 
benefits of NGS has, perhaps unexpectedly, accrued from exome and genome sequencing of 
large populations who were not selected for the presence of genetic cardiomyopathies, but 
generally in the context of exome sequencing studies of complex traits. The aggregation of these 
sequences in readily queriable formats in the Exome Aggregation Consortium (ExAC) and later 
Genome Aggregation Database (gnomAD) databases has provided new scientific insights and 
directly impacted clinical variant interpretation in cardiomyopathy (Karczewski et al. 2019, Lek et 
al. 2016). These datasets have clearly shown that the standard of proof for a variant in a new 
gene to be considered causal in the literature has been too low in some instances. An important 
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paper considering some published findings in the light of variant frequencies in the ExAC 
database illustrated that interrogation of a sufficiently large NGS database of disease-free controls 
cast doubt on the pathogenicity of some previously published variants, or in some cases even 
whole genes, due to their high population frequency (Tayal et al. 2017, Walsh et al. 2017). The 
ExAC and/or gnomAD databases have been incorporated into a semi-automated decision-making 
tool for cardiomyopathies and other inherited cardiac conditions (ICCs) that integrates case-
specific data with expertly curated computational annotations, providing decision support for 
clinically detected variants according to the internationally accepted American College of Medical 
Genetics and Genomics (ACMG) guidelines (Whiffin et al. 2018). The impact of large databases 
such as gnomAD on variant interpretation in non-European populations is limited hitherto by the 
small number of non-Europeans that have had exome or genome sequencing; much work 
remains necessary to catalogue the extent of genetic variation in non-European populations in 
equal detail. 
 
Although several putative cardiomyopathy genes have been discovered through NGS 
experiments, the exact impact of these genes on the disease phenotype is yet to determined. 
Understanding these may improve our knowledge of how primary genetic mutations, possibly in 
concert with modifier variants, could alter the phenotypic expression of a disease, leading to a 
better understanding of genotype-phenotype correlations. This review (Section 1.4) investigates 
how NGS technologies have advanced the field of genetic cardiomyopathy by enabling the 
discovery of new disease-causing genes, and considers the likely future roles for panel testing, 
exome sequencing and genome sequencing in cardiomyopathy. 
 
1.4.1 An overview of next-generation sequencing 
 
The sequencing of genetic information (such as genes) is a fundamental first step in the study of 
hereditary diseases. The traditional method of sequencing, referred to as Sanger sequencing, 
involves directly sequencing short fragments of DNA using dye-labelled terminator nucleotides. 
Sanger sequencing is often prohibitively expensive and time consuming in large-scale sequencing 
projects. In the last decade, the emergence of second-generation, or NGS, technologies has 
enabled the rapid and simultaneous sequencing of large tracts of DNA. Although several different 
NGS platforms are available and are reviewed more thoroughly elsewhere (Heather and Chain 
2016, Reuter, Spacek, and Snyder 2015), they all involve the clonal amplification and parallel 
reading of spatially separated target regions of DNA (Morey et al. 2013). Third-generation 
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sequencing technologies such as Oxford Nanopore are being introduced, in which much longer 
fragments of DNA can be sequenced (Magi et al. 2018); these technologies, however, are beyond 
the scope of this review as they are not yet in routine use. 
 
Briefly, NGS involves the fragmentation of DNA (usually by mechanical means) into smaller 
pieces, followed by targeted enrichment to capture specific genomic regions (i.e. target genes or 
the exome; this step is omitted in genome sequencing). Clonal amplification is then necessary to 
increase the signal generated in the sequencing stage (Morey et al. 2013). Sequencing involves 
the parallel, cyclic reading of each target DNA fragment. The most commonly used chemistries 
for sequencing include Illumina sequencing-by-synthesis, Ion Torrent semiconductor sequencing 
and pyrosequencing (Heather and Chain 2016, Reuter, Spacek, and Snyder 2015). With each 
incorporation of a nucleotide, the technologies produce a signal such as light, fluorescence or 
hydrogen ions – the detection of these signals by a camera or a semiconductor, and the 
interpretation of these signals by a computer, allows the nucleotide sequence of each fragment 
to be determined. 
 
The sequencing process produces short sequence reads for each DNA fragment, and the first 
challenge in data processing is to determine the order in which these fragments occur in the 
human genome (Morey et al. 2013). Another important step in bioinformatic processing is the 
removal of low-quality sequence reads or alignments, and the identification of sequence variants. 
These variants are typically defined as any sequence deviation from the human reference 
genome. It is these deviations that are investigated for potential pathogenic mutations in human 
patients, and the quandary that many researchers face is differentiating benign polymorphisms 
from true disease-causing mutations. 
 
1.4.2 Exome sequencing in cardiomyopathy 
 
Exome sequencing, also known as whole exome sequencing, is an NGS technique in which only 
the protein-coding region of the genome (accounting for 1-2% of the genome) is sequenced. By 
focussing on coding regions, variants within introns and possible regulatory regions may be 
omitted; however, approximately 85% of all disease-causing variants have been reported to occur 
in coding regions or splice sites (Choi et al. 2009). It should be noted that as the role of intronic 
and regulatory variants in disease continues to be elucidated, this 2009 statistic may eventually 
prove to be an overestimate. An advantage of exome sequencing is a reduction in data generation 
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(compared to sequencing the entire genome), while enriching the data for variants likely to cause 
disease (Bamshad et al. 2011, Choi et al. 2009). Additionally, the technique is unbiased and 
allows for the investigation of genes that have never been associated with cardiomyopathy before 
(Rabbani, Tekin, and Mahdieh 2014). Limitations of exome sequencing include the heterogeneity 
in capture efficiency across the exome, and the difficulty of assessing genes not previously 
reported to cause cardiomyopathy (Rehm et al. 2013). Despite this, exome sequencing remains 
the method of choice in cardiomyopathy research due to the relative cost-effectiveness of the 
technique and has been used to identify new disease genes for ACM, DCM, HCM, RCM and 
LVNC. These will be discussed below. 
 
1.4.2.1 Exome sequencing in dilated cardiomyopathy 
 
To date, 12 new DCM genes have been identified through exome sequencing, compared to one 
identified through targeted sequencing and one through whole genome sequencing (Table 1.1). 
Despite familial DCM being inherited in a typically dominant pattern, all but one of the 12 new 
genes were described in families with AR disease, and of these, eight were reported in paediatric 
cardiomyopathies. Exome sequencing has so far had limited applicability in novel gene discovery 
in AD or adult-onset DCM. 
 
Mutations in ALPK3 have been identified in five cardiomyopathy families, four of which were 
consanguineous (Table 1.1). Originally reported by Almomani et al. (2016) in two DCM families 
of Dutch and Moroccan ancestry, further genetic screening identified additional ALPK3 mutations 
in a DCM family of Turkish descent as well as a Pakistani HCM family (Almomani et al. 2016, 
Phelan et al. 2016). In total, five patients were discovered to carry homozygous truncating 
mutations in ALPK3; three of these patients died within five days of birth, but two survived to the 
age of 11 years, at which stage their disease showed a severe HCM phenotype (Almomani et al. 
2016). In two of the families, ALPK3 truncating mutations were associated with AR DCM that was 





Table 1.1: New DCM disease genes identified through NGS 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
ADRB2 c.742delG (p.V248Wfs*19) 0 
Digenic (inherited with 
TTN mutation) 














Phelan et al. 
(2016) 





















































0 Heterozygous AD DCM Chinese family Exome sequencing 
Yuan et al. 
(2017) 




Barefield et al. 
(2017) 





et al. (2017) 















Iuso et al. 
(2018) 




Iuso et al. 
(2018) 



































Long et al. 
(2015) 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
AD, autosomal dominant; AR, autosomal recessive; DCM, dilated cardiomyopathy; gnomAD, Genome Aggregation Database; HCM, hypertrophic cardiomyopathy; 
MAF, minor allele frequency; SNP, single nucleotide polymorphism
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PPCS was implicated as a novel DCM gene when rare mutations in the gene were detected using 
exome sequencing in two families of Arabic and European ancestry with early-onset AR DCM 
(Iuso et al. 2018). The age of onset in mutation carriers ranged from two weeks to three years, 
and three of the five affected individuals’ cardiomyopathy was fatal. Yeast cells transformed with 
the mutations were unable to grow efficiently, while patient fibroblasts had reduced levels of 
Coenzyme A which could be rescued by increasing expression of unmutated PPCS. Reducing 
expression of the gene in fruit flies led to a significant impairment of heart function (Iuso et al. 
2018). 
 
In contrast to ALPK3 and PPCS, mutations in the genes ASNA1, FBXO32, GATAD1, KCNJ12, 
NRAP, PLEKHM2, SOD2, SYNM and TAF1A were reported in single DCM families (Almomani et 
al. 2020, Al-Yacoub et al. 2016, Long et al. 2015, Long et al. 2017, Theis et al. 2011, Truszkowska 
et al. 2017, Verhagen et al. 2019, Yuan et al. 2017, Zhang et al. 2019). These genes have not 
been associated with cardiomyopathy since their original report. 
 
XIRP2 was not reported as a primary disease-causing gene, but rather as a potential modifier of 
the disease. The reason for this was that a patient, who had severe, early-onset DCM, carried 
TNNT2 mutations that had previously been associated with a milder form of DCM (Li et al. 2001, 
Long et al. 2015): compound heterozygous truncating mutations in XIRP2 were identified in this 
patient using exome sequencing and were suggested to contribute to the disease phenotype 
(Long et al. 2015). Such genetic modifiers were not considered by other authors but may explain 
phenotypic variability, where the effect of mild mutations can be exacerbated by the presence of 
additional genetic variation. Several rare deleterious XIRP2 gene variants were identified by 
sequencing the gene in Chinese individuals with sudden unexplained nocturnal death or Brugada 
syndrome, indicating that XIRP2 may contribute to arrhythmic phenotypes (Huang et al. 2018). 
An exome sequencing investigation of 142 DCM patients indicated that loss-of-function mutations 
in PDLIM5 may act as modifiers which increase the susceptibility of the heart to the development 
of cardiomyopathy (Verdonschot et al. 2019). 
 
1.4.2.2 Exome sequencing in hypertrophic cardiomyopathy 
 
Exome sequencing has enabled the identification of an additional three genes, FLNC, MTO1 and 




Table 1.2: New HCM disease genes identified through NGS 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
FLNC 
c.4824G>A (p.A1539T) 0 Heterozygous AD HCM Spanish family Exome sequencing 
Valdés-Mas et al. 
(2014) 
Various† Various† Various† 
ACM, DCM, HCM, 
RCM, LVNC 
Various† Various† 
Brodehl et al. 
(2016); Brun et al. 
(2020); Gómez et 
al. (2017); Hall et 
al. (2020) Jaafar et 
al. (2016); Liu et al. 
(2019); Ortiz-
Genga et al. 
(2016); Reinstein et 
al. (2016); 
Rojnueangnit et al. 
(2019); Tucker et 
al. (2017); Valdés-
Mas et al. (2014)  
MTO1 




Compound heterozygous AR HCM Italian family Exome sequencing Ghezzi et al. (2012) 
Various† Various† Various† HCM Various† Various† 
Baruffini et al. 
(2013); Ghezzi et 
al. (2012); O'Byrne 
et al. (2018); Taylor 
et al. (2014)  
SMYD1 
c.675delA (p.K225Nfs*8) 0 Not specified LVNC Chinese patient Exome sequencing Liu et al. (2019) 
c.814T>C (p.F272L) 0.000004 De novo HCM Chinese patient Exome sequencing Fan et al. (2019) 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
† See Appendix A for a full list of reported mutations 
ACM, arrhythmogenic cardiomyopathy; AD, autosomal dominant; AR, autosomal recessive; DCM, dilated cardiomyopathy; gnomAD, Genome Aggregation 





Two siblings with severe infantile recessive HCM, both of whom died within 40 days of birth, were 
found to carry compound heterozygous mutations in MTO1 upon exome sequencing (Ghezzi et 
al. 2012). Mutations in the gene have subsequently been reported in several sporadic and familial 
cases of HCM (Baruffini et al. 2013, Ghezzi et al. 2012, O'Byrne et al. 2018, Taylor et al. 2014). 
Fibroblasts from mutation-carrying patients demonstrated a reduced mitochondrial respiration 
rate which could be rescued by transfection with wildtype MTO1 (Ghezzi et al. 2012). Subsequent 
investigation of Mto1 null mice indicated slight ventricular dilation, arrhythmia, fibrosis and 
degeneration of myofibres in the absence of Mto1 (Becker et al. 2014). 
 
The muscle filamin gene FLNC was first associated with myofibrillar myopathy before mutations 
in the gene were reported by Valdés-Mas et al. (2014) in patients with sporadic and familial forms 
of HCM. It has since emerged as an important cause of cardiomyopathy, with numerous rare 
truncating mutations found in additional HCM patients as well as individuals with ACM, DCM, 
RCM and LVNC (Begay et al. 2016, Brodehl et al. 2016, Brun et al. 2020, Gómez et al. 2017, Hall 
et al. 2020, Jaafar et al. 2016, Janin et al. 2017, Liu et al. 2019, Nozari et al. 2018, Ortiz-Genga 
et al. 2016, Reinstein et al. 2016, Rojnueangnit et al. 2019, Tucker et al. 2017). FLNC is a 
sarcomeric, actin-binding protein that has also been shown to interact with muscular intercalated 
discs and play a role in cellular signalling. Expression of the human FLNC mutations in rat 
cardiomyocytes led to abnormal FLNC protein aggregation and disrupted protein structure 
(Valdés-Mas et al. 2014), while FLNC mutations introduced into human stem cell-derived 
cardiomyocytes reduced their contractility (Tucker et al. 2017). Transcriptomic analysis of left 
ventricular tissue indicated a potential dysregulation of cell adhesion, extracellular matrix 
organisation and cardiovascular development amongst FLNC mutation carriers compared to age-
matched controls (Hall et al. 2019). 
 
Using exome sequencing, a Chinese patient with severe HCM and atrial enlargement was found 
to carry a de novo missense mutation in the gene SMYD1 (Fan et al. 2019). Due to its known role 
in heart development (Nagandla et al. 2016), as well as a prior mouse model demonstrating 
cardiac hypertrophy in the absence of the gene (Franklin et al. 2016), SMYD1 was previously 
considered a candidate gene for HCM. The missense mutation was predicted to affect the nuclear 
localisation signal domain of the protein, and an impaired localisation to the nucleus was 
demonstrated in human cardiomyocytes in cell culture transfected with the mutant gene (Fan et 
al. 2019). This is the first association of the gene with human disease phenotypes (Fan et al. 
2019), although two mutations in the gene have been reported since: a truncating mutation in 
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LVNC (Liu et al. 2019), and an unspecified homozygous mutation in severe paediatric DCM 
(Coyan et al. 2019). 
 
1.4.2.3 Exome sequencing in left ventricular noncompaction 
 
Through exome sequencing, the genes HCN4, NNT and PTEN have been associated with LVNC 
(Table 1.3) (Bainbridge et al. 2015, Milano et al. 2014, Tang et al. 2018). 
 
In a large family with AD LVNC and sinus bradycardia, the only variant that segregated with 
disease was a mutation in HCN4 (Milano et al. 2014). HCN4 encodes a pacemaking ion channel 
protein which is expressed in myocardial cells (primarily in the sino-atrial node), where it is 
suggested to play a role in heart rate modulation (D'Souza et al. 2017). Although mutations in the 
gene had been linked to bradycardia and other arrhythmias before (Baruscotti et al. 2010), this 
was the first time the gene had been associated with structural heart defects. Subsequently, 
mutations in HCN4 have been described in seven additional European families with similar clinical 
phenotypes (sinus bradycardia and LVNC) (Bainbridge et al. 2015, Millat et al. 2015, Schweizer 
et al. 2014). Knockout of HCN4 in mice led to the development of sinus arrhythmia, while 
overexpression of the gene attenuated bradycardia (Kozasa et al. 2018). 
 
NNT was identified as a potential novel gene for familial and sporadic LVNC by exome sequencing 
(Bainbridge et al. 2015). Silencing NNT orthologues in zebrafish caused cardiac oedema, 
bradycardia and significant contractile dysfunction, supporting the role of the gene in LVNC 
pathogenesis (Bainbridge et al. 2015). However, the gene has not been identified as a cause of 
cardiomyopathy in other studies as yet. Exome sequencing was also used to reveal the digenic 
inheritance of GATA4 and PTEN mutations in a single LVNC patient (Tang et al. 2018). While 
GATA4 mutations have been associated with DCM phenotypes (Li et al. 2013), this was the first 
association of PTEN with cardiomyopathy in humans. GATA4 and PTEN have both been 
implicated in signalling pathways in cardiomyocyte differentiation (Ang et al. 2016, Aoyagi and 
Matsui 2011), and Tang et al. (2018) suggest that dysregulation of these pathways may underlie 
the development of LVNC in this patient. 
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Table 1.3: New LVNC disease genes identified through NGS 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
HCN4 







Milano et al. 
(2014) 







Milano et al. 
(2014) 
c.1444G>C (p.G482R) 0 Heterozygous 
LVNC with 
sinus brady 
Consanguineous Dutch family 
Exome 
sequencing 
Milano et al. 
(2014) 
c.1444G>C (p.G482R) 0 Heterozygous LVNC with SND German family 
Targeted 
sequencing 
Schweizer et al. 
(2014) 






Millat et al. (2015) 






Schweizer et al. 
(2014) 
c.2648C>G (p.P883R) 0.007727 Heterozygous 
LVNC with 
sinus brady 
Not specified; single proband 
Candidate gene 
screen 










Bainbridge et al. 
(2015) 
c.829G>T (p.D277Y) 0 Not specified LVNC Not specified; single proband 
Candidate gene 
screen 
Bainbridge et al. 
(2015) 
PTEN c.517C>T (p.R173C) 0 







Tang et al. (2018) 







Saito et al. (2018) 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
brady, bradycardia; gnomAD, Genome Aggregation Database; LVNC, left ventricular noncompaction; MAF, minor allele frequency; RBBB, right bundle branch block; 






1.4.2.4 Exome sequencing in arrhythmogenic cardiomyopathy 
 
Two new ACM genes, CDH2 and TJP1, have been identified through exome sequencing to date 
(Table 1.4). 
 
CDH2 was first associated with ACM when Mayosi et al. (2017) reported a missense mutation in 
the gene in a multi-generation South African family with ACM, as well as an additional de novo 
mutation in a sporadic ACM patient. The latter mutation was found to segregate with disease in a 
European family (Turkowski et al. 2017). Similarly, four TJP1 missense mutations were identified 
using exome sequencing and candidate gene screens in four European ACM families and 
patients (De Bortoli et al. 2018). CDH2 and TJP1 both encode protein components of gap 
junctions and area composita, and are known to interact with each other as well as cardiac actin 
and other known ACM genes (Roberts 2018, Vermij, Abriel, and van Veen 2017), suggesting that 




Table 1.4: New ACM disease genes identified through NGS 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
CDH2 
c.686A>C (p.N229P) 0 Heterozygous AD ACM South African family Exome sequencing Mayosi et al. (2017) 
c.1219G>A (p.D407N) 0 Heterozygous Sporadic ACM South African patient 
Candidate gene 
screen 
Mayosi et al. (2017) 
c.1219G>A (p.D407N) 0 Heterozygous AD ACM European family Exome sequencing 
Turkowski et al. 
(2017) 
TJP1 
c.793C>T (p.R265W) 0.000011 Heterozygous ACM Italian patient Targeted sequencing 
De Bortoli et al. 
(2018) 
c. 986C>T (p.S329L) 0.000059 Heterozygous ACM Dutch/German patient Targeted sequencing 
De Bortoli et al. 
(2018) 
c.1079A>T (p.D360V) 0 Heterozygous ACM Dutch/German patient Targeted sequencing 
De Bortoli et al. 
(2018) 




De Bortoli et al. 
(2018) 
TP63 c.796C>T (p. R266*) 0 Heterozygous ACM 
Not specified; non-
consanguineous family 
Targeted sequencing Poloni et al. (2019) 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 







1.4.2.5 Exome sequencing in restrictive cardiomyopathy 
 
Through exome sequencing, two novel genes for RCM have been identified, KIF20A and 
TMEM87B. 
 
TMEM87B was identified as a potential RCM gene by Yu et al. (2016) when they described a 
paediatric patient presenting with several symptoms suggestive of syndromic disease in addition 
to RCM. This patient was found to have a deletion at chromosome 2q13, and many of the 
phenotypic features observed in the patient were consistent with 2q13 microdeletion syndrome. 
However, the cardiovascular phenotype was more severe than expected, including atrial septal 
defect, biatrial enlargement and RCM. Exome sequencing revealed a potentially deleterious 
mutation, c.1366A>G (p.N456D), in TMEM87B (Yu et al. 2016). The missense variant p.N456D 
was hemizygous in the patient, as TMEM87B maps to the microdeletion region of chromosome 
2. Although little is known about the function of TMEM87B, and mutations in the gene have not 
been identified in cardiomyopathy since, prior experiments silencing expression of the gene in 
zebrafish led to the development of heart defects (Russell et al. 2014). 
 
Compound heterozygous KIF20A variants were reported in two siblings with a severe, congenital, 
right ventricular form of RCM (Louw et al. 2018). KIF20A encodes a member of the kinesin family 
of mitotic proteins, and patient fibroblasts demonstrated reduced microtubule motility during cell 
division. Although it has not been implicated in cardiomyopathy since, KIF20A was demonstrated 
by the authors to play a role in zebrafish heart development and function, with silencing 
expression of the gene leading to thicker ventricular walls and signs of heart failure (Louw et al. 
2018). 
 
1.4.3 Whole genome sequencing in cardiomyopathy 
 
Whole genome sequencing is a technique which has great potential for unbiased screening of all 
genes for their role in cardiomyopathy, as it involves the capture and sequencing of the entire 
genome. This allows for the generation of vast amounts of genetic information, including variation 
in intronic and intergenic regions. This means that promotor region variation or variation in other 
regulatory regions can be assessed; these areas are usually omitted when using exome or 
targeted sequencing approaches. However, the challenges involved in the interpretation of non-
coding variants remain considerable; an even higher proportion of variants of uncertain 
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significance (VUSs) in noncoding regions may confidently be expected than have been 
encountered in panel testing and exome sequencing thus far. Because of the elimination of a 
capture step in whole genome sequencing, coverage of exons tends to be more uniform; in other 
disease settings, genome sequencing has proven more sensitive than exome sequencing to 
detect rare germline exonic SNVs for this reason (Meynert et al. 2014, Turner et al. 2016). It is 
important to note that neither exome nor genome sequencing entirely cover their genomic targets; 
the extent and reasons for reduced coverage have been explored in the literature (Sanghvi et al. 
2018). 
 
A comprehensive search of the PubMed database for all eligible studies encompassing certain 
criteria (heritable or sporadic non-syndromic forms of cardiomyopathy were investigated, NGS 
was used to study the patients, and a clear genetic cause of disease was reported) produced very 
few whole genome sequencing cardiomyopathy studies, published between 2011 and March 
2021, presumably due to the current challenges with data storage, data analysis and sequence 
coverage. Although many variants may occur in introns and between genes, analysing their 
potential pathogenic effects remains difficult. A singe novel cardiomyopathy gene, MYBPHL, was 
identified through genome sequencing when a coding, truncating variant in the gene was 
discovered in a family with AD DCM and conduction abnormalities (Barefield et al. 2017). 
Although the function of the gene is unknown, and mutations in MYBPHL have not been reported 
in other cardiomyopathy cases to date, the authors demonstrated its high expression in human 
and mouse atria and interactions with the cardiac myofilament (Barefield et al. 2017). Deletion of 
the gene in mice led to a DCM phenotype and susceptibility to arrhythmias. In other genome 
sequencing studies, only mutations in known cardiomyopathy genes were reported (Guo et al. 
2017, Esslinger et al. 2017). 
 
1.4.4 Targeted sequencing in cardiomyopathy 
 
The application of NGS to the sequencing of a finite number of genes is known as targeted 
sequencing. Gene panels typically include the major disease-associated genes and, although 
predesigned panels are commercially available, custom panels are often used. In some countries 
such as the UK, a process of national standardisation of genetic testing is underway to eliminate 
variations within healthcare systems regarding how genetic testing is offered to patients, and how 
it may form part of patient management. Targeted panel sequencing is now used for diagnostic 
purposes in these countries, as established cardiomyopathy genes are screened for reported and 
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new disease-causing mutations. Diagnostic genetic panel testing for ICCs is not currently 
available in South Africa, or any other African country to our knowledge. 
 
The advantage of NGS panels is that high sequence coverage can be achieved. Panels are also 
easily customisable and can vary considerably, ranging from few genes to hundreds of genes 
(Glotov et al. 2015, Waldmüller et al. 2015). A single ICC panel involving many genes can be run 
straightforwardly on a DNA sample, and only the genes consistent with the patient’s clinical 
presentation interrogated, facilitating standardisation. However, targeted sequencing is often 
limited to the coding regions and exon/intron boundaries, so intronic and promoter region variants 
may not be detected. Another disadvantage is that, by focussing on a gene panel, targeted 
sequencing is largely unsuitable for novel gene discovery unless candidate genes are 
incorporated into the design of the panel. Panel size is also a matter of some contention, and 
there is no clear consensus on whether larger panels incorporating disease genes from various 
heritable cardiomyopathies are more useful than cardiomyopathy-specific gene panels. Several 
reports have indicated that increasing the number of genes on a panel does not correlate with an 
increase in genetic diagnoses, but merely increases the number of VUSs and unclear genetic 
findings (Alfares et al. 2015, Burns et al. 2017, Ouellette et al. 2018, Pugh et al. 2014, Thomson 
et al. 2019, Walsh et al. 2017). 
 
Although NGS panels are usually limited to known cardiomyopathy genes, targeted sequencing 
has been used to identify novel genotype-phenotype relationships, illustrating the genetic overlap 
which is characteristic of the cardiomyopathies. Gene panels have been used to describe novel 
associations of ACM, HCM and channelopathy gene mutations in DCM (Haas et al. 2015, 
Mahdieh et al. 2018), ACM gene mutations in LVNC and DCM (Klauke et al. 2017, Ramond et al. 
2017), HCM gene mutations in LVNC and RCM (Brodehl et al. 2017, Schaefer et al. 2014, Wu et 
al. 2015) and channelopathy or muscular dystrophy genes (AKAP9, DMD and OBSCN) with 
cardiomyopathy (Forleo et al. 2017). In these studies, the variants were rare or absent in the 
ExAC and/or gnomAD populations, and many of them met established criteria for pathogenicity 
(Richards et al. 2015), supporting a causative role of these genes in other forms of 
cardiomyopathy. 
 
Although exome or genome sequencing may be more suitable for research and discovery, NGS 
panels can be designed to include candidate genes and this way, suspected cardiomyopathy 
genes can be sequenced. This approach was used by Waldmüller et al. (2015) to identify a 
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truncating mutation in ADRB2 as a candidate cause of DCM (Table 1.1). Although biologically a 
plausible candidate gene, in the absence of further evidence or additional family members, this 
variant was classed as a VUS. Similarly, a truncating mutation in TP63 was reported in an ACM 
patient (Poloni et al. 2019) (Table 1.4) and a TRPM4 mutation was identified in a case of LVNC 
and cardiac conduction disease, although it is probable that other genetic factors may be 
contributing to the LVNC phenotype in this case (Saito et al. 2018) (Table 1.3). 
 
In a Web-based discrete choice experiment, Buchanan et al. (2019) sought to identify the key 
attributes of panel testing, exome and genome sequencing that drove test selection in UK 
practitioners who order genetic tests for ICCs. Their results indicated that as of early 2019, 
practitioners had a strong preference for panel tests over exome or genome sequencing. The key 
drivers of choice, perhaps unsurprisingly, were identification of more causative variants, a yield 
of fewer VUSs, and lower cost. Respondents were willing to pay an additional 117 GBP for each 
1% of additional diagnostic yield from a genetic test; we interpret this figure as high and somewhat 
at odds with the strong preference expressed for panel testing (Buchanan et al. 2019). 
 
1.4.5 Challenges and opportunities in genomic research of cardiomyopathy 
 
NGS has enabled global progress in the field of heritable cardiomyopathy chiefly through the 
availability of panel testing that can screen known cardiomyopathy genes with a high degree of 
accuracy. The data presented here also indicates that NGS has proved of some value through 
the elucidation of new disease genes, though this has primarily been in paediatric or syndrome-
associated cardiomyopathy. Moreover, NGS has not yet found traction in LMICs such as those in 
Africa, where there are large gaps in knowledge of the genetics of cardiomyopathy. Aside from 
two genes identified in Chinese patients, and a single gene reported in South African patients, 







Figure 1.4: Global distribution of new disease genes identified by next-generation sequencing. Countries of origin were identified by the first 
author’s affiliation. Where more than one affiliation was present or the first authorship was joint (gene symbols marked by an asterisk), all countries 
were included. Countries shaded in light orange indicate one cardiomyopathy gene was identified by a primary author from that country, countries 
shaded in dark orange indicate two to four such authors were identified. Countries shaded in red indicate more than five new cardiomyopathy genes 
were identified by a primary author from that country. Created with MapChart.net © 
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The investigation of variants at the genome- or exome-level should become mainstream when 
NGS is used for non-diagnostic purposes (research and discovery). As the cost of sequencing 
decreases and NGS becomes more accessible, it will be applied more routinely in the study and 
genetic diagnosis of cardiomyopathy. Although progress has been made, there are still challenges 
in NGS data analysis that must be overcome. The continued use of exome and genome 
sequencing in research will require an improvement in our ability to analyse genes outside of the 
known cardiomyopathy genes, and better analysis of noncoding and intronic variation for their 
contribution to heritable disease. It has been suggested, for example, that deep-intronic variation 
in known cardiomyopathy genes may contribute to the development of HCM by affecting 
transcription and splicing factor binding sites (Mendes de Almeida et al. 2017). An intronic variant 
in MYBPC3 has recently been shown to account for as much as 1% of HCM (Harper et al. 2020). 
Furthermore, even when the disease-causing variant is identified in a family, substantial 
phenotypic variability is often observed and unexplained (Hershberger and Siegfried 2011). This 
may be due to genetic modifiers, but understanding this variability may lie within transcriptomics 
and epigenomics (Alimadadi et al. 2020, Haywood et al. 2020, Ito et al. 2017), other NGS 
technologies that are rarely used in the study of cardiomyopathy. 
 
Currently, exome and targeted sequencing appear to be the methods of choice when investigating 
the heritable cardiomyopathies, possibly due to the costs of whole genome sequencing combined 
with challenges in data analysis. Targeted sequencing has limited scope for novel gene discovery, 
and although several new genotype-phenotype correlations have been described, the applicability 
of panel sequencing is most beneficial in a diagnostic setting. The identification of known disease-
causing mutations through cardiomyopathy gene panels requires little interpretation; caution is 
advisable, however, when analysing VUSs that arise from panel sequencing. The majority of 
reported novel cardiomyopathy genes were identified through exome sequencing. As a great 
proportion (> 85%) of pathogenic mutations occurs in the coding regions of the genome (Choi et 
al. 2009), the suitability of exome sequencing for novel gene discovery is as expected. 
 
There is little consensus as to what qualifies a genetic variant as disease-causing, particularly in 
the cardiomyopathies, and it is likely that there are notable interlaboratory differences in variant 
interpretation, especially regarding VUSs. However, the use of sequencing data in medical 
genetics is contingent on the ability to distinguish pathogenic from benign variants. ACMG 
guidelines place the greatest pathogenic potential, regardless of disease type, upon truncating 
nonsense, frameshift and splice region mutations, particularly when these variants occur in genes 
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where loss-of-function mutations are known to cause disease (Richards et al. 2015). When these 
mutations occur early in the protein-coding sequence, or disrupt functionally important regions, 
the disease-causing potential is evident. Many cardiomyopathy-causing mutations are missense, 
and the challenge often arises in the distinction between low-impact VUSs and pathogenic 
missense variants. There are numerous in silico prediction algorithms which can be used to 
quantify the potential impact of a variant based on factors such as the protein sequence and the 
evolutionary conservation of the affected residue (Adzhubei et al. 2010, Kumar, Henikoff, and Ng 
2009, Schwarz et al. 2014). However, these tools may over-call variants as pathogenic and are 
not reliable when assessing variants of milder impact (Choi et al. 2012, Richards et al. 2015). 
Indeed, there are variants that would be classified as benign using bioinformatic prediction tools 
that have been shown, using in vitro functional work, to have a pathogenic effect (Hedley et al. 
2013). Moreover, these computational tools were not designed to predict pathogenicity in a 
diagnostic setting, and some may be biased due to the training and validation datasets used 
(Grimm et al. 2015). The outputs of these prediction tools should therefore be interpreted 
cautiously and are not definitive proof of pathogenicity. These difficulties in data analysis are only 
magnified when investigating variants at the genome- or exome-level. Due to the vast amount of 
data these techniques generate, exome and genome sequencing may produce many variants 
which are clinically ambiguous based on existing knowledge. There are currently no guidelines 
for reporting of VUSs, and some laboratories may choose to report VUSs in candidate genes to 
their patients (Vears, Sénécal, and Borry 2017). However, it is advisable to retain data about 
VUSs until knowledge improves, with the aim to definitively classify these variants as pathogenic 
or benign (Matthijs et al. 2016). 
 
A total of 26 potential new cardiomyopathy genes were reported in the literature between 2011 
and 2019, 23 of which were from exome sequencing experiments. Although most of the genes 
were identified in DCM patients, arguably the greatest impact has come from the genes reported 
in ACM, LVNC and HCM. FLNC, HCN4 and MTO1 have been demonstrated as mutation hotspots 
for numerous forms of heritable cardiomyopathy (Baruffini et al. 2013, Janin et al. 2017, Millat et 
al. 2015, Nozari et al. 2018, O'Byrne et al. 2018, Ortiz-Genga et al. 2016, Schweizer et al. 2014, 
Taylor et al. 2014, Tucker et al. 2017). FLNC and HCN4 now often appear on cardiomyopathy 
panels for diagnostic screening (Dewar et al. 2017, Oliveira et al. 2015), demonstrating the 
potential power of exome studies and the ultimate goal in cardiomyopathy research. The 
identification of CDH2 and TJP1 as novel ACM genes suggests the pathogenic site of adhesion-
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related ACMs to extend beyond the cardiac desmosome, encompassing the entirety of the 
intercalated disc (De Bortoli et al. 2018, Mayosi et al. 2017, Turkowski et al. 2017). 
 
In contrast, 15 novel DCM genes were identified in family studies but only mutations in ALPK3 
and PPCS have been reported in additional cardiomyopathy families. The variants in ADRB2, 
ASNA1, FBXO32, GATAD1, KCNJ12, MYBPHL, NRAP, PLEKHM2, SOD2, SYNM, TAF1A and 
XIRP2 may therefore qualify as VUSs even though most of them are considered rare enough to 
cause disease (Table 1.1). The absence of additional families does not necessarily contradict a 
variant’s disease-causing potential, and clarity may be provided through appropriate functional 
assays. For example, significant impairments in autophagy were reported in patient tissues 
carrying FBXO32 and PLEKHM2 mutations, suggesting a mechanism whereby these mutations 
may cause disease (Al-Yacoub et al. 2016, Muhammad et al. 2015). Knockouts of taf1a and 
asna1 in zebrafish were able to recapitulate the DCM phenotype, causing heart failure and death 
within 6 to 11 days (Long et al. 2017, Verhagen et al. 2019), whereas similar experiments with 
gatad1 in zebrafish were inconclusive with one out of six mutant fish exhibiting an enlarged heart 
(Yang et al. 2016). 
 
Identifying the genetic cause of disease using NGS is challenging due to the numerous variables 
that are involved and inherent limitations in the techniques. It is unclear how many NGS studies 
have failed to characterise disease-causing mutations in human patients to date. Nevertheless, 
the validation of findings is an important aspect of NGS study design. As demonstrated above, 
approaches to this include the identification of other patients with similar phenotypes who also 
carry mutations in the putative cardiomyopathy gene, or the investigation of these genes using in 
vitro or in vivo models to determine their role in pathogenesis. 
 
1.5 Modelling cardiomyopathy in cell culture 
 
One approach to the functional investigation of candidate genes is to characterise the effects of 
gene loss or mutation in human cells in culture. Induced pluripotent stem cells (iPSCs) are stem 
cells that can be derived from adult fibroblasts through expression of just four transcription factors 
(Takahashi and Yamanaka 2006). They may therefore be used to model human disease by 




When investigating heritable cardiomyopathy, it is noteworthy that iPSCs can be differentiated 
into cardiomyocytes (Lian et al. 2013). One strategy is to compare iPSC lines derived from control 
individuals and patients carrying known disease-causing mutations; however, inter-individual 
genetic variation may influence phenotypic expression or otherwise reduce confidence that 
observed phenotypic differences are due to the mutation alone (Reinhardt et al. 2013, Soldner 
and Jaenisch 2012). An alternative approach which overcomes these limitations is the generation 
of isogenic iPSC lines which are propagated and subsequently genetically engineered to carry 
the mutations of interest, for example using the clustered regularly-interspaced short palindromic 
repeats (CRISPR)/Cas9 system (Soldner and Jaenisch 2012). This technique will be useful in 
determining whether a candidate gene is necessary for normal cardiomyocyte function and will 
indicate the potential of mutations within the gene to cause cardiomyocyte dysfunction. However, 
as the heart is a complex organ comprised of multiple cell types including cardiomyocytes, the 
effect of specific mutations on the structure and functioning of the entire heart cannot be 
elucidated through cell culture alone. In order to investigate the organ-level effects of genetic 
mutations, in vivo animal models may be preferable. 
 
1.6 Animal models of cardiomyopathy 
 
Disease models are an important tool in research, allowing novel insights into the mechanisms of 
human disease. In the cardiomyopathies, animal models may be used to investigate the role of 
novel genes in heart development or function and consider whether proposed pathogenic 
mutations are likely to cause disease in humans. Although mouse models are widely used to 
study various human conditions, they are of limited use in cardiomyopathy research due to 
significant physiological and genetic differences between human and murine hearts. For instance, 
the mouse heart beats at a rate approximately ten times faster than that of human hearts, and 
has a higher ventricular expression of the Myh6 gene, whereas in humans the slower MYH7 
isoform is predominantly expressed in the ventricles (Duncker et al. 2015). Furthermore, 
homozygous mutations of known cardiomyopathy genes are often embryonic lethal in mice, while 
mice heterozygous for these mutations are phenotypically normal (Gramlich et al. 2009), although 
heterozygosity is the typical disease state in human cardiomyopathy. The mouse heart may 
therefore not be considered sufficiently representative of the human myocardium in the modelling 
of cardiomyopathies (Duncker et al. 2015). Given these limitations of the mouse model, alternative 




The zebrafish has been used as a successful model of numerous human disorders, varying from 
tuberculosis and neurological conditions (Tobin et al. 2010, Zdebik et al. 2013), to CVD. Although 
anatomically very different from humans, zebrafish have proved successful models of human 
disease because of the similarities between the species in terms of the genes expressed during 
development, and the regulatory networks which drive cell fate. The zebrafish genome project, 
which was initiated in 2001, demonstrated that approximately 70% of human genes have a 
zebrafish orthologue, and 82% of known disease-causing genes (according to the Online 
Mendelian Inheritance in Man database) have at least one zebrafish orthologue (Howe et al. 
2013).  
 
Characteristics of zebrafish which make it a favourable organism in the modelling of disease 
include their high prolificacy, rapid ex utero development and the fact that they can be maintained 
in large numbers at relatively low cost (Lieschke and Currie 2007). Zebrafish larvae are 
transparent for up to three weeks post fertilisation, which makes the high-resolution visualisation 
of inner organs possible, for example through the use of fluorescent markers or proteins (Pan et 
al. 2013). When modelling CVD, zebrafish may be preferred because the circulatory system is 
not required for oxygenation for up to seven days after fertilisation – during this time, their larvae 
are able to oxygenate through diffusion alone (Sehnert et al. 2002). Therefore, genetic defects 
which cause severe cardiac dysfunction can be analysed in vivo. While superficially different from 
mammalian hearts, the zebrafish heart displays various similarities at the developmental and 
cellular levels, and has been used to model congenital heart defects, arrhythmias and 
cardiomyopathies (Asnani and Peterson 2014). 
 
Zebrafish are particularly amenable to genetic manipulation, and have been used to identify novel 
genes involved in cardiac development by forward genetic screens (Bendig et al. 2006, Knöll et 
al. 2007). In relation to cardiomyopathies, a potential use of the zebrafish model is to investigate 
the role of genetic mutations identified in familial cases of the disease, as described for asna1, 
taf1a and gatad1 above (Section 1.4.5) (Long et al. 2017, Verhagen et al. 2019, Yang et al. 2016). 
Mechanisms of genetic manipulation which can be employed in the zebrafish include gene 
silencing through antisense morpholino oligonucleotide injection, gene overexpression by the 
injection of mRNAs, and genome editing using transcription activator-like effector nucleases 
(TALENs) or CRISPR/Cas9 (Bedell and Ekker 2015, Bill et al. 2009, Chang et al. 2013). With 
these techniques, the function of different genes in zebrafish cardiac development can be 
analysed. Zebrafish models of cardiomyopathy have been successfully used to validate the 
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pathogenicity of variants by demonstrating their ability to impair cardiac function (Bainbridge et 
al. 2015, Dhandapany et al. 2014, Norton et al. 2011, Shehata et al. 2015). It is this potential of 
the zebrafish model to recapitulate human disease phenotypes, within a short timeframe, that 
makes it an attractive in vivo system, particularly where possible pathogenic genetic variants are 
identified but which have yet to be functionally validated. Given the advantages of modelling CVD 
in zebrafish, pursuing such a model may be beneficial to understanding the genetics of 





Given that approximately 50% of all cardiomyopathy patients lack a genetic determinant of 
disease, the genes which have been identified to date cannot account for the total genetic 
contribution to heritable cardiomyopathy. The yield of genetic testing in idiopathic DCM is 
considerably lower than other forms of cardiomyopathy, although the role of genetics is likely 
underestimated in these cases due to the influences of low mutation penetrance, de novo 
mutations, small family sizes or mutations in presently uncharacterised disease genes (Mestroni 
et al. 2014, McNally and Mestroni 2017). It is therefore expected that additional genetic causes 
of cardiomyopathy exist, especially in DCM, a disease characterised by much genetic 
heterogeneity and a high proportion of idiopathic cases.  
 
As discussed previously, exome sequencing is a technique that may allow the detection of these 
causes of cardiomyopathy, by focussing genetic analysis on variants that are likely to have a 
functional effect. Applying this technique in a family setting should reduce genetic ambiguity and 
increase the chances of mutation detection. The genetics of cardiomyopathy in Africa is largely 
unknown, and it is probable that further analysis of this genetically unique population may identify 
more genes of interest (Shaboodien et al. 2020). Research previously conducted in a South 
African family identified a novel ACM-causing gene using exome sequencing (Mayosi et al. 2017), 
and it is anticipated that similar analyses in the local population may help close the gap in our 







1.8 Aim and objectives 
 
The aim of this study is to identify the disease-causing variants in South African cases of familial 
cardiomyopathy. This will be addressed through the following objectives: 
 
1. Identify possible disease-causing variants in families affected by cardiomyopathy using 
exome sequencing. 
2. Investigate candidate genes for their role in heart development or function in vivo using 
CRISPR/Cas9 knockout in zebrafish. 
3. Investigate specific mutations for their potential to cause cardiomyopathy phenotypes in 




Chapter 2 Methods 
 
2.1 Study design 
 
The African Cardiomyopathy and Myocarditis Registry Programme (IMHOTEP) is a broad 
investigation into the aetiology and genetics of cardiomyopathy in Africa, for which ethical 
approval was obtained from the Human Research Ethics Committee (HREC), UCT (HREC 
reference no. 766/2014). The first primary objective of IMHOTEP is to define the clinical, 
electrocardiographic, autonomic, imaging, histological and genetic characteristics of 
cardiomyopathy and myocarditis in children and adults in Africa (Kraus 2019). HREC approval 
was also obtained for this sub-study of IMHOTEP (HREC reference no. 111/2019) (Appendix B). 
In this study, patients from IMHOTEP with clear familial forms of cardiomyopathy, and their 
relatives, were investigated using exome sequencing in an attempt to identify the genetic causes 
of their disease, in accordance with the first objective of IMHOTEP. 
 
2.1.1 Study participants 
 
In total, five probands and 34 relatives who were recruited between 1997 and 2017 were included 
in this investigation. Written informed consent was obtained from each participant, as well as a 
blood sample for molecular analysis (Appendix C). Assent was obtained when recruiting children 
over the age of 8 years, in addition to consent from their parents or legal guardians, which was 
obtained from minors of all age. Eligible patients were identified during routine screening at the 
cardiac clinics at Groote Schuur Hospital (GSH) and Red Cross War Memorial Children’s Hospital 
(RCH), Cape Town, South Africa. Eligibility was determined by a primary diagnosis of 
cardiomyopathy (Section 2.1.2) and a positive family history for the disease (at least one 
additional family member with a similar diagnosis). Index patients were excluded if they were 
diagnosed with secondary causes of cardiomyopathy, systemic arterial hypertension (> 160/100 
mmHg), coronary artery disease, pericardial diseases, congenital heart disease, pulmonary 
disease or valvular heart disease. 
 
2.1.2 Diagnosis and screening 
 
All patients and their relatives were screened for cardiomyopathy at the cardiac clinics at GSH or 
RCH. Each case was reviewed by a diagnostic panel of experts at GSH, consisting of specialists 
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in cardiomyopathy, electrophysiology, cardiac imaging and histopathology, to determine each 
patient’s diagnosis as following ESC guidelines (Elliott et al. 2008). Study participants were 
assessed with chest X-ray, electrocardiography (ECG), echocardiography and basic blood 
investigations of haemoglobin levels, white blood cell count, as well as renal and liver function 
(Kraus 2019). When clinically indicated, patients and their family members were also screened 
using cardiac magnetic resonance imaging (CMR) and/or Holter monitoring. 
 
DCM and HCM were diagnosed according to ESC guidelines, contingent on the absence of 
hypertension or valve disease that may cause the observed abnormalities (Elliott et al. 2008). The 
ESC defines ACM histologically as progressive replacement of right ventricular myocardium with 
adipose and fibrous tissue, and the presence of right ventricular dysfunction with or without left 
ventricular involvement (Elliott et al. 2008). The diagnosis of ACM was made on the basis of 
International Task Force criteria (Table 2.1), in which ACM diagnoses are classified using major 
and minor criteria as definite (two major criteria, one major and two minor criteria, or four minor 
criteria), borderline (one major and one minor criteria, or three minor criteria) or possible (one 
major or two minor criteria) (Marcus et al. 2010). 
 
Demographic and clinical information was collected during patient enrolment into the IMHOTEP 
parent study. Demographic data that was used in this investigation was patient sex, self-reported 
ethnicity and family history. Detailed family histories were obtained by a genetic counsellor during 
the recruitment process and were used in this investigation in the determination of potential 
inheritance patterns of disease. Clinical information was used to correlate identified genetic 
mutations with disease status. This clinical data included disease status (classified as affected, 













Table 2.1: International Task Force criteria for ACM 
Major criteria Minor criteria 
1. Global and/or regional dysfunction and structural alterations 
By 2D echocardiogram 
Regional RV akinesia, dyskinesia or aneurysm and one of the 
following (end diastole): 
• Parasternal long axis view ≥ 32 mm or ≥ 19 mm/m2 
• Parasternal short axis view ≥ 36 mm or ≥ 21 mm/m2 
• Fractional area change ≤ 33% 
 
By MRI 
Regional RV akinesia or dyskinesia or dyssynchronous RV 
contraction and one of the following: 
• RV end diastolic volume ≥ 110 ml/m2 male or ≥ 100 ml/m2 
female 
• RV ejection fraction ≤ 40% 
 
By RV angiography 
Regional RV akinesia, dyskinesia or aneurysm 
 
By 2D echocardiogram 
Regional RV akinesia or dyskinesia and one of the following 
(end diastole): 
• Parasternal long axis view 29-32 mm or 16-19 mm/m2 
• Parasternal short axis view 32-36 mm or 18-21 mm/m2 
• Fractional area change 33-40% 
 
By MRI 
Regional RV akinesia or dyskinesia or dyssynchronous RV 
contraction and one of the following: 
• RV end diastolic volume 100-110 ml/m2 male or 90-100 
ml/m2 female 




2. Tissue characterisation of wall 
Residual myocytes < 60% by morphometric analysis, (or < 50% 
if estimated), with fibrous replacement of the RV free wall 
myocardium in at least one sample, with or without fatty 
replacement of tissue on endomyocardial biopsy 
Residual myocytes 60-75% by morphometric analysis, (or 50-
65% if estimated), with fibrous replacement of the RV free wall 
myocardium in at least one sample, with or without fatty 
replacement of tissue on endomyocardial biopsy 
3. Repolarisation abnormalities 
Inverted T waves in right precordial leads (V1, V2 and V3) or 
beyond in individuals > 14 years of age (in the absence of 
complete RBBB QRS ≥ 120 msecs) 
Inverted T waves in leads V1 and V2 in individuals > 14 years of 
age (in the absence of complete RBBB), or in V4, V5, or V6. 
Inverted T waves in leads V1, V2, V3 and V4 in individuals > 14 
years of age in the presence of complete RBBB 
4. Depolarisation/conduction abnormalities 
Epsilon wave (reproducible low amplitude signals between end 
of QRS complex to onset of the T wave) in the right precordial 
leads (V1 to V3) 
• Late potentials by signal averaged ECG in at least one of 
three parameters in the absence of a QRS duration of ≥110 
msecs on the standard ECG 
• Filtered QRS duration: ≥ 114 ms 
• Duration of terminal QRS < 40 μV (LAS): ≥ 38 ms 
• Root mean square voltage of terminal 40 ms: ≥ 20 μV 
• Terminal activation duration of QRS ≥ 55 ms measured 
from the nadir of the S wave to the end of the QRS, 
including R', in V1, V2 or V3, in the absence of complete 
RBBB 
5. Arrhythmias 
Non-sustained or sustained VT of left bundle branch 
morphology with superior axis (negative or indeterminate QRS 
in II, III, AVF and positive in AVL) 
• Non sustained or sustained VT of RV outflow configuration, 
LBBB morphology with inferior axis (positive QRS in II, III, 
AVF and negative in AVL) or of unknown axis 
• Greater than 500 ventricular extrasystoles/24 hours by 
Holter 
6. Family history 
• ACM confirmed in a first-degree relative who meets current 
task force criteria 
• ACM confirmed pathologically at autopsy or surgery in a 
first-degree relative 
• Identification of a pathogenic mutation categorised as 
associated or probably associated with ACM in the patient 
under evaluation 
• History of ACM in a first-degree relative in whom it is not 
possible or practical to determine if the family member 
meets current task force criteria 
• Premature sudden death (< 35 years) due to suspected 
ACM in a first-degree relative 
• ACM confirmed pathologically or by current Task Force 
Criteria in second-degree relative 
Adapted from Marcus FI. 2010. Circulation, 121(13):15-18. µV, microvolt; 2D, two-dimensional; ACM, arrhythmogenic 
cardiomyopathy; AVF, augmented vector foot; AVL, augmented vector left; ECG, electrocardiography; LAS, low 
amplitude signal duration; LBBB, left bundle branch block; m, metre; ml, millilitre; mm, millimetre; ms, millisecond; MRI, 




2.2 DNA extraction  
 
Blood samples obtained from the participants during recruitment were used to isolate DNA for 
use in downstream molecular processes. 
 
2.2.1 DNA extraction and storage 
 
Genomic DNA was extracted from all probands and family members using either the Gentra® 
Puregene® blood kit (Qiagen, Hilden, Germany) or the PAXgene® Blood DNA kit (Qiagen), 
following the manufacturer’s instructions (Appendix D). DNA samples were anonymised and 
archived at -80°C in the Cardiovascular Genetics laboratory, Hatter Institute for Cardiovascular 
Research in Africa (HICRA), UCT. 
 
2.2.2 DNA quality control 
 
DNA extracts were quantified using a NanoDrop® 2000 spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, DE USA) and diluted to working concentrations of 100 ng/µl. The 
integrity of the DNA was investigated using agarose gel electrophoresis on 1% (w/v) agarose gels 
(Appendix E). A 100 bp DNA ladder (New England BioLabs (NEB), Ipswich, MA USA) was 
included as a marker on each gel. Both the DNA samples and ladder were stained with                   
3X GelRed® nucleic acid stain (Biotium, Fremont, CA USA). DNA was visualised using a Uvitec 
Xplorer D55 (Uvitec Cambridge, Cambridge, UK) and the Xplorer 1D software version 15.08 
(Uvitec Cambridge). 
 
2.3 Exome sequencing 
 
Exome sequencing was performed on the proband of each family, as well as at least one other 
clinically screened family member (Table 2.2). The sequencing reactions were performed at the 
Centre for Proteomic and Genomic Research (CPGR), Cape Town, or Central Analytical Facilities 
(CAF), Stellenbosch University (Table 2.2). At CPGR, exonic regions were captured using the Ion 
AmpliSeqTM Exome RDY kit (Thermo Fisher Scientific, Waltham, MA USA) and Ion XpressTM 
Barcode Adapters 1-16 kit (Thermo Fisher Scientific), while the IonCode™ Barcode Adapters 1-
384 kit (Thermo Fisher Scientific) was used at CAF. At both facilities, templates for sequencing 
were prepared using the Ion PITM Hi-QTM Chef kit (Thermo Fisher Scientific) or the Ion PITM Chip 
36 
 
kit v3 (Thermo Fisher Scientific). The enriched exonic regions were sequenced using an Ion 
ProtonTM high-throughput sequencer (Thermo Fisher Scientific). 
 
 
Table 2.2: Samples used for exome sequencing 
Family Individuals Disease status IMHOTEP code 











































ACM 142.6JEA  
ACM 142.4MIC 





Unaffected, possible carrier 
Affected, deceased 
Unaffected, possible carrier 
 
DCM 435.3MUT  
DCM 435.1CLE 
DCM 435.2DAV 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; IMHOTEP, 
the African Cardiomyopathy and Myocarditis Registry Programme 
 
 
2.4 Exome sequencing data analysis 
 
Sequencing reads were aligned to the H. sapiens reference genome sequence (UCSC version 
hg19) using the Ion ReporterTM platform (Thermo Fisher Scientific) and the AmpliSeqTM Exome 
Hi-Q germline workflow version 5.10 (Thermo Fisher Scientific). Exome variant data was 
downloaded for annotation and filtering. 
 
2.4.1 Variant annotation 
 
Computations were performed using facilities provided by UCT’s ICTS High Performance 
Computing team (hpc.uct.ac.za). Variant files were annotated using Ensembl Variant Effect 
Predictor (VEP) release 94 (McLaren et al. 2016), on the UCT High Performance Cluster 
(Appendix F). The annotation databases that were included in the pipeline were gene symbol, 
Ensembl transcript and protein identifiers, Human Genome Variation Society (HGVS) 
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nomenclature, gnomAD frequency data, dbSNP identifiers, as well as SIFT and PolyPhen 
predictions of pathogenicity. 
 
2.4.2 Filtering and bioinformatic analysis of exonic variants 
 
The VEP output from each family was subjected to standard filters: variants were filtered based 
on global gnomAD minor allele frequency (MAF) ≤ 0.01, variant consequence (including insertions 
and deletions, as well as missense, nonsense and splice donor or acceptor variants), allele ratio 
> 0.3, and Combined Annotation Dependent Depletion (CADD) score > 20. CADD scores were 
not included in the VEP output and were determined manually (https://cadd.gs.washington.edu/) 
for all variants that passed the first three filters (Rentzsch et al. 2019). All intronic, intergenic and 
other non-coding variants were excluded from the analysis. Variants were then filtered according 
to all potential inheritance patterns determined from the family history. 
 
All variants in a panel of 250 known or candidate cardiomyopathy genes (Appendix G) were 
explored for possible pathogenic variants. The bioinformatics tools MutationTaster 
(http://www.mutationtaster.org/), SIFT (https://sift.bii.a-star.edu.sg/), PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) and M-CAP (http://bejerano.stanford.edu/mcap/) were 
used to determine the predicted pathogenicity of each variant (Adzhubei et al. 2010, Jagadeesh 
et al. 2016, Schwarz et al. 2014, Sim et al. 2012).  
 
The population databases 1000 Genomes (https://www.ensembl.org/index.html) (The 1000 
Genomes Project Consortium 2015), Exome Variant Server (EVS) 
(http://evs.gs.washington.edu/EVS/), ExAC (http://exac.broadinstitute.org/) (Lek et al. 2016) and 
gnomAD (https://gnomad.broadinstitute.org/) (Karczewski et al. 2019), were used to determine 
the frequency of each variant in known population groups. Variants with allele frequencies > 0.01 
in any database were excluded from further analysis. 
 
The conservation of mutated amino acids was checked in chimpanzee (P. troglodites), macaque 
(M. mulatta), mouse (M. musculus), cat (F. catus), chicken (G. gallus), zebrafish (D. rerio) and 
frog (X. xenopus) by using the ClustalW multiple sequence alignment tool in BioEdit version 7.2.5 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html) to compare the protein sequence of each gene 
to the H. sapiens reference sequence. Conservation was assessed according to amino acid 
classification as previously described (Dagan, Talmor, and Graur 2002, Zhang 2000).  
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2.4.3 Gene prioritisation 
 
All variants occurring in the cardiomyopathy gene panel (Appendix G) were prioritised, particularly 
mutations occurring in genes reported to cause a similar phenotype. However, genes outside of 
the cardiomyopathy panel were also considered. This process was of particular importance when 
no mutations were found in any known cardiomyopathy genes. These genes were searched in 
the PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), Genotype-Tissue Expression (GTex) 
(https://gtexportal.org/home/) and Mouse Genome Informatics (MGI) databases 
(http://www.informatics.jax.org/) to assess any links to the heart and its functioning.  
 
PubMed was used to find any prior literature implicating the gene in the development of 
cardiomyopathy or normal heart function. GTex was used to determine the expression of the gene 
in the heart; any genes with no recorded expression in the heart (left ventricle) were excluded. 
MGI is a database of mouse models, and any genes that have been functionally investigated in 
mice and showed cardiovascular defects were prioritised. However, genes that have no mouse 
models recorded were not excluded. Genes of interest were identified based on their function, 
expression in the heart and the results of prior animal studies. The potential impact of the variants 
in these genes was assessed as for those occurring in the cardiomyopathy panel. 
 
2.4.4 Candidate selection 
 
Variants in both known and putative cardiomyopathy genes were assessed based on the results 
of the bioinformatics and gene prioritisation analyses (Sections 2.4.2 and 2.4.3). Truncating 
(nonsense and frameshift) and splice site mutations were prioritised, as were missense variants 
that were predicted deleterious by at least three of the pathogenicity prediction tools (Table 2.3). 
Priority was given to variants affecting genes with functional links to the heart and its function (as 
determined by PubMed and MGI database searches). On this basis, candidate variants were 








Table 2.3: Pathogenicity prediction tools used for the scoring of variants 
Prediction 
software 
Scoring system Interpretation 
CADD Ranks variants using a scaled score that combines 
conservation, protein-level changes, functional genomic data 
and transcript information (Rentzsch et al. 2019) 
≤ 20: benign 
> 20: deleterious 
M-CAP Combines previous prediction tools, such as SIFT and 
PolyPhen-2, with machine learning and sequence 
conservation data (Jagadeesh et al. 2016) 
≤ 0.025: benign 
> 0.025: deleterious 
MutationTaster Uses a Bayes classifier to produce a binary output 
(‘polymorphism’ or ‘disease causing’) reported with a 





PolyPhen-2 Scores missense variants based on sequence, structural and 
evolutionary (phylogenetic) information, as well as the protein 
function (Adzhubei et al. 2010) 
≤ 0.450: benign 
> 0.450: deleterious 
SIFT Scores missense variants based on sequence conservation 
and the physical properties of the amino acids (Sim et al. 
2012) 
> 0.05: benign 
≤ 0.05: deleterious 
CADD, Combined Annotation Dependent Depletion; M-CAP, Mendelian Clinically Applicable Pathogenicity; PolyPhen, 
Polymorphism Phenotyping; SIFT, Sorting Intolerant From Tolerant 
 
 
2.5 Validation and segregation analysis 
 
All candidate variants were assessed using polymerase chain reaction (PCR) followed by high 
resolution melt (HRM) analysis of the PCR products. The presence of each variant in additional 
family members was also investigated using PCR-HRM. PCR products were purified and 
sequenced by Sanger sequencing to validate the variants. 
 
2.5.1 PCR conditions and analysis 
 
Target DNA regions from probands and family members were amplified using singleplex PCR-
HRM. Each reaction contained 50 ng DNA, 1X GoTaq® Colourless Flexi buffer (Promega, 
Madison, WI USA), 3 mM MgCl2 (Promega), 0.4X EvaGreen® dye in water (Biotium), 0.4 µM of 
each primer (Table 2.4) (Integrated DNA Technologies, Inc., Coralville, IA USA), 0.2 mM dNTPs 
(NEB) and 0.5 U GoTaq® DNA polymerase (Promega), in a final volume of 25 µl. The reactions 
were conducted in a Corbett Rotor-Gene 6000 (Qiagen). Standard thermal cycling conditions 
included an initial denaturation step of 95°C for 10 mins, followed by 50 cycles of denaturation at 
95°C for 5 s, annealing at 55°C for 10 s and extension at 72°C for 10 s. A final HRM step was 
included in which the reaction temperature was increased from 72°C to 95°C in 0.1°C increments. 
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Table 2.4: Primers for validation and segregation analysis 
Gene Variant  
(HGVS code) 



















































































































Ta 60°C;  














bp, base pairs; HGVS, Human Genome Variation Society; Ta, annealing temperature 
 
 
PCR products were separated on a 2% (w/v) agarose gel in order to determine the specificity of 
the reaction. Agarose gel electrophoresis was performed and visualised as described previously 
(Section 2.2.2). In instances where non-specific amplification was observed, the PCR conditions 
were adjusted by optimising the annealing temperature (Ta) or concentration of MgCl2 in the 
reaction, or the reactions were performed using the Type-It® HRM PCR kit (Qiagen) or the Q5® 
High-Fidelity PCR kit (NEB) (Table 2.4). To optimise Ta and MgCl2 concentration, the amplification 
of target product was determined at Ta ranging from 50°C to 60°C and/or MgCl2 concentrations 
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ranging from 1 mM to 5 mM. For amplification using the Type-It® HRM PCR kit, 1X HRM PCR 
Master Mix was added to 0.2 µM of each primer (Table 2.4) and 50 ng DNA, in a total reaction 
volume of 25 µl. Thermal cycling conditions were as standard (Ta 55°C) and were conducted in a 
Corbett Rotor-Gene 6000 (Qiagen). When amplifying using the Q5® High-Fidelity PCR kit, 1X Q5 
High-Fidelity Master Mix was added to 2.5 µM of each primer (Table 2.4) and 50 ng template 
DNA, to a total volume of 25 µl. Reaction conditions included initial denaturation at 98°C for 30 s, 
followed by 30 cycles of denaturation at 98°C for 10 s, annealing for 15 s (at a temperature 
determined by gradient PCR) and extension at 72°C for 30 s. A final extension step at 72°C was 
conducted for 2 mins. These reactions were performed on an Eppendorf Mastercycler Pro S 
(Eppendorf, Hamburg, Germany). Upon completion, they were HRM analysed using a Corbett 
Rotor-Gene 6000 (Qiagen), in which the reaction temperature was increased from 72°C to 95°C 
in 0.1°C increments, in the presence of 0.4X EvaGreen® dye (Biotium). 
 
The Corbett Rotor-Gene 6000 Application software version 1.7 was used to visualise the 
amplification of the target DNA regions and their melt profiles. Melt curves from the patient DNA 
were compared to those from their family members in order to determine the melt profiles of 
samples containing and lacking the variants of interest. The presence of the variants was 
confirmed by purification and Sanger sequencing of the PCR amplicons (Sections 2.5.2 and 
2.5.3). 
 
2.5.2 PCR product purification 
 
PCR products were purified using alkaline phosphatase (AP) and exonuclease I (ExoI) digestion. 
Each reaction contained 1 U FastAPTM (Thermo Fisher Scientific) and 2 U ExoI (Thermo Fisher 
Scientific), with 5 µl PCR product in a final volume of 20 µl. Purification reactions were conducted 
using a Labnet MultigeneTM Gradient thermal cycler (Labnet International, Inc., Edison, NJ USA) 
and consisted of a 37°C incubation period of 1 hr followed by a 75°C step for 15 mins. 
 
2.5.3 Sanger sequencing reaction conditions 
 
Sequencing was performed using the BigDye® Terminator v3.1 Cycle Sequencing kit (Thermo 
Fisher Scientific). Sequencing reactions included 3 µl purified PCR product, 1X sequencing buffer, 
4 µl BigDye® Terminator 3.1 Ready Reaction Mix and 0.1 µM primer, to a total volume of 20 µl. 
The reactions were conducted in a Labnet MultigeneTM Gradient thermal cycler (Labnet 
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International, Inc.), where thermal cycling conditions consisted of initial denaturation at 98°C for 
5 mins, followed by 30 cycles of denaturation at 96°C for 30 s, annealing at 50°C for 30 s and 
extension at 60°C for 4 mins. Sequencing products were visualised by capillary electrophoresis 
using an ABI PRISM® 3130xl Genetic Analyser (Applied Biosystems, Waltham, MA USA) at the 
DNA Sequencing Unit, CAF, Stellenbosch University. 
 
2.5.4 Analysis of sequencing products 
 
Sequencing electropherograms were visualised and edited using FinchTV software version 1.4.0 
(http://www.geospiza.com/Products/finchtv.shtml). This involved the removal of indistinct regions 
at the ends of the electropherograms and confirming each base call in the remaining sequence. 
The edited sequences were aligned to a reference sequence downloaded from the Ensembl 
database (https://www.ensembl.org/index.html) (Table 2.5) using the ClustalW multiple sequence 
alignment tool in the BioEdit Sequence Alignment Editor version 7.2.5 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html). The alignment was analysed at the position of 
interest to determine if the expected variant from the exome sequencing output was present. 
 
 
Table 2.5: Gene and transcript database accession numbers 
Gene Ensembl gene ID Ensembl transcript ID NCBI RefSeq ID 
ABCB4 ENSG00000005471 ENST00000265723 NM_000443 
DSC2 ENSG00000134755 ENST00000280904 NM_024422 
GLA ENSG00000102393 ENST00000218516 NM_000169 
HEXB ENSG00000049860 ENST00000261416 NM_000521 
ITGB5 ENSG00000082781 ENST00000296181 NM_002213 
KCNK10 ENSG00000100433 ENST00000319231 NM_138317 
KCNH2 ENSG00000055118 ENST00000262186 None 
KCNN3 ENSG00000143603 ENST00000271915 NM_002249 
LAMA3 ENSG00000053747 ENST00000313654 NM_198129 
MYH7 ENSG00000092054 ENST00000355349 NM_000257 
MYOM1 ENSG00000101605 ENST00000356443 None 
NDUFB1 ENSG00000183648 ENST00000329559 NM_004545 
NRP1 ENSG00000099250 ENST00000265371 None 
POLG ENSG00000140521 ENST00000268124 NM_001126131 
PXDNL ENSG00000147485 ENST00000356297 NM_144651 
SORBS2 ENSG00000154556 ENST00000355634 None 
TJP1 ENSG00000104067 ENST00000346128 NM_003257 
TRPV1 ENSG00000196689 ENST00000571088 None 
TTN ENSG00000155657 ENST00000589042 NM_001267550 






2.5.5 Assessment of variant pathogenicity 
 
Variants were classified as ‘pathogenic’, ‘likely pathogenic’, ‘benign’, ‘likely benign’ or ‘of uncertain 
significance’, using the ACMG’s Standards and Guidelines for the Interpretation of Sequence 
Variants (Richards et al. 2015). Following these guidelines, each variant was assessed for 
pathogenicity using population, computational, functional, segregation, de novo and other data.  
 
2.6 Functional modelling of candidate variants in zebrafish embryos 
 
Candidate genes and/or variants were modelled using genetic manipulations in zebrafish. These 
included CRISPR/Cas9 targeting of the zebrafish orthologues of known and candidate 
cardiomyopathy genes (pkp2, myh7 and polg) and mRNA overexpression of the human POLG 
variant c.2492A>G. This work was performed in collaboration with Novartis Institutes for 
BioMedical Research (NIBR) Inc., Cambridge, MA USA, and the University of Manchester, UK. 
 
2.6.1 CRISPR/Cas9 knockout of cardiomyopathy genes 
 
In this model, the CRISPR/Cas9 system was used to target and disrupt the candidate ACM gene 
POLG (Chapter 4) as well as the known cardiomyopathy genes MYH7 and PKP2. PKP2 and 
MYH7 are genes which have well-characterised associations with ACM and DCM/HCM 
phenotypes, respectively, and were used as positive controls. 
2.6.1.1 Single guide RNA design and synthesis 
 
Single guide RNAs (sgRNAs) were designed to target three genes in zebrafish: myh7 
(ENSDARG00000079564), pkp2 (ENSDARG00000023026) and polg (ENSDARG00000060951). 
An in-house UCSC genome browser at NIBR (Cambridge, MA USA) was used to identify potential 




Table 2.6: Single guide RNA sequences for CRISPR/Cas9 
Gene Human 
orthologue 




sgRNA sequence (5` - 3`) 
myh7 MYH7 85.6% 8:16543250-16543273 (-) GCTTTCACATACTCTTCATCTGG 
pkp2 PKP2 36.8% 4:17057073-17057096 (-) GTTGCTGTAGTCGGTTCAGCCGG 
polg POLG 67.6% 25:9339993-9340016 (+) GGCGGATGGAGAGAGCCAAAAGG 
sgRNA, single guide RNA 
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Oligonucleotides containing the selected sgRNA sequence (Table 2.6), flanked by a T7 promoter 
site (5`-GAAATTAATACGACTCACTATAGG-3`) and a 20 bp universal primer recognition 
sequence (5`-GTTTTAGAGCTAGAAATAGC-3`) were PCR amplified using the Q5® High-Fidelity 
PCR kit (NEB) to create double-stranded DNA. Each reaction contained 1X Q5® High-Fidelity 
master mix, 2 µM universal primer (5` - AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGAT 
AACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC - 3`) and 2 µM of the sgRNA-
specific oligonucleotide (Integrated DNA Technologies, Inc.) to a total volume of 50 µl. Reactions 
were conducted in an Eppendorf Mastercycler Pro S (Eppendorf). The reaction conditions 
consisted of a 2 min 95°C hold, followed by 5 cycles of 95°C for 20s, 58°C for 20s and 72°C for 
30s. A final step of 72°C for 2 mins was also included. 
 
The resulting double-stranded DNA product was purified using the QIAquick PCR purification kit 
(Qiagen) following the manufacturer’s instructions (Appendix H). The purified PCR products were 
analysed using a NanoDrop® 8000 (NanoDrop Technologies Inc.) and electrophoresis on a 1.2% 
E-gel® agarose gel (Thermo Fisher Scientific), to check the quantity and integrity of the DNA. 
 
SgRNAs were generated by in vitro T7 transcription using the MEGAshortscriptTM T7 
Transcription kit (Thermo Fisher Scientific). Each reaction contained 1X T7 Reaction Buffer,       
7.5 mM T7 ATP, CTP, GTP and UTP Solutions, 2 µl T7 Enzyme Mix and 1 µg template DNA, to 
a total volume of 20 µl. The reactions were incubated at 37°C overnight before treatment with       
1 µl TURBO DNase I (Thermo Fisher Scientific) and incubation at 37°C for a further 15 mins. 
SgRNAs were then purified using the MEGAclearTM Transcription Clean-Up kit (Thermo Fisher 
Scientific) following the standard protocol (Appendix H). The sgRNAs were quantified using a 
NanoDrop® 8000 spectrophotometer (NanoDrop Technologies Inc.). Aliquots of sgRNA were 
stored in working solutions of up to 500 ng/µl at -80°C. 
 
2.6.1.2 Zebrafish used for CRISPR/Cas9 
 
The zebrafish line used for CRISPR/Cas9 knockout was previously generated at NIBR 
(Cambridge, MA USA). The fish were genetically engineered to express the monomeric red 
fluorescent protein mCherry in cardiomyocytes driven by the cmlc2 promotor (cmcl2:mCherry), 
resulting in a fluorescent red heart transgenic line. Males and females from this line were housed 




2.6.1.3 Zebrafish breeding and embryo collection 
 
The cmcl2:mCherry zebrafish were bred in paired matings to generate fertilised embryos. The 
afternoon before embryos were required, males and females were separated and placed in 
breeding tanks filled with system water. A single male and single female were transferred to each 
breeding tank, separated by a divider overnight. The following morning, the dividers were 
removed and the fish allowed to breed. Within 10-30 mins, embryos were collected and washed 
with E3 water containing methylene blue (0.002 g/l) (Appendix E). 
 
2.6.1.4 Injection of CRISPR/Cas9 
 
Injections were performed using a FemtoJet® 5247 (Eppendorf). Approximately 1 ng Cas9 protein 
(PNA Bio Inc., Thousand Oaks, CA USA) and 0.5 ng sgRNA were injected into zebrafish embryos 
at the single-cell stage of development (n = 125 per experimental group). Uninjected control 
embryos (n = 125) from the same clutch were allowed to develop normally. All embryos were 
incubated at 28°C in E3 water with methylene blue (Appendix E) for 3-4 days. 
 
2.6.1.5 Imaging and phenotypic analysis 
 
At three days post fertilisation (dpf), injected and control zebrafish larvae (n = 5 per group) were 
anaesthetised using tricaine (Appendix E; dose 0.0167%) and visualised using two-photon 
microscopy. A custom-built microscope at NIBR was used (Figure 2.1). Images were generated 
at approximately 60 frames per second at a wavelength of 720 nm, using a 16x objective and 2x 
optical zoom. The hearts were viewed in 10 planes at a total depth of 140 µm. Video files were 
analysed using DanioScope (Noldus, Wageningen, The Netherlands) to capture still images of 
each heart during ventricular diastole. Images of the ventricles were taken from when they were 
most relaxed. These images were then used to measure the ventricle area, length and thickness 





Figure 2.1: Two-photon microscope setup for viewing of zebrafish embryos. An upright microscope 
was used with two sources of excitation: (A) laser excitation, with the light path towards the specimen 
indicated in pink. The reflected light path (grey/red) is directed towards PMTs for conversion into a 
computer-readable signal. The scan lens (L2) is used to filter the wavelength of excitation. (B) LED 
excitation, with light path towards the specimen indicated in purple lines. The reflected light path (green) is 
directed towards an ORCA-Flash4.0 CCD camera. CCD, charge-coupled device; PMT, photomultiplier 
tube. Image courtesy of Dr Peixin Zhu (NIBR). 
 
 
2.6.1.6 DNA extraction and sequencing 
 
DNA was isolated from zebrafish embryos after imaging in order to assess the CRISPR activity 
in the knockout fish. Whole embryos were digested by incubation with 25 mM NaOH at 95°C for       
15 mins, followed by neutralisation with 40 mM Tris-HCl. The CRISPR target regions were PCR 
amplified using the Q5® High-Fidelity PCR kit (NEB). Each reaction contained 1X Q5® High-
Fidelity master mix, 4 µM of each primer (Table 2.7) and 1 µl DNA to a total volume of 50 µl. 
Reaction conditions consisted of a 2 min 94°C hold, followed by 30 cycles of 94°C for 15 s, 58°C 
for 15 s and 72°C for 30s. A final step of 72°C for 1 min was also included. NGS of the amplicons 






Table 2.7: Primers used for assessing CRISPR activity 
Gene target Forward primer (5` - 3`) Reverse primer (5` - 3`) 
myh7 (8:16543250-16543273) CGCAATAGGCAATAGCATTCCGG CCTTATAGTGCTCATAATGTTTC 
pkp2 (4:17057073-17057096) CCACAGCAGAGTCGATATCCGCA CCACCAACATTTGACTGACATCT 
polg (25:9339993-9340016) CCGGTGGCAGACGTTCGTACGAT CCTAGCTCGCAGTGTTTGGTCTT 
 
 
2.6.1.7 Statistical analysis 
 
Differences between experimental groups were investigated using R version 3.6.1 (https://www.r-
project.org/) and plotted using the ggplot2 package (https://ggplot2.tidyverse.org/). Two-tailed 
independent t-tests and analysis of variance (ANOVA) tests were performed to compare the 
means between groups, as the values were normally distributed. Post-hoc statistical power 
analyses were performed using G*Power version 3.1.9.2 (Faul et al. 2007). Kaplan-Meier survival 
analysis was used to compare survival rates between larval groups. Survival plots were created 
using the survminer package of R (https://cran.r-project.org/web/packages/survminer/index.html). 
Pearson’s correlation was used to assess potential relationships between numerical variables. In 
all analyses, p-values < 0.05 were considered statistically significant. Statistical outliers were 
defined as values 1.5 interquartile ranges (IQRs) from the first or third quartiles. 
 
2.6.2 Mutant mRNA overexpression 
 
To further explore the role of POLG in ACM, a second zebrafish model was employed. In this 
model, mRNA carrying the mutation of interest (c.2492A>G) was generated and introduced to 
zebrafish embryos in a transient gene overexpression analysis. 
 
2.6.2.1 Isolation of human POLG 
 
Human POLG was amplified using the high fidelity Pfu DNA polymerase (Promega). Primers were 
designed to amplify the entire coding region of POLG at an expected product size of 3.7 kb (Table 
2.8). The primers were also used to introduce the restriction enzyme (RE) recognition sites for 
Cla1 and Xba1 into the 5` and 3` ends of the gene, respectively. Each amplification reaction 
consisted of 1X Pfu DNA polymerase reaction buffer (Promega), 200 µM dNTPs (Bioline, 
Taunton, MA USA), 0.1 µM of each cloning primer (Table 2.8), 0.5 µM POLG cDNA (OriGene, 
Rockville, MD USA) and 1.25 U Pfu DNA polymerase (Promega) to a final volume of 50 µl. 
Reactions were conducted in a Bio-Rad T100TM thermal cycler (Bio-Rad Laboratories, Hercules, 
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CA USA). Thermal cycling conditions consisted of an initial denaturation step of 95°C for 2 mins, 
followed by 34 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 30 s and extension 
at 72°C for 4 mins, followed by a final extension step of 72°C for 5 mins. 
 
 
Table 2.8: Primers used for the amplification and site-directed mutagenesis of POLG cDNA 
Primer function Direction Primer sequence (5` - 3`) 
POLG amplification and introduction of Cla1 RE site 





Site-directed mutagenesis Forward TCAGGCACCCCGACTGTGATGAGGAAGGCCT 




RE, restriction enzyme  
 
 
PCR products were visualised using agarose gel electrophoresis. The total PCR products from 
each reaction were separated on a 1% agarose gel (Appendix E) loaded with 1:10 (stain:agarose) 
SafeViewTM nucleic acid stain (NBS Biologicals, Huntingdon, UK) and compared to Quick-Load® 
1 kb DNA ladder (NEB) (Appendix E). Amplicons were then gel purified using the Isolate II PCR 
and Gel kit (Bioline) following the manufacturer’s instructions (Appendix I). 
 
2.6.2.2 Cloning of human POLG 
 
Purified PCR products were digested using ClaI and XbaI, as was PCS2+ plasmid (Figure 2.2). 
Each digest contained 10 U ClaI (NEB), 20 U XbaI (NEB), 1X CutSmart® buffer (NEB) and 5 µl 
of the purified PCR product, in a total reaction volume of 50 µl. Reactions were incubated at 37°C 






Figure 2.2: Plasmid map for the PCS2+ expression vector. Indicated are the positions of restriction 
enzyme sites (blue) and primer binding sites or promotor sequences (green). The plasmid also contains an 




The digested POLG coding region amplicons were then ligated into the PCS2+ vector. Ligation 
reactions consisted of 1X T4 DNA Ligase Reaction buffer (NEB), 10 µl POLG insert, 1.5 µl PSC2+ 
plasmid and 600 U T4 DNA Ligase (NEB). Ligation reactions were incubated at 4°C overnight. 
 
2.6.2.3 E. coli replication of POLG vector 
 
The recombinant POLG-carrying PCS2+ plasmids were introduced to E. coli cells for selection 
and amplification. Each cloning reaction was transferred to a vial of One ShotTM TOP10 chemically 
competent E. coli cells (Thermo Fisher Scientific). The reactions were left on ice for 30 mins before 
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heat shock at 42°C for 30 s. After this step, 1 mL S.O.C. medium (Thermo Fisher Scientific) was 
added to each reaction. The E. coli cells were incubated at 37°C for 1 hr in a bacterial shaker at 
200 rpm and spread on an ampicillin plate (Appendix E). Plates were incubated at 37°C overnight 
in order to facilitate selection of plasmid-containing cells, as well as amplification of the DNA. 
 
Five colonies were picked from each ampicillin plate and cultured in LB broth (Appendix E) and 
ampicillin at a concentration of 1:1000. The colonies were incubated at 37°C overnight in a 
bacterial shaker at 120 rpm. Plasmids were recovered from E. coli host cells using the Isolate II 
Plasmid Mini kit (Bioline), following the manufacturer’s protocol (Appendix I). 
 
Each recovered plasmid was digested using ClaI and XbaI to check for the presence of POLG 
insert. Digestion reactions contained 2.5 U ClaI (NEB), 5 U XbaI (NEB), 1X CutSmart® buffer 
(NEB) and 5 µl of the purified plasmid. Reactions were incubated at 37°C for 15 mins before 
separation and visualisation on a 1% (w/v) agarose gel. Samples were loaded with                        
1:10 (stain:agarose) SafeViewTM nucleic acid stain (NBS Biologicals) and compared to Quick-
Load® 1 kb DNA ladder (NEB) (Appendix E). 
 
2.6.2.4 Site-directed mutagenesis of POLG 
 
Plasmids that were confirmed to carry the POLG insert were used as template for site-directed 
mutagenesis. The QuikChange Lightning Multi Site-Directed Mutagenesis kit (Agilent, Santa 
Clara, CA USA) was used, in which each reaction contained 1X QuikChange Lightning Multi 
reaction buffer, 10% QuikSolution, 50 ng mutagenic primer (Table 2.8), 1 µl dNTP mix, 100 ng 
POLG-containing PCS2+ plasmid and 1 µl QuikChange Lightning Multi enzyme blend, to a total 
volume of 25 µl. 
 
Thermal cycling conditions consisted of a 95°C hold for 2 mins, followed by 30 cycles of 95°C for 
20 s, 55°C for 30 s and 65°C for 4 min, followed by a final step at 65°C for 5 mins. The resulting 
plasmids were then transformed into E. coli cells, cultured overnight and recovered as described 






2.6.2.5 Confirmation of POLG mutation 
 
Sanger sequencing was conducted on each plasmid isolate to check for the presence of the 
c.2492A>G mutation in the vector. For each sequencing reaction, 0.4 µM of primer (Table 2.8) 
was added to 1 µl plasmid, in a total reaction volume of 10 µl. Sequencing reactions were 
conducted at the Genomic Technologies Core Facility, University of Manchester. Sequences were 
aligned to the expected POLG sequence to determine their similarity. 
 
2.6.2.6 In vitro transcription and mRNA recovery 
 
Plasmids that were confirmed to harbour the POLG c.2492A>G mutation (Section 2.6.2.5) were 
used as template for an in vitro transcription reaction to generate mRNA. A control plasmid that 
did not carry the mutation was also used to generate wild type POLG mRNA. Plasmids were first 
linearised through digestion with KpnI: each reaction contained 10 U KpnI-HF (NEB),                       
1X CutSmart® buffer (NEB) and 1 µg plasmid, in a total volume of 50 µl. Reactions were 
conducted at 37°C for 15 mins, and the linearised plasmids recovered using the Isolate II PCR 
and Gel kit following the manufacturer’s protocol (Appendix I). 
 
The linearised plasmids were then transcribed in vitro using the mMessage mMachine SP6 kit 
(Thermo Fisher Scientific), according to the manufacturer’s instructions. Each reaction contained 
1X Reaction Buffer, 1X NTP/CAP, 2 µl Enzyme Mix and up to 1 µg template DNA, and was 
incubated at 37°C for 2 hr before treatment with 1 µl TURBO DNase and further incubation at 
37°C for 15 mins. The RNA was purified with the MEGAclearTM Transcription Clean-Up kit and 
eluted in RNase-free water (Thermo Fisher Scientific) (Appendix H). 
 
The mRNA was quantified using a NanoDrop® 8000 spectrophotometer (NanoDrop Technologies 
Inc.), and visualised on a 1% (w/v) agarose gel (Appendix E). All mRNA was diluted to working 
concentrations of 100 ng/µl and stored at -80°C. 
 
2.6.2.7 Zebrafish lines used for mRNA overexpression 
 
Wild type AB zebrafish were used for mRNA overexpression experiments. Zebrafish were raised 
and maintained at The University of Manchester Biological Services Unit under standard 
conditions (Westerfield 2000). Adult zebrafish husbandry was approved by the University of 
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Manchester Animal Welfare and Ethical Review Board, and all experiments were performed in 
accordance with UK Home Office regulations. 
 
2.6.2.8 Zebrafish breeding and embryo collection 
 
Paired mating was set up as described previously (Section 2.6.1.3). Fertilised embryos were 
harvested and washed in E3 media containing methylene blue (0.002 g/l) (Appendix E) and used 
for RNA injection experiments. 
 
2.6.2.9 Injection of mRNA into zebrafish embryos 
 
Injections were performed using a PLI-90 pico-injector (Harvard Apparatus, Holliston, MA USA). 
The dose of mRNA was optimised by injecting 25 pg, 50 pg, 100 pg or 200 pg of wild type POLG 
mRNA into single-cell zebrafish embryos and monitoring them until 5 dpf. The heart rate of each 
injected fish was determined at 3 dpf (Section 2.6.2.10), and statistically analysed (Section 
2.6.2.11). Experimental embryos were injected with 50 pg mutant POLG mRNA in a total volume 
of 2 nl (n = 135). Control fish included sibling embryos (from the same clutch) that were injected 
with 50 pg wild type POLG mRNA in a volume of 2 nl (n = 75). In all experiments, control groups 
also included fish injected with an equivalent volume of nuclease-free water (n = 75) and 
uninjected embryos (n = 75). Embryos from all groups were incubated at 28°C and were 
monitored regularly until visualisation at 3 dpf. 
 
2.6.2.10 Imaging and phenotypic analysis 
 
At 3 dpf, larvae from all experimental groups were mounted in 3% methylcellulose (Appendix E) 
and viewed on a Leica MZ9.5 stereomicroscope. The larvae were not treated with tricaine 
anaesthetic. Videos of 30 frames per second were generated at 10x magnification. The videos 
were analysed using DanioScope (Noldus) to measure heart rhythm, cardiac output and chamber 
size. 
 
2.6.2.11 Statistical analysis 
 
Differences between groups were investigated as described before (Section 2.6.1.7). Because 
the heart rate was not normally distributed, differences between experimental groups were 
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calculated using two-tailed Mann-Whitney U tests and Kruskal-Wallis tests, and the median from 
each group was reported. Statistical outliers (1.5 IQRs from the first or third quartiles) were 
removed from the analysis. Differences in ventricular measurements and flow rates, which were 
normally distributed, were investigated using two-tailed independent t-tests and ANOVA to 
compare means between groups. P-values < 0.05 were considered statistically significant. Post-






Chapter 3 Mutations in established cardiomyopathy genes as the cause of 




Heritable cardiomyopathies are characterised by marked clinical and genetic heterogeneity. The 
genetic diversity displayed by cardiomyopathy includes both locus heterogeneity, whereby 
mutations in different genes can cause the same form of cardiomyopathy, and allelic 
heterogeneity, in which one gene may be associated with different types of cardiomyopathy (Mayo 





Figure 3.1: The genetic overlap between different types of cardiomyopathy. Adapted from Van 
Tintelen JP et al. Cardiovasc Res, 101(4):572. ACM, arrhythmogenic cardiomyopathy; DCM, dilated 
cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left ventricular non-compaction; RCM, 
restrictive cardiomyopathy 
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Advances in sequencing technology have only emphasised the substantial genetic overlap 
amongst the different cardiomyopathy phenotypes. For instance, NGS gene panels have been 
used to describe novel associations of ACM, HCM and channelopathy gene mutations in DCM 
(Haas et al. 2015, Mahdieh et al. 2018), ACM gene mutations in LVNC and DCM (Klauke et al. 
2017, Ramond et al. 2017) and HCM gene mutations in LVNC and RCM (Brodehl et al. 2017, 
Schaefer et al. 2014, Wu et al. 2015). Similarly, the genes HCN4, FLNC and MTO1, which were 
identified in exome sequencing studies, have since been demonstrated as mutation hotspots for 
numerous forms of heritable cardiomyopathy (Baruffini et al. 2013, Brun et al. 2020, Hall et al. 
2020, Janin et al. 2017, Liu et al. 2019, Millat et al. 2015, Nozari et al. 2018, Ortiz-Genga et al. 
2016, Schweizer et al. 2014, Taylor et al. 2014, Tucker et al. 2017). 
 
To our knowledge, the genetic heterogeneity of cardiomyopathy is largely unexplored in the South 
African patient population. In this chapter, three families with cardiomyopathy are investigated 
and found to illustrate this genetic diversity of cardiomyopathy. 
 
3.2 Family 1 (DCM 389) 
 
3.2.1 Clinical history of Family 1 
 
In 2014, a multi-generation family with AD DCM was recruited at GSH. The family consisted of 
three affected female siblings and their affected father (Figure 3.2). The proband, III:4, was 
diagnosed with severe DCM at the age of 44 years with an ejection fraction (EF) of 22%. Her 
father (II:2) underwent a heart transplant but died before he could be enrolled into the study. The 
proband’s sisters (III:6 and III:8) were also diagnosed with DCM in their fifth decades of life, but 
with variable phenotypes: individual III:6 had similarly severe DCM to the proband (EF of 10-15%), 
while the youngest sister (III:8) had DCM that recovered to a normal EF during treatment. 
 
DNA from all sisters and some of their children and grandchildren was available in this 
investigation. Although they were clinically examined and found to be unaffected, all the children 
(generation IV) and grandchildren (generation V, not shown) were below the age of disease onset 
in this family (range: 2 to 28 years). The proband’s son (IV:1) had an end-diastolic left ventricular 
internal diameter of 56 mm when he was screened at the age of 19 years, which was within normal 
values but borderline dilated. Two of the proband’s cousins (III:2 and III:3) were examined in their 






Figure 3.2: Pedigree indicating disease segregation in Family 1. Squares represent males and circles 
represent females. Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate 
affected individuals. Blue shading indicates DCM. No shading indicates that the individual has no reported 
conditions. Numbers in Roman numerals are the generation number while Arabic numerals denote 
individuals. The index case is indicated with an arrow. 
 
 
3.2.2 Genetic analysis of Family 1 
 
Exome sequencing was conducted on two affected individuals from the family: the proband and 
her sister, individual III:6. The third affected sibling (III:8) was recruited after the study began, and 
their father died before the study began, so these individuals were not included in the exome 
sequencing; however, DNA from individual III:8 was used for segregation analysis. The 
sequencing generated a total of 46,720 variants in both individuals, at a mean sequence coverage 
of 120x. Family history was indicative of AD inheritance. After filtering, 84 variants remained 



























Figure 3.3: Filtering of exome sequencing data from Family 1. Exome sequencing produced a total of 
46,720 variants, of which 84 met the filtering criteria. CADD, Combined Annotation Dependent Depletion; 
gnomAD, Genome Aggregation Database; MAF, minor allele frequency  
 
 
Two of the variants occurred in genes on the cardiomyopathy panel (Table 3.1): missense 
mutations were found in the genes MYOM1 and MYH7. Other genes not previously associated 
with cardiomyopathy were also considered, but many were excluded due to low expression in the 
heart or a lack of functional relevance to DCM (Appendix J). However, three genes were 






10,568 gnomAD MAF ≤ 0.01 
1,632 missense, splicing or 
truncating variant
481 inheritance pattern







Table 3.1: Candidate variants in Family 1 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
Cardiomyopathy panel             
MYH7 c.4394C>T p.S1465L 0 0 0 0 D (0.581) D (0.67) D (0) B (0.322) 25.4 4553.0 Yes 7/7 
MYOM1 c.139A>G p.S47G 0.003 0.005796 0.007187 0.00201 NS D (0.76) B (0.08) B (0.079) 21.9 214.6 NA 5/7 
               
Other genes             
ABCB4 c.523A>G p.T175A 0.006 0.01062 0.01163 0.00846 NS D (0.99) D (0.01) D (0.952) 24.2 1.2 Yes 6/7 
LAMA3 c.4643A>G p.D1548G 0.002 0.0008778 0.0009064 0.00240 B (0.012) D (0.99) B (0.06) D (0.795) 25.1 1.2 No 4/7 
TJP1 c.1412A>G p.N471S 0.005 0.009164 0.009114 0.00975 NS D (0.99) D (0.02) B (0.040) 23.2 14.9 Yes 7/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 





The variants in TJP1 and LAMA3 were excluded due to lack of segregation with disease 
phenotype (Appendix K). The variant ABCB4 c.523A>G (p.T175A) was of interest because the 
same variant was reported to track with disease in an Italian family with AD atrial fibrillation and/or 
atrial flutter (Maciag et al. 2015). Although it tracked with DCM in this family too (Appendix K), 
ABCB4 p.T175A was too common in the ExAC and gnomAD databases to be considered the 
primary pathogenic variant in this family (Table 3.1). 
 
The variant MYOM1 c.139A>G was homozygous in individual III:6 and was excluded. The MYH7 
c.4394C>T (p.S1465L) variant was validated (Figure 3.4) and determined to be sufficiently rare 
in the population, as MYH7 p.S1465L was absent in all population databases checked. It is a 
missense variant, and the affected amino acid was highly conserved in all species (Figure 3.5): 
all species had the same residue as humans (serine) or alanine or threonine, which are non-
radical amino acid changes (Zhang 2000). Due to these factors, the MYH7 tail region variant was 









Figure 3.4: Validation of MYH7 c.4394C>T identified in Family 1. (A) Sanger sequencing to confirm the 
presence of MYH7 c.4394C>T in affected individual III:4 (indicated with an arrow), (B) Sanger sequencing 











H. sapiens A E W K Q K Y E E S Q S E L E S S Q K E A R S 
M. mulatta A E W K Q K Y E E S Q S E L E S S Q K E A R S 
P. troglodites A E W K Q K Y E E S Q S E L E S S Q K E A R S 
F. catus A E W K Q K Y E E S Q S E L E S S Q K E A R S 
M. musculus A E W K Q K Y E E S Q S E L E S S Q K E A R S 
G. gallus S E W K Q K F E E S Q T E L E S S Q K E A R S 
D. rerio A E W K Q K Y E E S Q S E L E S S Q K E A R S 
X. tropicalis S E W K Q K F E E S Q A E L E S S Q K E A R S 
 
Figure 3.5: MYH7 c.4394C>T identified in Family 1. (A) Protein structure of MYH7 with position of the 
p.S1465L mutation marked with an arrow, (B) Multiple species conservation alignment of the p.S1465 





Figure 3.6: Pedigree indicating segregation of MYH7 c.4394C>T in Family 1. Individuals marked ‘MYH7 
pos’ were heterozygous for the variant, and those marked ‘MYH7 neg’ tested negative for it. DNA was not 
available for unmarked individuals. Squares represent males and circles represent females. Shaded 
symbols indicate affected individuals. Blue shading indicates DCM. No shading indicates that the individual 
has no reported conditions. Numbers in Roman numerals are the generation number while Arabic numerals 
denote individuals. The index case is indicated with an arrow. 
Myosin head Neck Myosin tail 
p.S1465L 
MYH7 pos MYH7 pos MYH7 pos 
MYH7 pos MYH7 
pos MYH7 pos MYH7 pos 
MYH7 neg MYH7 neg MYH7 neg 
MYH7 neg MYH7 neg 
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3.2.3 Discussion: MYH7 mutations as a cause of DCM 
 
The sarcomere is composed of thick and thin filaments that together make up the contractile 
apparatus of muscle tissue. MYH7 encodes the heavy chain component of cardiac muscle cells 
(Tajsharghi and Oldfors 2012). Myosin heavy chains are characterised by a globular actin-binding 
head region and a rod-like helical tail, which is used for dimerisation of the protein (Figure 3.5A). 
 
Typically, mutations in MYH7 are associated with HCM, a disorder characterised by marked 
ventricular hypertrophy as opposed to the dilatation observed in DCM. In fact, mutations in MYH7 
are the second most common cause of HCM, accounting for up to 20% of all cases (Marian and 
Braunwald 2017). However, genetic overlap between DCM and HCM is not uncommon, and 
approximately 3-4% of DCM cases have been attributed to mutations in MHY7 already (McNally 
and Mestroni 2017, Merlo et al. 2013, Millat et al. 2011, Wasielewski et al. 2014, Zhao et al. 2015). 
 
The mutation found in Family 1 occurred in the tail region of the MYH7 protein (Figure 3.5). The 
majority of reported pathogenic HCM MYH7 mutations are in the head and neck domains, which 
are involved in actin binding and muscle contraction, but DCM-causing mutations have been 
observed to occur more frequently in the tail domain of MYH7 (Walsh et al. 2010). A most notable 
example is the Dutch founder mutation MYH7 c.5754C>G (p.N1918K) which was described in 15 
families with DCM and/or congenital heart defects (van der Linde et al. 2017). Other tail region 
mutations include c.3942C>G (p.D1314E) and c.4377G>T (p.K1459N), reported in two 
Portuguese DCM patients (Sousa et al. 2019), and c.2770G>A (p.E924K), which was coinherited 
with a LAMA4 mutation to cause severe paediatric cardiomyopathy (Abdallah et al. 2019). 
 
MYH7 tail region mutations have also been described in infantile bi-ventricular noncompaction 
(Miura et al. 2019) and a unique adult-onset form of systolic cardiomyopathy characterised by 
heart failure and reduced EF in the absence of ventricular hypertrophy or dilation (Yang et al. 
2018). In the latter case, the c.2543A>G (p.E848G) mutation was demonstrated to impair the 
interaction of MYH7 protein with MYBPC3 and cause contractile dysfunction of patient-derived 
heart tissue (Yang et al. 2018). The basis for how MYH7 tail region mutations lead to 
cardiomyopathy is unclear, although this study indicates that it may involve disrupted protein-
protein interactions in the sarcomere. It is also consistent with the present finding of a pathogenic 
mutation in the MYH7 tail region in this family. The high sequence conservation of the p.S1465 
residue and surrounding region in many species indicates its functional importance. 
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3.2.4 Assessment of the pathogenicity of MYH7 c.4394C>T 
 
For genes that have been associated with disease already, established criteria of pathogenicity 
can be used to investigate their disease-causing potential. The most widely used variant 
pathogenicity guidelines are those published by the ACMG, which were discussed earlier 
(Chapter 1). However, missense mutations may be difficult to interpret as they seldom cause a 
complete loss of gene function. The greatest evidence is if the same mutation has been reported 
in other affected individuals or if the mutation occurs at or near the site of other known disease-
causing mutations (Richards et al. 2015). Other lines of evidence that may be pursued are in vitro 
or in vivo functional investigations, or co-segregation in large family pedigrees. 
 
The MYH7 variant identified in Family 1 occurred in the tail region of the protein, a region with 
several observational links to DCM (Abdallah et al. 2019, Sousa et al. 2019, van der Linde et al. 
2017, Walsh et al. 2010). The occurrence of MYH7 c.4394C>T within this region is moderate 
evidence of pathogenicity. An adaptation of the ACMG variant classification guidelines for MYH7-
associated cardiomyopathies emphasises segregation within seven or more family members as 
indicative of pathogenicity, or presence of the mutation in 15 different, unrelated probands (Kelly 
et al. 2018). Unfortunately, due to the small family size and the late onset of disease, segregation 
analysis was only possible in three affected individuals (Figure 3.6). Importantly, the variant did 
not occur in any unaffected individual who was the age of disease onset. The modified guidelines 
also consider variants that are significantly more prevalent in cases compared to controls. It is 
unfortunate that a South African control population could not be screened in this investigation. 
However, this variant was completely absent in all control databases checked (totalling 150,463 
individuals), indicating that this is likely a private pathogenic mutation in this family. 
 
Following the ACMG guidelines, this variant fulfils moderate and supporting criteria (such as 
segregation with disease, rarity and computational predictions of deleteriousness) sufficient for a 
classification of ‘likely pathogenic’. As the progeny of the affected siblings reach the age of 








3.3 Family 2 (HCM 50) 
 
3.3.1 Clinical history of Family 2 
 
Family 2 was recruited at GSH in 2014 and encompasses two individuals who were diagnosed 
with HCM (Figure 3.7). The family consists of the proband (II:2) and his mother (I:2), who were 
53 and 74 years of age respectively at the time of recruitment. Both individuals showed signs of 
ventricular hypertrophy on echocardiography and were described as having an arrhythmic 





Figure 3.7: Pedigree indicating disease segregation in Family 2. Squares represent males and circles 
represent females. Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate 
affected individuals. Red shading indicates HCM. No shading indicates that the individual has no reported 
conditions. Numbers in Roman numerals are the generation number while Arabic numerals denote 
individuals. The index case is indicated with an arrow.  
 
 
The medical history of the extended family is unclear at this stage. The proband’s mother had two 
additional children, although one died at the age of 12 years in a motor vehicle accident. The 
proband’s sister has not been screened, although to the best of our knowledge she is 
asymptomatic and was 55 years old at the time of recruitment. DNA was therefore only available 
for individuals I:2 and II:2. 
 
3.3.2 Genetic analysis of Family 2 
 
After exome sequencing, 48,103 variants were observed and annotated in both individuals at a 
mean sequence coverage of 137x. Due to the family history, a dominant mode of inheritance was 
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considered when filtering the exome data. Of the total 48,103 variants, 92 met the filtering criteria 

























Figure 3.8: Filtering of exome sequencing data from Family 2. Exome sequencing produced a total of 
48,103 variants, of which 92 met the filtering criteria. CADD, Combined Annotation Dependent Depletion; 
gnomAD, Genome Aggregation Database; MAF, minor allele frequency  
 
 
Three variants occurred in the known cardiomyopathy genes GLA, MYBPC3 and PKP2, as well 
as variants in the putative cardiomyopathy genes GBE1 (glycogen storage disease) and LAMA2 
(muscular dystrophy) (Table 3.2). Although predicted deleterious by various pathogenicity 
prediction tools, the missense variants in MYBPC3 and PKP2 were reported as likely benign for 
cardiomyopathy and other cardiovascular abnormalities (ClinVar accession nos.: 
RCV000157319.1, RCV000244315.2, RCV000476215.3, RCV000172579.2, RCV000231874.4 
and RCV000249816.1). 
48,103 total variants
10,983 gnomAD MAF ≤ 0.01 
1,706 missense, splicing or 
truncating variant
510 inheritance pattern







Table 3.2: Candidate variants in Family 2 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
Cardiomyopathy panel             
GBE1 c.664A>G p.N222D 0 0 0 0 D (0.040) D (0.99) B (0.37) B (0.021) 22.4 24.5 Yes 3/7 
GLA c.774_775delAC p.P259R*5 0 0 0 0 NS D (1) NS NS 35.0 4.0 Yes NS 
LAMA2 c.7040G>T p.G2347V 0.004 0.000157 0.0001156 0 D (0.148) D (0.99) D (0) D (0.952) 32.0 33.1 No 5/7 
MYBPC3 c.3392T>C p.I1131T 0 0.001064 0.000840 0.05670 D (0.184) D (0.99) D (0.04) B (0.400) 24.3 1369.0 Yes 7/7 
PKP2 c.1592T>G p.I531S 0.001 0.004722 0.004722 0.00323 NS D (0.80) D (0) D (0.974) 24.8 84.1 Yes 6/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 





The GLA variant, in contrast, was absent in all population databases checked. Other genes not 
present in the cardiomyopathy panel were also considered, but no candidates were identified 
(Appendix L). GLA c.774_775delAC (p.P259Rfs*5) is a two bp frameshift deletion. The variant, 
which was confirmed by Sanger sequencing (Figure 3.9), is predicted to result in protein 
truncation at residue 259 (Figure 3.10). The wild type GLA protein (UniProt ID P06280) is 429 
amino acids long; the mutation results in loss of the terminal 171 amino acids (approximately 40% 
of the protein) and termination of the protein within 5 residues. Due to its disruptive effects on the 
GLA protein and the prior involvement of GLA in HCM phenocopies, GLA c.774_775delAC was 
considered the most likely disease-causing variant in this family. Because DNA was not available 
for additional family members, segregation analysis beyond these individuals was not possible; 










Figure 3.9: Validation of GLA c.774_775delAC identified in Family 2. (A) Sanger sequencing to confirm 
the presence of GLA c.774_775del in affected individual I:2 (point of disruption indicated with an arrow), 
(B) Sanger sequencing confirms the absence of the variant in an unaffected control individual, IV:1, from 









Figure 3.10: Protein structure of GLA. The position of the p.P259Rfs*5 mutation is indicated (marked 
with an arrow). TIM, triosephosphate isomerase 
 
 
3.3.3 Discussion: GLA mutations as a cause of HCM phenocopy 
 
GLA encodes the lysosomal α-galactosidase A, an enzyme which hydrolises glycosphingolipids 
such as globotriaosylceramide (GL-3) in various tissues and organs. Deficient or absent α-
galactosidase A activity, caused by GLA mutations, results in Anderson-Fabry disease (Fabry 
disease), which is characterised by the accumulation of GL-3 in the lysosomes of cells throughout 
the body (Eng et al. 1993, Hagège et al. 2019). Although clinical signs of Fabry disease typically 
include kidney, dermatological, neurological and cardiac manifestations, many variants of the 
disorder have been reported, including predominantly cardiac variants (Havndrup et al. 2010, 
Linhart et al. 2007). These variants can manifest as a multisystemic disorder (Linhart et al. 2007) 
or may mimic the HCM phenotype (Havndrup et al. 2010). In fact, cardiovascular complication is 
considered the leading cause of mortality amongst Fabry disease patients: a systematic review 
of 4,185 patients found that 75% of deaths were attributable to cardiovascular causes such as 
SCD (Baig et al. 2018). Cardiac hypertrophy and myocardial fibrosis in Fabry disease have been 
ascribed to the deposition of GL-3 in cardiomyocytes, while accumulation of GL-3 in conduction 
tissue can lead to arrhythmias or short PR intervals in patients (Hagège et al. 2019). Because the 
underlying genetics and aetiology of the disorders are distinct, Fabry disease is regarded as an 
HCM phenocopy. 
 
In European HCM cohorts, approximately 1-5% of patients have been found to have GLA 
mutations (Adalsteinsdottir et al. 2014, Azevedo et al. 2019, Cecchi et al. 2017, Cecconi et al. 
2016, Havndrup et al. 2010, Jääskeläinen et al. 2019, Monserrat et al. 2007, Rubattu et al. 2016). 
Similarly, analysis of a cohort of Korean HCM patients revealed a GLA mutation rate of 4.6% (Seo 
et al. 2016). Fabry disease may therefore constitute an important contribution to HCM prevalence, 
particularly amongst individuals without known sarcomeric gene mutations (Havndrup et al. 2010). 




The prevalence of Fabry disease or GLA mutations in South African patients is unknown, although 
targeted sequencing of GLA and 14 other HCM genes in 43 South African HCM patients did not 
identify any pathogenic GLA mutations (Ntusi et al. 2016). Other investigations of HCM in South 
African patients have focussed primarily on the known HCM genes MYBPC3 and MYH7 
(Moolman, Brink, and Corfield 1993, 1995, Moolman-Smook et al. 1998, Moolman-Smook et al. 
1999, Posen et al. 1995). To the best of our knowledge, therefore, this is the first report of a GLA 
mutation in South African patients with unexplained left ventricular hypertrophy. 
 
The mutation identified in Family 2 was a 2 bp deletion resulting in premature protein termination 
and possible nonsense-mediated decay. This means that, rather than exerting a dominant 
negative effect, this mutation likely acts through haploinsufficiency of the GLA gene. Although 
missense mutations in GLA have been linked to the cardiac variant of Fabry disease 
(Adalsteinsdottir et al. 2014, Azevedo et al. 2019, Barman et al. 2019, Brito et al. 2014, Cecconi 
et al. 2016, Germain et al. 2018, Havndrup et al. 2010, Jääskeläinen et al. 2019, Oder et al. 2017, 
Pavlu et al. 2019, Valtola et al. 2020), similar truncating GLA mutations have been described in 
HCM previously, including splice site and nonsense mutations (Cecconi et al. 2016, Jääskeläinen 
et al. 2019, Juang et al. 2019, Militaru et al. 2018, Seo et al. 2016, Watanabe et al. 2013, Zhao et 
al. 2017, Liang et al. 2020), as well as the 2 bp deletion GLA c.718_719delAA (p.K240E*5) that 
was reported in an Italian HCM patient with atrial fibrillation and ventricular tachycardia (Cecconi 
et al. 2016). This mutation shows many similarities with the c.774_775delAC mutation found in 
Family 2; the same protein domain is disrupted, and the mutation carriers were noted to have 
arrhythmic phenotypes. Indeed, the cardiac variant of Fabry disease may frequently present with 
arrhythmias such as short PR interval, atrial fibrillation, ventricular tachycardia and sinus 
bradycardia (Azevedo et al. 2019, Brito et al. 2014, Cecchi et al. 2017, Havndrup et al. 2010, 
Monserrat et al. 2007, Poulin et al. 2015, Seo et al. 2016, Watanabe et al. 2013). 
 
The cardiac variant of Fabry disease is typically late-onset, presenting as unexplained left 
ventricular hypertrophy in middle-aged or older patients (Brito et al. 2018, Nakao et al. 1995). 
Both global left ventricular hypertrophy and asymmetrical septal hypertrophy (such as in 
sarcomeric HCM) have been observed in Fabry disease (Cecchi et al. 2017, Hagège et al. 2019, 
Nakao et al. 1995). It is thought that Fabry disease may mimic HCM through GLA mutations that 
do not completely disrupt GLA protein function: individuals with ‘classical’ Fabry disease have no 
detectable GLA activity, while the GLA protein in patients with the cardiac variant retains residual 
(approximately 10%) enzymatic activity (Brito et al. 2014, Eng et al. 1993, Hagège et al. 2019, 
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Oder et al. 2017, Smid et al. 2015). Due to the vast clinical heterogeneity of Fabry disease, 
distinguishing it from HCM can be challenging without CMR T1 mapping (Karur et al. 2018) or 
clinical genetic testing (Brito et al. 2014, Brito et al. 2018). However, identifying pathogenic GLA 
mutations in HCM patients can lead to a subsequent diagnosis of Fabry disease in these 
individuals. This has important implications for patient management, as antiarrhythmic drugs are 
unsuitable for Fabry disease and will not prevent arrhythmias or SCD (Acharya, Doppalapudi, and 
Tallaj 2015). Enzyme replacement therapy, in contrast, is available to rescue GLA function and 
may improve left ventricular hypertrophy (Weidemann et al. 2009, Yamamoto et al. 2019, 
Yogasundaram et al. 2017). 
 
3.3.4 Assessment of the pathogenicity of GLA c.774_775delAC 
 
According to the ACMG guidelines, the strongest evidence of pathogenicity is placed upon 
truncating variants in genes in which loss of function is known to cause disease (Richards et al. 
2015). The GLA frameshift mutation c.774_775delAC, identified in HCM patients in Family 2, is 
an example of such a variant. Similar truncating deletions have been reported in Fabry disease 
and HCM (Cecconi et al. 2016, Jääskeläinen et al. 2019, Juang et al. 2019, Militaru et al. 2018, 
Seo et al. 2016, Watanabe et al. 2013, Zhao et al. 2017); this, coupled with the absence of the 
variant in all population databases checked, provides very strong evidence that this is the 
causative mutation in this family. Although only two family members were screened in this 
investigation, this variant is classed as a pathogenic mutation using the ACMG criteria. 
 
3.4 Family 3 (DCM 3) 
 
3.4.1 Clinical history of Family 3 
 
Identified at GSH in 1997, Family 3 is a large family with DCM spanning two known generations 
(Figure 3.11). The family consists of four affected individuals, three of whom were brothers (III:6, 
III:8 and III:9). One of the brothers, individual III:6, died before the study began and could not be 
recruited. The fourth affected individual (IV:1) was the nephew of the other patients. DNA from 
the two brothers (III:8 and III:9) and their nephew (IV:1) was available in this study, as was DNA 







Figure 3.11: Pedigree indicating disease segregation in Family 3. Squares represent males and circles 
represent females. Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate 
affected individuals. Blue shading indicates DCM, green shading indicates diabetes mellitus and brown 
shading indicates obesity. No shading indicates that the individual has no reported conditions. Numbers in 
Roman numerals are the generation number while Arabic numerals denote individuals. The index case is 
indicated with an arrow. 
 
 
The clinical features of the participants varied and may be complicated by the comorbidities 
diabetes mellitus and obesity that affect some individuals in the family (Figure 3.11). The proband 
(III:9) and his brother (III:6) and nephew (IV:1) were all diagnosed with severe DCM with marked 
systolic dysfunction and NYHA class II - IV heart failure (Table 3.3). The age of diagnosis in these 
individuals was between 25 and 31 years, and they all received heart transplants. Individual III:8 
was diagnosed with milder DCM with a slightly dilated left ventricle and no heart failure at the age 
of 33 years. Despite this phenotypic variability, all affected individuals in the family have 
subsequently died due to their disease.  
 
The proband had three sisters who were screened and found to be phenotypically unaffected, 
despite mild left ventricular enlargement in two of them (Table 3.3). The third sister (III:2) was the 
mother of affected individual IV:1. Although other offspring of the affected individuals were 





Table 3.3: Clinical screening of Family 3 




ECG Echocardiography Clinical status 
III:2 40 None Sinus rhythm LVEDD 4.48 cm, FS 44% Normal 
III:3 38 None Sinus rhythm 
T wave inversion 
(V1) 
LVEDD 5.9 cm, FS 30%, 
slightly dilated LA, LV 
Mildly dilated, 
unaffected 
III:4 37 None Sinus rhythm 
T wave inversion 
(V1) 
LVEDD 5.3 cm, FS 34%, 
slightly dilated LV 
Borderline dilated, 
unaffected 
III:6 25 Dyspnoea 








LVEDD 7.7 cm, FS 11% 
LV dilated and poorly 
contracting, LA enlarged, 











LVEDD 5.4 cm, FS 24% 
No LV regional wall 




III:9 31 Dyspnoea 











IV:1 31 Dyspnoea 
NYHA class II 
Sinus rhythm 
 






IV:5 18 None Sinus rhythm - Unknown 
IV:6 12 None Sinus rhythm  
T wave inversion 
LVEDD 5.26 cm, FS 39%, 
normal heart 
Normal 
* Age at the time of diagnosis and/or screening  
DCM, dilated cardiomyopathy; ECG, electrocardiography; FS, fractional shortening; LA, left atrium; LV, left ventricle; 




3.4.2 Genetic analysis of Family 3 
 
Exome sequencing was conducted on individuals III:8, III:9 and IV:1, yielding a total of 69,110 
variants in these individuals. A mean sequence coverage of 144x was achieved in the three 
sequencing reactions. Considering X-linked or AD inheritance patterns, 21 variants met the 
filtering criteria (Figure 3.12; Appendix M) and were analysed further. Many of the variants were 
excluded due to low pathogenicity prediction or a lack of functional relevance to the heart 
(Appendix M). However, other heterozygous variants that were not present in all affected 
individuals were considered, to allow for the analysis of more complex inheritance patterns such 



























Figure 3.12: Filtering of exome sequencing data from Family 3. Exome sequencing produced a total of 
69,110 variants, of which 21 met the filtering criteria. CADD, Combined Annotation Dependent Depletion; 
gnomAD, Genome Aggregation Database; MAF, minor allele frequency  
 
 
3.4.2.1 Cardiomyopathy panel genes 
 
On the cardiomyopathy panel, two TTN variants and a single SYNE2 variant were found in all 
individuals (Table 3.4). The TTN variants were excluded due to a high MAF in ExAC and gnomAD 
sub-populations (East Asian population: MAF > 0.02 each), while the SYNE2 variant was 
predicted benign by all prediction tools, and the affected amino acid was not conserved in any of 
the tested species (Table 3.4). 
69,110 total variants
18,963 gnomAD MAF ≤ 0.01 
3,421 missense, splicing or 
truncating variant
259 inheritance pattern







Table 3.4: Candidate variants in Family 3 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
Cardiomyopathy panel – in all patients             
SYNE2 c.12001_12002inv p.W4001Q 0 0 0 0 NS B (0.99) NS B (0) 23.7 9.1 No 0/7 
TTN c.16529A>G p.Y5510C 0.007 0.002240 0.002213 0.00025 NS D (0.99) NS D (0.715) 21.0 67.7 Yes 3/7 
TTN c.76739C>T p.T25580M 0.005 0.001661 0.001618 0.00917 NS D (0.99) NS B (0.191) 22.2 67.7 Yes 5/7 
               
Cardiomyopathy panel – other patterns             
DSC2 c.2642T>A p.L881H 0 0 0 0 D (0.226) D (0.99) D (0) D (0.999) 31.0 5.6 Yes 7/7 
PKP2 c.2540T>C p.L847P 0 0 0 0 D (0.139) D (0.99) D (0) D (0.971) 26.8 84.1 Yes 7/7 
               
X-linked variants             
FAM104B c.331C>T p.R111* 0 0.000461 0.000034 0 NS B (0.98) NS NS 34.0 3.8 NA NS 
               
Other genes             
KCNK10 c.1052A>G p.N351S 0 0 0 0 D (0.046) D (0.99) B (0.2) D (0.997) 26.1 1.0 NA 7/7 
TRPV1 c.860C>T p.T287M 0.001 0.000504 0.000223 0.00086 D (0.035) D (0.99) D (0.1) D (0.999) 24.4 4.0 Yes 6/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 






When considering other inheritance patterns (i.e. variants not present in all three individuals), two 
variants of interest were identified on the cardiomyopathy panel. PKP2 c.2540T>C (p.L847P) was 
found in individuals III:8 and III:9, while DSC2 c.2642T>A (p.L881H) was detected in individual 
IV:1 only (Table 3.4). These variants were of interest because they were not detected in any 
population databases. PKP2 p.L847P was identified in this family previously (Mbele 2008). The 
presence of DSC2 p.L881H was confirmed (Figure 3.13) and segregation analysis of both variants 
performed (Figure 3.14). Because neither variant was present in all three affected individuals, 
they did not segregate with disease. The presence of DSC2 p.L881H in individuals IV:1, IV:6 and 
III:7 (Figure 3.14) led to the conclusion that individuals III:1 and III:7 may be biologically related. 
A single individual (IV:6) tested positive for both PKP2 p.L847P and DSC2 p.L881H; however, he 
was lost to follow-up and could not be contacted during the investigation. PKP2 p.L847P and 
DSC2 p.L881H were also predicted deleterious by all the pathogenicity prediction tools and 
affected highly conserved protein regions: all species either matched the human leucine residue 








Figure 3.13: Validation of DSC2 c.2642T>A identified in Family 3. (A) Sanger sequencing to confirm 
the presence of DSC2 c.2642T>A in affected individual IV:1 (indicated with an arrow), (B) Sanger 







Figure 3.14: Pedigree indicating segregation of DSC2 and PKP2 variants in Family 3. Individuals marked ‘PKP2 pos’ were heterozygous for the 
c.2540T>C variant and those marked ‘PKP2 neg’ tested negative for it, while individuals marked ‘DSC2 pos’ were heterozygous for the c.2642T>A 
variant and those marked ‘DSC2 neg’ tested negative for it. Genotypes in brackets were inferred based on the offspring and partners’ genotypes. 
DNA was not available for unmarked individuals. Squares represent males and circles represent females. Symbols that are crossed out indicate 
deceased individuals. Shaded symbols indicate affected individuals. Blue shading indicates DCM, green shading indicates diabetes mellitus and 
brown shading indicates obesity. No shading indicates that the individual has no reported conditions. Numbers in Roman numerals are the generation 




PKP2 pos; DSC2 neg PKP2 pos; DSC2 neg PKP2 neg; DSC2 pos 
PKP2 pos; DSC2 pos PKP2 pos; DSC2 neg 
PKP2 neg; DSC2 neg PKP2 pos; DSC2 neg PKP2 pos; DSC2 neg PKP2 
pos; DSC2 neg 




H. sapiens A S K A A S V L L Y S L W A H T E L H H A Y K 
M. mulatta A S K A A S V L L Y S L W A H T E L H H A Y K 
P. troglodites A S K A A S V L L Y S L W A H T E L H H A Y K 
F. catus A S K A A S V L L Y S L W A H T E L H H A Y K 
M. musculus A S K A A S V L L Y S L W A H T E L H H A Y K 
G. gallus A S K A A S V L L Y S L W A H T D L S H A Y K 
D. rerio A G Q A A C V L L H T L W R H S E L H S S F K 
X. tropicalis T G K A A S I V L Y S M W A H Q D L H S T Y K 
 
B 
H. sapiens G C C S E R Q E E D G L E F L D N L E P K F R 
M. mulatta G C C S E R Q E E D G L E F L D N L E P K F R 
P. troglodites G C C S E R Q E E D G L E F L D N L E P K F K 
F. catus G C C S E R Q E E D G L E F L D N L E P K F R 
M. musculus G C C S D L Q E E D G L E F L D H L E P K F R 
G. gallus G C C S D Q H E E E A L D F L D Q L E P K F R 
D. rerio G C C S I L G E Q E S M E F L N T L G P K F R 
X. tropicalis G C C S D F R D E D K M D F L N H L E P K F R 
 
Figure 3.15: Residue conservation of the DSC2 and PKP2 missense variants in Family 3. Multiple 
species conservation alignment of (A) the p.L547 residue of PKP2 (shaded in blue), and (B) the p.L881 
residue of DSC2 (shaded in blue). 
 
 
3.4.2.2 Other genes 
 
Two variants in genes outside the cardiomyopathy panel were also considered due to literature 
supporting their potential role in cardiomyopathy phenotypes (Table 3.4). The variants TRPV1 
c.860C>T (p.T287M) and KCNK10 c.1052A>G (p.N351S) were selected as candidates. TRPV1 
has been implicated in cardiac protection from ischaemia/reperfusion myocardial injury (Gao et 
al. 2015, Jiang et al. 2018, Sexton et al. 2007, Sun et al. 2014, Zhong and Wang 2007), sepsis-
induced dysfunction (Chen et al. 2018), overload-induced hypertrophy (Wang et al. 2014) and 
diabetes mellitus (Li et al. 2018, Wei et al. 2009, Zheng et al. 2015) in mouse and/or rat models. 
Expression of the gene has also been shown to be reduced in the hearts of rats with DCM (Smith 
et al. 2005). Given the potential role of TRPV1 in DCM and protection of the heart from diabetic 
injury, the gene was of interest as diabetes mellitus is a comorbidity in this family. However, the 
TRPV1 variant c.860C>T was not validated in the affected individuals (Figure 3.16). Interestingly 
though, the variant was found in the son of individual III:3 (not shown on pedigree) (Figure 3.16), 








Figure 3.16: Lack of validation of TRPV1 c.860C>T identified in Family 3. (A) Sanger sequencing 
shows the absence of TRPV1 c.860C>T in affected individual IV:1 (indicated with an arrow), (B) Sanger 
sequencing shows the homozygous variant in an unaffected family member (indicated with an arrow). 
 
 
KCNK10 encodes a stretch-activated two-pore-domain potassium channel, a class of proteins 
involved in the regulation of cellular excitability. Although not much is known about its function, 
KCNK10 expression has been demonstrated in the hearts of mice, zebrafish and humans, as well 
as other tissues (Gierten et al. 2012, Schmidt et al. 2017, Staudacher et al. 2011), and was 
recently reported as the second-most abundant stretch-activated two-pore-domain potassium 
channel in the heart, with predominant expression in the atria (Schmidt et al. 2017). Expression 
of KCNK10 was increased almost five-fold in patients with severe heart failure (Schmidt et al. 
2017), while antiarrhythmic drugs and beta-blockers have been shown to inhibit KCNK10 protein 
function in human cells and zebrafish larvae (Gierten et al. 2012, Kisselbach et al. 2014). The 
KCNK10 variant c.1052A>G (p.N351S) was absent in all population databases checked but was 
confirmed by Sanger sequencing to be present in the affected individuals in Family 3 (Figure 
3.17). It may therefore be a private mutation occurring only within this family. Segregation analysis 
indicated the variant was present in all affected patients as well as some unaffected individuals in 
the family (Appendix N). The missense variant occurred at an amino acid residue that is highly 









Figure 3.17: Validation of KCNK10 c.1052A>G identified in Family 3. (A) Sanger sequencing to confirm 
the presence of KCNK10 c.1052A>G in affected individual IV:1 (indicated with an arrow), (B) Sanger 
sequencing confirms the absence of the variant in unaffected individual IV:6 (indicated with an arrow). 
 
 
3.4.2.3 X-linked variants 
 
A single X-linked variant met the filtering criteria and was analysed (Table 3.4). The truncating 
variant FAM104B c.331C>T (p.R111*) was sufficiently rare to be considered disease-causing; 
however, the variant was predicted benign, probably because it only affects the terminal six amino 
acids of the protein. This variant was therefore not considered further. Because only males are 
known to be affected by disease in this family, X-linked inheritance is still a highly likely option.  
 
3.4.3 Discussion: PKP2 and DSC2 mutations as causes of DCM 
 
PKP2 and DSC2 both encode components of the cardiac desmosome. The desmosome mediates 
cell-cell adhesion and electrical coupling in cardiomyocytes, and mutations in these genes have 
traditionally been associated with ACM. Up to 60% of ACM patients carry mutations in 




The pathological basis of DCM is substantially more heterogeneous than ACM and may be at 
least partially attributed to desmosomal dysfunction. Several desmosomal mutations have been 
described in DCM patients who do not fulfil the Task Force criteria for ACM, including mutations 
in PKP2 and DSC2 (Elliott et al. 2010, García-Pavía et al. 2011, Klauke et al. 2017, Marston et 
al. 2015). In particular, a study of end-stage DCM heart transplant recipients reported that up to 
13% of cases may harbour ACM-causing or novel desmosomal gene mutations (García-Pavía et 
al. 2011), while the novel mutation PKP2 c.2035C>T (p.H697Y) was found in a large Turkish 
family with a history of DCM and heart transplant (Klauke et al. 2017). In the latter investigation, 
the PKP2 variant alone could not explain the DCM phenotype, and the authors suggest that 
additional genetic factors may be involved. 
 
These studies mirror the genetic findings in Family 3, in which novel missense mutations in PKP2 
and DSC2 were found. Although neither variant independently tracked with disease, all affected 
individuals carried either mutation. Both variants were absent in all population databases 
checked, but PKP2 p.L847P has been reported in another South African patient with ACM 
(Watkins et al. 2009). When it was first discovered in this family, PKP2 p.L847P was considered 
benign for DCM although pathogenic for ACM (Mbele 2008). However, the rarity of the variant 
combined with high sequence conservation and the presence of DSC2 p.L881H, a highly similar 
variant, in the family, means the significance of PKP2 p.L847P in this family should be 
reconsidered. With the exception of segregation with disease, both variants meet all criteria for 
pathogenicity. It is therefore possible that PKP2 p.L847P and DSC2 p.L881H do contribute to the 
DCM phenotype in this family. Of interest is individual IV:6, who was found to carry both mutations. 
Phenotypic analysis of this individual should indicate if these variants are indeed disease-causing; 
unfortunately, this participant is currently lost to follow-up. It is also probable that other factors are 
involved in this family, such as comorbidities that may worsen the cardiac phenotype, or other 
genetic mutations. 
 
Other genetic factors such as KCNK10 p.N351S and TRPV1 p.T287M were considered for their 
disease-causing potential in this family. Both genes were selected as candidates due to prior 
implications with cardiac function. However, the most likely inheritance pattern that would explain 
the disease segregation in this family is X-linked recessive inheritance. Because no candidates 
were identified on the X chromosome, any other inheritance pattern that is investigated will need 
to include incomplete penetrance. Therefore, while KCNK10 may be an interesting disease 
candidate in this family, its role in DCM pathogenesis cannot be elucidated based on segregation 
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analysis alone. The role of potassium channels such as KCNK10 in DCM in the absence of 
arrhythmic phenotypes is unclear at this stage. Due to the presence of two mutations in 
established cardiomyopathy genes in this family, the variation in KCNK10 may best be considered 
as a potential modifier of disease. 
 
3.4.4 Assessment of the pathogenicity of PKP2 c.2540C>T and DSC2 c.2642T>A  
 
In Family 1, the difficulty associated with the interpretation of missense variants in small families 
was discussed (Section 3.2.4). Similar limitations were observed in Family 3. Although more 
relatives were available for genetic analysis, the family only contained three affected patients, 
limiting the ability of segregation analysis alone to provide clarity regarding pathogenicity. Two 
ultra-rare mutations in the cardiomyopathy genes PKP2 and DSC2 were identified in this family, 
although neither segregated entirely with the disease phenotype (Figure 3.14). While these 
variants did not occur in mutational hot spots for cardiomyopathy, the close proximity of these 
variants to other known or likely disease-causing mutations should be noted (Table 3.6). These 
include truncating and missense mutations within the affected protein domains in Family 3, 
meaning that disruption of these protein domains may be sufficient to cause disease. In particular, 
the PKP2 c.2540T>C variant has been reported in two patients with ACM (Tayal et al. 2017, 
Watkins et al. 2009). However, nonsynonymous VUSs have been reported in these regions of 
DSC2 and PKP2 as well (data not shown); this indicates that interpretation of mutations in the 
affected domains of these proteins may be challenging. 
 
The absence of the PKP2 and DSC2 variants in large population studies, alone, is insufficient 
proof for their potential to cause disease. However, combined with computational predictions 
indicating the deleteriousness of the mutations and the evolutionary conservation of affected 
protein residues, there is moderate and supporting evidence that these mutations could contribute 
to the disease phenotype in this family. Following the ACMG criteria, these variants should be 
classified as VUSs at this stage. The possibility that other genetic factors (such as KCNK10 or 








Table 3.5: Reported mutations in the vicinity of the DSC2 and PKP2 variants in Family 3 
Mutation Protein domain(s) ClinVar status Source 
Reported DSC2 variants    
c.2186del (p.729fs*4) Desmosomal cadherin Pathogenic VCV000662906 
c.2200C>T (p.Q734*) Desmosomal cadherin Pathogenic VCV000568186 
c.2463C>A (p.Y821*) Desmosomal cadherin Pathogenic VCV000575762 








None Family 3 
    
Reported PKP2 variants    
c.2443_8delinsGAAA 
(p.N815fs*11) 
Armadillo repeat 5 Likely pathogenic VCV000188663 
c.2377del (p.S837fs*94) Armadillo repeat 5 Pathogenic VCV000177995 
c.2522T>C (p.S841F) Armadillo repeat 5 Likely pathogenic VCV000201966 
c.2531T>C (p.L844P) Armadillo repeat 5 Likely pathogenic VCV000201967 
c.2540T>C (p.L847P) Armadillo repeat 5 Uncertain significance 
Family 3; 
VCV000419976 
c.2554del (p.E852fs*79) None Pathogenic VCV000464426 
fs, frameshift; VCV, ClinVar accession number 
 
 
3.5 Chapter summary 
 
Although the allelic heterogeneity of familial cardiomyopathy has been characterised in 
international cohorts, this aspect of the disease has, to the best of our knowledge, not been 
reported in South Africa to date. In this chapter, three families are presented in which exome 
sequencing was used to identify potential causes of disease, and novel mutations were found in 
known cardiomyopathy genes. In particular, the finding of a pathogenic truncating GLA mutation 
in Family 2 resulted in the genetic re-diagnosis of those individuals with Fabry disease, an HCM 
phenocopy. Fabry disease and GLA mutations are frequently described in international HCM 
cohorts, representing between 1% and 5% of the total burden of HCM (Adalsteinsdottir et al. 
2014, Cecchi et al. 2017, Monserrat et al. 2007, Seo et al. 2016). However, this is the first report 
of a Fabry disease-causing mutation in South African HCM patients. This indicates that, although 
rare, Fabry disease may contribute to HCM phenotypes in South African patients, similar to 
observations in other populations. 
 
In Families 1 and 3, both of whom had DCM, missense mutations were identified in known ACM 
and HCM genes. These families may therefore illustrate the genetic overlap that is characteristic 
of heritable cardiomyopathy. The presence of both MYH7 and desmosomal gene mutations in 
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DCM patients has been reported elsewhere (Abdallah et al. 2019, García-Pavía et al. 2011, 
Sousa et al. 2019, van der Linde et al. 2017). However, like the GLA mutation in Family 2, this is 
the first description of such genotype-phenotype correlations in South African cardiomyopathy 
patients. To date, PKP2 mutations in South African patients have been limited to individuals 
diagnosed with ACM (Watkins et al. 2009), while MYH7 mutations have only been reported in 
HCM patients (Moolman, Brink, and Corfield 1993, Ntusi et al. 2016, Posen et al. 1995). Based 
on the genetic analyses, the MYH7 c.4394C>T mutation was classed as likely pathogenic, 
meaning that there is a high likelihood that this is the disease-causing mutation in Family 1 
(Richards et al. 2015). The desmosomal gene mutations in Family 3, in contrast, are VUSs even 
though they fulfil many of the criteria for pathogenicity. Further phenotypic characterisation of 
mutation carriers in this family may help in the resolution of the genetic uncertainty surrounding 
these variants, but the possibility that other genetic variation may play a role cannot be ignored. 
Although genes outside the cardiac panel were considered in all cases, the analysis of this family 
in particular illustrates how exome sequencing data can be used to detect candidate 
cardiomyopathy genes. The variant KCNK10 c.1052A>G was identified as a possible modifier of 
the disease phenotype in Family 3; nevertheless, the greatest pathogenic potential in this family, 
based on current evidence, still resides in the known cardiomyopathy gene mutations DSC2 
c.2642T>A and PKP2 c.2540T>C. 
 
The interrogation of exome sequencing data for potential new cardiomyopathy genes is most 
suitable in families where no mutations are found in the cardiac panel. The identification of 
candidate disease genes forms the basis of the next chapter, in which two such families are 




Chapter 4 Variants in novel cardiomyopathy genes as the possible cause of 




NGS is used to screen numerous genes simultaneously for genetic variation. This technology can 
be used in cardiomyopathy research to identify mutations within known cardiomyopathy genes, 
as described earlier (Chapter 3). However, exome sequencing also allows the exploration of 
genes that have not yet been associated with cardiomyopathy; this is particularly useful in patients 
in whom investigation of known disease genes has yielded no results. In this section, two such 
families are described. 
 
4.2 Family 4 (ACM 142) 
 
4.2.1 Clinical history of Family 4 
 
Family 4 was identified at GSH in 2015 (Figure 4.1). The proband, individual IV:2, was first 
diagnosed with definite ACM at the age of 50 years after being hospitalised following a traffic 
accident and suffering an in-hospital cardiac arrest (survived). He presented with classical 
features of arrhythmogenic right ventricular cardiomyopathy (ARVC), including major structural 
abnormalities of the right ventricle wall, repolarisation abnormalities, late potentials and recurrent 
ventricular arrhythmias, as well as marked left ventricular scarring on CMR. Gene panel testing 
conducted in the UK did not identify any pathogenic mutations in this patient. 
 
Subsequently, his sister (IV:4) suffered a SCD at the age of 43 years. Post-mortem examination 
of her heart found non-specific features of cardiomyopathy, including mild right ventricular 
dilatation with some fatty infiltration and interstitial and focal areas of fibrosis involving the 
ventricular walls and septum (similar to the proband). She was found to fulfil criteria for early-
stage ACM even though the macroscopic findings were not sufficient to confidently support a 
diagnosis of ARVC (morphometric analysis: adipose tissue 17.5%, fibrosis 10.2%, myocardium 
72.3%). Other first-degree relatives were then screened at GSH. Due to the positive family history 
of disease, clinical abnormalities on signal-averaged ECG and 24 hr-Holter, and patchy/diffuse 
left ventricular fibrosis on CMR, individual IV:3 (46 years) and the proband’s mother (III:2) (75 




The proband’s father (III:1), older brother (IV:1) and uncle (III:4) were clinically evaluated and 
found to be clinically unaffected with no late gadolinium enhancement on CMR. This, together 
with a history of suspected cardiac events (e.g. SCD) in several of the mother’s family members, 
suggests inheritance of the disease from the maternal side of the family. While ischaemic heart 
disease could not be convincingly excluded as a contributing factor in some of the sudden deaths 







Figure 4.1: Pedigree indicating disease segregation in Family 4. Squares represent males and circles 
represent females. Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate 
affected individuals. Purple shading indicates individuals diagnosed with ACM, while grey shading indicates 
sudden cardiac death. No shading indicates that the individual has no reported cardiomyopathy. Numbers 
in Roman numerals are the generation number while Arabic numerals denote individuals. The index case 
is indicated with an arrow. 
 
 
4.2.2 Genetic analysis of Family 4 
 
Exome sequencing was conducted on four affected family members (III:2, IV:2, IV:3, IV:4). In 
total, 51,341 variants were found in all four affected individuals and after applying additional filters 
and considering AD inheritance (Figure 4.2), 13 variants remained, occurring in 13 genes (Table 
4.1). None of the variants occurred in a known cardiomyopathy gene, meaning that the cause of 
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this heritable condition may be due to a mutation in another gene or more complex inheritance 



























Figure 4.2: Filtering of exome sequencing data from Family 4. Exome sequencing produced a total of 
51,341 variants, of which 13 met the filtering criteria. CADD, Combined Annotation Dependent Depletion; 





2,479 gnomAD MAF ≤ 0.01 
254 missense, splicing or truncating 
variant
187 inheritance pattern







Table 4.1: Candidate variants in Family 4 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
Other genes             
ADAL c.196T>G p.C66G 0 0.000008 0.000008 0 D (0.448) D (0.99) D (0.01) D (0.607) 29.4 6.2 No 6/7 
ATG2A c.2036G>T p.R679L 0 0.000093 0.000051 0 B (0.009) D (0.96) D (0.02) D (0.858) 23.3 6.5 NA 4/7 
DHTKD1 c.1079T>C p.V360A 0.001 0.003534 0.003349 0.00438 D (0.468) D (0.83) D (0) D (0.744) 24.1 7.3 No 4/7 
ENGASE c.1190C>T p.S397F 0 0.000351 0.000314 0.00031 D (0.098) D (0.99) D (0) D (0.839) 26.3 11.6 NA 4/7 
FPGS c.253C>T p.R85W 0.001 0.002434 0.002596 0.00246 D (0.123) D (0.99) D (0) D (1.000) 27.5 13.5 No 5/7 
GOLGA5 c.842G>A p.R281Q 0.001 0.002675 0.002912 0.00400 D (0.028) D (0.99) D (0) D (0.999) 31.0 10.7 No 7/7 
HEXB c.1250C>T p.P417L 0.001 0.000659 0.000588 0.00046 D (0.184) D (0.99) D (0.02) D (0.893) 22.2 27.6 No 5/7 
NDUFB1 c.257G>C p.R86P 0 0.000025 0.000047 0.00008 D (0.125) D (0.92) D (0.05) D (1.000) 26.5 119.0 NA 4/7 
POLG c.2492A>G p.Y831C 0.002 0.006277 0.007011 0.00785 NS D (0.99) B (0.17) D (0.995) 23.3 23.7 Yes 7/7 
RAD54L2 c.2845G>C p.E949Q 0 0.000757 0.000483 0.00077 D (0.085) D (0.99) B (0.06) D (0.979) 27.1 3.1 No 5/7 
SRPRA c.1448G>A p.G483D 0.002 0.005052 0.005423 0.00900 NS D (0.99) B (0.08) B (0.383) 28.0 41.8 NA 7/7 
SYMPK c.1844G>A p.R615H 0.003 0.007678 0.007384 0.00769 NS D (0.99) D (0.05) B (0.362) 23.7 10.5 No 6/7 
USP36 c.598C>A p.H200N 0.003 0.005148 0.004762 0.00646 NS D (0.99) B (0.11) B (0.192) 23.2 4.5 No 5/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 





The genes with the highest expression in the heart were HEXB, NDUFB1, POLG and SRPR 
(Table 4.1). Only the variants in HEXB, NDUFB1 and POLG were predicted deleterious by 
MutationTaster, SIFT and/or Polyphen, and were investigated further. HEXB c.1250C>T 
(p.P417L) and NDUFB1 c.257G>C (p.R86P) were both validated by Sanger sequencing, but 
these variants were also present in the unaffected older brother of the proband (IV:1) and 
therefore excluded (Appendix O). The POLG c.2492A>G (p.Y831C) variant (Figures 4.3 and 4.4), 
however, was present in all affected individuals within this family but was absent in the proband’s 
older brother and uncle, both of whom were confirmed clinically to have no signs of disease, on 
both ECG and CMR (Figure 4.5). This missense variant affected a highly conserved protein 
residue, as all species carry either a tyrosine or a phenylalanine residue at that position (Figure 
4.4B); both are large nonpolar amino acids (Zhang 2000). In addition, POLG was the only gene 









Figure 4.3: Validation of POLG c.2492A>G identified in Family 4. (A) Sanger sequencing to confirm the 
presence of POLG c.2492A>G in affected individual IV:4 (indicated with an arrow), (B) Sanger sequencing 













H. sapiens A L P R A V I R H P D Y D E E G L Y G A I L P 
M. mulatta A L P R A V I R H P D Y D E E G L Y G A I L P 
P. troglodites A L P R A V I R H P D Y D E E G L Y G A I L P 
F. catus A L P R A V T R H P R Y D E E G R Y G A I L P 
M. musculus A L P R V V T R H P S F D E E G H Y G A I L P 
G. gallus E L P R A V T R H P A Y S E E E D Y G A I L P 
D. rerio E L P R S V R L H Q D Y D E E G Q Y G A I L P 
X. tropicalis E L P R T I T R D P E Y D E E N K Y G C I L P 
 
Figure 4.4: POLG c.2492A>G identified in Family 4. (A) Protein structure of POLG with position of the 
p.Y831C mutation marked with an arrow, (B) Multiple species conservation alignment of the p.Y831 residue 




Figure 4.5: Pedigree indicating segregation of POLG c.2492A>G in Family 4. Individuals marked 
‘POLG pos’ were heterozygous for the variant and those marked ‘POLG neg’ tested negative for it. DNA was 
not available for unmarked individuals. Squares represent males and circles represent females. Symbols 
that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. Purple 
shading indicates individuals diagnosed with ACM, while grey shading indicates sudden cardiac death. No 
shading indicates that the individual has no reported cardiomyopathy. Numbers in Roman numerals are the 
generation number while Arabic numerals denote individuals. The index case is indicated with an arrow. 
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POLG neg POLG 
neg 
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neg 
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4.2.2.1 Possible genetic modifiers 
 
Due to the phenotypic variability in Family 4, additional genetic factors were considered in the 
proband (the only family member with ‘classical’ features of ACM) and his sister (IV:4; the only 
family member to suffer an SCD). Seven potential genetic modifiers were identified in the siblings 
(Table 4.2), both in known cardiomyopathy genes and putative genes that were characterised 
using the same criteria as before (Section 2.4.4).  
 
In the proband, three mutations were identified in the cardiomyopathy panel, including two 
truncating mutations in KCNH2 and KCNN3 that were false positives of exome sequencing. TTN 
mutations typically cause DCM, although overlaps with ACM and other arrhythmic phenotypes 
have been described (Brun et al. 2014, Corden et al. 2019, König et al. 2017, Kryczka et al. 2018, 
Lyu, Chen, and Xu 2018, Nielsen et al. 2018, Tayal et al. 2017, Taylor et al. 2011, Verdonschot 
et al. 2018). The missense mutation TTN c.24083G>C (p.G8028A) was identified in the proband 
and it was confirmed upon Sanger sequencing (Figure 4.6). However, this variant was also 








Figure 4.6: Validation of TTN variants identified in Family 4. (A) Sanger sequencing to confirm the 
presence of TTN c.3899A>G in affected individual IV:4 (indicated with an arrow), (B) Sanger sequencing 
to confirm the presence of TTN c.24083G>C in affected individual IV:2 (indicated with an arrow). 
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Table 4.2: Candidate genetic modifiers in Family 4 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
Present in proband (IV:2)             
KCNH2 c.2805delC p.S936P*38 0 0 0 0 NS D (1) NS NS 35.0 26.6 Yes 3/7 
KCNN3 c.202C>T p.Q68* 0 0 0 0 NS D (1) NS NS 36.0 0.4 No 4/7 
TTN c.24083G>C p.G8028A 0 0 0.000032 0 D (0.049) D (0.99) NS D (0.935) 23.1 66.8 Yes 1/7 
               
Present in SCD individual (IV:4)             
PXDNL c.2218C>T p.P740S 0 0.006198 0.005093 0.00508 NS D (0.89) D (0.01) D (0.995) 23.0 15.6 NA 2/7 
SORBS2 c.322T>C p.F108L 0.004 0.008899 0.009501 0.00754 NS D (0.99) B (0.49) B (0.448) 24.7 67.1 Yes 7/7 
TTN c.3899A>G p.Y1300C 0.0002 0.000017 0.000020 0 D (0.028) D (0.99) NS D (1) 23.0 66.8 Yes 0/7 
ZSCAN10 c.1253insC p.T419D*168 0 0 0 0 NS D (1) NS NS 22.5 0.01 Yes 3/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 






Four potential modifiers were present in individual IV:4 (Table 4.2). Like the proband, a missense 
TTN mutation was identified in this sibling. The other candidates were not in the cardiomyopathy 
panel but were prioritised based on their reported function or expression: PXDNL, a peroxidase-
like protein that is expressed only in cardiomyocytes and localises to the cell-cell junctions (Péterfi 
et al. 2014); SORBS2, an actin-binding Z-disk protein and cardiac regulator which is highly 
expressed in the heart and may play a role in myofibril structure and functioning as well as cardiac 
hypertrophy and diabetic cardiomyopathy (Bang et al. 2014, Fu et al. 2018, Rönty et al. 2005, 
Sanger et al. 2010, Shao, Chen, and Zheng 2018, Wang, Golemis, and Kruh 1997); and 
ZSCAN10, a transcription factor, knockout of which did not have significant effects on mouse 
heart functioning (Kraus et al. 2014). ZSCAN10 was therefore not investigated further. SORBS2 
c.322T>C was found only in the SCD individual and her mother (Figure 4.7; Appendix P). While 
the variants in PXDNL, SORBS2 and TTN variants were all confirmed by Sanger sequencing to 
be real (Figures 4.6 and 4.8), PXDNL c.2218C>T and TTN c.3899A>G were both identified in the 





Figure 4.7: Pedigree indicating segregation of SORBS2 c.322T>C in Family 4. Individuals marked 
‘SORBS2 pos’ were heterozygous for the variant and those marked ‘SORBS2 neg’ tested negative for it. DNA 
was not available for unmarked individuals. Squares represent males and circles represent females. 
Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. 
Purple shading indicates individuals diagnosed with ACM, while grey shading indicates sudden cardiac 
death. No shading indicates that the individual has no reported cardiomyopathy. Numbers in Roman 
numerals are the generation number while Arabic numerals denote individuals. The index case is indicated 
with an arrow. 
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Figure 4.8: Validation of PXDNL and SORBS2 variants identified in Family 4. (A) Sanger sequencing 
to confirm the presence of PXDNL c.2218C>T in affected individual IV:4 (indicated with an arrow), (B) 
Sanger sequencing confirms the absence of PXDNL c.2218C>T in individual IV:3 (indicated with an arrow), 
(C) Sanger sequencing to confirm the presence of SORBS2 c.322T>C in affected individual IV:4 (indicated 
with an arrow), (D) Sanger sequencing confirms the absence of SORBS2 c.322T>C in individual IV:3 







4.2.3 Discussion: POLG mutations as a putative cause of ACM 
 
The proband in Family 4 met several diagnostic criteria for a definite diagnosis of ARVC. However, 
the prominent phenotypic features amongst the affected family members were the presence of 
ventricular fibrosis and ventricular ectopy or arrhythmias, and the subsequent diagnosis of ARVC 
in other affected family members was mainly driven by the positive family history. The lack of 
classical pathological and histological findings of ARVC in these individuals supports a non-
specific ACM phenotype in the family. 
 
The genetic mutations that most frequently cause ACM are found in PKP2, DSC2, DSG2, JUP 
and DSP (Ohno 2016). These five genes encode components of the desmosome, a structure that 
maintains cell-cell adhesion between cardiomyocytes (Haugaa et al. 2016, Ohno 2016). The 
recent identification of disease-causing CDH2 mutations in ACM patients in South Africa means 
that the pathological site of ACM may extend beyond the desmosome to encompass the 
adherence junction of the intercalated disc (Mayosi et al. 2017). Mutations in other genes such 
as DES, PLN, CTNNA3 and RYR2 have also been implicated in ACM (Ohno 2016), expanding 
the scope of arrhythmia-causing mutations beyond the genes that code for the proteins of the 
intercalated disc. This indicates that genes that affect any aspect of cardiomyocyte functioning 
may play a role in the development of ACM. It was this class of genes that was considered for 
causative mutations in Family 4, as no mutations were found in desmosomal genes or other 
known ACM loci (Table 4.3). Instead, filtering of the exome sequencing data identified the POLG 
c.2492A>G variant as the possible disease-causing variant in this family. 
 
POLG encodes the catalytic subunit of mitochondrial DNA polymerase. As a mitochondrial 
protein, mutations in the gene have been associated with several conditions such as chronic 
progressive external ophthalmoplegia, Parkinson’s disease, skeletal myopathies and various 
syndromic phenotypes (Cohen, Chinnery, and Copeland 2018). In a case report, ultrastructural 
analysis of the heart tissue from a paediatric liver failure patient carrying two POLG mutations 
(p.A467T and p.K1191N) showed cardiac mitochondrial defects and an accumulation of lipids in 
the myocardium (Müller-Höcker et al. 2011). This was the first indication that germ-line mutations 






Table 4.3: Coding region variation in known ACM genes in Family 4 
Gene Variant Protein change Carriers gnomAD MAF  MT CADD 
CTNNA3 c.1787G>A p.S596N IV:2, IV:4 0.4130 B (0.99) 12.1 
DSC2 c.111A>G p.L37= III:2, IV:2, IV:3, IV:4 0.1133 B (0.99) 0.1 
DSC2 c.2326A>G p.I776V IV:4 0.1217 B (0.99) 10.1 
DSG2 c.861C>T p.N287= III:2, IV:2, IV:3, IV:4 0.4183 B (8.0-6) 3.2 
DSG2 c.887A>G p.F296C IV:2, IV:3 0 B (0.99) 23.0 
DSG2 c.2318G>A p.R773K III:2, IV:2, IV:3, IV:4 0.2604 B (0.99) 16.4 
DSG2 c.3321T>C p.V1107= III:2, IV:2, IV:3, IV:4 0.4296 B (1.6-9) 18.2 
DSP c.741T>G p.A247= III:2, IV:2, IV:3, IV:4 0.9993 B (1.6-7) 0.1 
DSP c.2091A>G p.G697= III:2, IV:2, IV:3, IV:4 0.7633 B (0.99) 7.9 
DSP c.2631G>A p.R877= III:2, IV:2, IV:3, IV:4 0.7702 B (1.6-24) 10.2 
DSP c.2862C>T p.C954= III:2, IV:2, IV:3, IV:4 0.2434 B (1.9-13) 10.4 
DSP c.5213G>A p.R1738Q III:2, IV:4 0.1750 B (0.99) 15.1 
DSP c.5498A>T p.E1833V IV:3, IV:4 0.009549 D (0.99)* 28.4 
DSP c.7122C>T p.T2374= IV:2, IV:3, IV:4 0.2862 B (9.5-16) 1.9 
DSP c.8472G>C p.G2824= IV:2, IV:3, IV:4 0.7095 B (3.7-18) 14.5 
JUP c.213T>C p.D71= IV:2, IV:3, IV:4 0.7176 B (4.6-22) 12.3 
JUP c.2089A>T p.M697L IV:2, IV:3, IV:4 0.6489 B (0.80) 15.7 
PKP2 c.1097T>C p.L366P III:2, IV:2, IV:4 0.1820 B (0.99) 13.5 
RYR2 c.2973A>G p.S991= III:2, IV:2, IV:3, IV:4 0.9240 B (1.7-15) 1.8 
RYR2 c.6906T>C p.L2302= III:2, IV:2, IV:3, IV:4 0.9877 B (1.4-17) 9.6 
RYR2 c.7806C>T p.H2602= IV:2, IV:3, IV:4 0.4778 B (2.8-17) 2.6 
RYR2 c.8873A>G p.Q2958R III:2, IV:2 0.2139 B (0.004) 22.6 
RYR2 c.9318T>G p.S3106= III:2, IV:2, IV:3, IV:4 0.9904 B (0.004) 0.7 
RYR2 c.10503C>T p.T3501= III:2, IV:2, IV:3, IV:4 0.9874 B (2.4-15) 2.8 
RYR2 c.10776C>T p.S3592= III:2, IV:2, IV:3, IV:4 0.9875 B (4.3-14) 0.04 
* Although predicted deleterious by MT, this variant was benign in ClinVar 
B, benign; CADD, Combined Annotation Dependent Depletion; D, deleterious; gnomAD, Genome Aggregation 




Investigation into animal models showed records of well-phenotyped mouse models with Polg 
mutations in the MGI database. The documented phenotypic effects of deficient Polg included 
dilated heart ventricles, increased heart weight and abnormal myocardial fibre morphology in Polg 
point mutation mice (Ross et al. 2013, Trifunovic et al. 2004), while a targeted transgenic mouse 
model recorded several cardiovascular phenotypes including cardiomyopathy, congestive heart 
failure, thickened ventricular walls and an enlarged heart. These transgenic mice, in which the 
point mutation Polg p.Y955C was targeted to the heart, were shown to develop significant cardiac 
defects including cardiomegaly, increased left ventricular mass and cardiomyocyte hypertrophy 
(Lewis et al. 2007). The phenotypic manifestations were attributed to mitochondrial dysfunction 
and increased oxidative stress. The enlargement of the heart in these animals is in keeping with 
the observed cardiac phenotype in individuals IV:2 and IV:4. Mice expressing the same mutation 
were later shown to have marked cardiac fibrosis, with a three-fold increase in scar tissue 
formation when compared to wild-type animals (Koczor et al. 2013). Again, this phenotype reflects 




The POLG c.2492A>G variant has been reported before. Mancuso et al. (2004) first associated 
the variant with mitochondrial DNA deletions in muscle sections from patients with familial 
Parkinson’s disease, ophthalmoplegia and neuropathy, and it has since been identified in patients 
with similar mitochondrial phenotypes (Wong et al. 2008, Woodbridge et al. 2013, Ylönen et al. 
2013). However, a contradictory study in 2008 detected the variant in 0.9% of the control 
population and considering certain European gnomAD sub-populations, it was reclassified as a 
VUS (Gui et al. 2012, Luoma et al. 2007, Wong et al. 2008). No other pathogenic mutation had 
been found in the family where the original POLG c.2492A>G variant was reported (Mancuso et 
al. 2004). In addition, no neurological or syndromic features were observed in Family 4. 
 
Collectively, the results of prior animal model studies of POLG make it a compelling candidate 
gene for cardiomyopathy in humans. Two prominent phenotypes observed in the affected family 
members in this study (cardiomyopathy and diffuse ventricular fibrosis) were also present in the 
transgenic mice (Koczor et al. 2013, Lewis et al. 2007). A previous project linked to this 
investigation identified an ultra-rare POLG VUS, c.3077G>A (p.R1026H) in another South African 
ACM proband (Booi 2017). This individual presented with cardiac arrest (survived), recurrent 
right-bundle-branch-block morphology ventricular tachycardias, and a DCM phenotype with 
biventricular dilatation and systolic dysfunction. While CMR was not performed in this patient, 
interstitial fibrosis was observed on endomyocardial biopsy. Although this phenotypic 
presentation is similar to the POLG variant carriers in Family 4, the c.3077G>A variant was 
classified as a VUS because no family members were available for segregation analysis. 
 
A possible limitation of this study is the choice of a MAF threshold of 0.01, as recent investigations 
have suggested that more stringent thresholds of up to 0.0001 may be beneficial due to the rarity 
of the disease (Tayal et al. 2017). The POLG c.2492A>G variant would not pass this MAF filter. 
However, POLG remains a viable candidate for several reasons, the most important of which is 
the work done in mice which supports the notion of POLG as a cardiomyopathy gene. With the 
exception of individual IV:4 who suffered a SCD, all carriers of the POLG c.2492A>G variant had 
sub-clinical forms of ACM, which was possibly exacerbated in the proband due to the car accident 
that led to his diagnosis with cardiomyopathy at the age of 50 years. The age of disease onset in 
this family ranged between 43 and 76 years, well above the average age of ACM onset of 33 
years (Bhonsale et al. 2015). It is plausible then that the disease-causing variant in this family 




Due to the identification of healthy PKP2 mutation carriers in ACM families, it has been proposed 
that digenic inheritance may be more prevalent in ACM than previously thought (König et al. 
2017). It may be that, in the present family, POLG c.2492A>G is coinherited with another 
pathogenic cardiomyopathy variant. However, despite rigorous screening of exome data from all 
four affected individuals, no other likely candidate was identified. Although it is possible that the 
true disease-causing variant may reside in intronic or intergenic regions of the genome (Harper 
et al. 2020), current knowledge of ACM genetics indicates that this is unlikely. Given that no other 
candidate mutation was evident upon analysis of all affected individuals, the potential role of 
POLG in the development of cardiomyopathy or arrhythmias was prioritised for functional 
investigation (Chapter 5). 
 
4.3 Family 5 (DCM 435) 
 
4.3.1 Clinical history of Family 5 
 
Recruited at GSH in 2016, Family 5 is a small, two-generation family of self-reported Congolese 
descent (Figure 4.9). The proband, individual II:3, presented with severe paediatric DCM at 16 
months and died by the age of 2 years. Both of his parents (I:1 and I:2) were screened in their 
fourth decades of life and found to be phenotypically normal. They had another son who was also 
affected with paediatric DCM and died before the study began (age 18 months), as well as a 
daughter who is unaffected but has not been recruited into the study as yet. The pattern of disease 
indicates that recessive or X-linked modes of inheritance are most likely: these and compound 




Figure 4.9: Pedigree indicating disease segregation in Family 5. Squares represent males and circles 
represent females. Symbols that are crossed out indicate deceased individuals. Blue shaded symbols 
indicate individuals diagnosed with DCM. No shading indicates that the individual has no reported 
cardiomyopathy. Numbers in Roman numerals are the generation number while Arabic numerals denote 
individuals. The index case is indicated with an arrow. 
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4.3.2 Genetic analysis of Family 5 
 
The trio of available individuals (I:1, I:2, II:3) was investigated using exome sequencing. The 
sequencing reaction generated 68,061 variants in total, at a mean sequence coverage of 136x. 
Of the 68,061 variants, 7 met the filtering criteria (Figure 4.10).  
 
No candidate X-linked variants were identified, while five AR variants and two compound 
heterozygous variants were found (Table 4.4). The recessive variants were largely predicted 
benign; the exceptions were the 4 bp insertion in ITPR2 that was much more common than VEP 
predicted, possibly due to annotation error, and the 4 bp deletion in LFNG. Although LFNG had 
reported cardiovascular phenotypes in knockouts, these were limited to the lung and/or retinal 
























Figure 4.10: Filtering of exome sequencing data from Family 5. Exome sequencing produced a total of 
68,061 variants, of which 7 met the filtering criteria. CADD, Combined Annotation Dependent Depletion; 
gnomAD, Genome Aggregation Database; MAF, minor allele frequency  
 
68,061 total variants
16,396 gnomAD MAF ≤ 0.01 
2,446 missense, splicing or 
truncating variant
76 inheritance pattern







Table 4.4: Candidate variants in Family 5 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
Autosomal recessive             
ITPR2 c.1409+2_3insGAGT - 0.710 0.652000 0.655100 0.36753 NS NS NS NS 35.0 1.5 No NS 
KIAA1671 c.1316A>G p.K439R 0 0 0 0 B (0.017) B (0.99) B (0.6) D (0.801) 22.3 2.5 No 3/7 
LFNG c.163_6del p.D55S*141 0 0 0 0 NS D (1) NS NS 21.6 2.3 Yes NS 
SH3BGR c.693_5dup p.E231dup 0 0 0 0 NS B (0.99) NS NS 22.7 58.4 NA NS 
TRMT13 c.142_3delinsAT p.A48M 0 0 0.000032 0 NS B (0.59) NS D (0.935) 22.9 3.7 NA 4/7 
               
Compound heterozygous             
ITGB5 c.146G>A p.C49Y 0 0.000247 0.000265 0.00062 D (0.120) D (0.99) D (0) D (1) 27.5 27.1 NA 6/7 
ITGB5 c.1929G>C p.E643D 0 0.000264 0.000272 0.00100 D (0.086) D (0.99) D (0.01) D (0.983) 26.0 27.1 NA 6/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 






The two compound heterozygous variants occurred in the gene ITGB5. They were predicted 
disease-causing by all pathogenicity prediction tools and affected highly conserved residues 
(Table 4.4). Although mouse knockout models have not yet been described for Itgb5, the gene 
was prioritised due to its potential role in several KEGG pathways relevant to cardiomyopathy, 
including focal adhesion, regulation of the actin cytoskeleton, integrin-mediated cell adhesion, 
ARVC, HCM and DCM (Kanehisa et al. 2019). A genome-wide association study of 10,898 
patients with coronary artery disease and 76,535 controls reported that variation in ITGB5 was 
associated with disease status and, together with other genetic risk factors, contributed to the risk 
of myocardial infarction, heart failure and cardiomyopathy (Verweij et al. 2017). The gene was 
also implicated in myocardial fibrosis and injury in a rat model of menopause, when 
cardioprotective agents were demonstrated to act at least in part through the down-regulation of 
left ventricular Itgb5 expression (Zhang et al. 2018). 
 
Two ITGB5 variants were identified in the proband. The maternally inherited c.146G>A (p.C49Y) 
and paternally inherited c.1929G>C (p.E643D) (Figure 4.11) both affect highly conserved protein 
residues in two distinct functional regions of the ITGB5 protein (Figure 4.12). Both variants were 




Figure 4.11: Pedigree indicating segregation of ITGB5 c.146G>A and c.1929G>C in Family 5. 
Individuals marked ‘c.146G>A pos’ and ‘c.1929G>C pos’ were heterozygous for those variants and those 
marked ‘c.146G>A neg’ and ‘c.1929G>C neg’ tested negative for them. DNA was not available for unmarked 
individuals. Squares represent males and circles represent females. Symbols that are crossed out indicate 
deceased individuals. Blue shaded symbols indicate individuals diagnosed with DCM. No shading indicates 
that the individual has no reported cardiomyopathy. Numbers in Roman numerals are the generation 






 c.146G>A neg; c.1929G>C pos c. 46G>A neg; c.1929G>C pos c.146G>A neg; 
c.1929G>C pos 
 c.146G>A neg; c.1929G>C pos c.1 G>A pos; c.1929G>C neg 














H. sapiens E C L L I H P K C A W C S K E D F G S P R S I 
M. mulatta E C L L I H P K C A W C S K E D F G S P R S I 
P. troglodites E C L L I H P K C A W C S K E D F G S P R S I 
F. catus E C L L I H P K C A W C F K E D F G S L R S V 
M. musculus E C L L I H P K C A W C S K E Y F G N P R S I 
G. gallus E C L L I H P K C A W C S K E E F G S T K S V 
D. rerio E C L L I H P S C A W C A Q E D F G Q A R T L 
X. tropicalis - - - - - - - - - - - - - - - - - - - - - - - 
 
C 
H. sapiens P D A C S T K D R C V E C L L L H S G K P D N 
M. mulatta P D A C S T K D R C V E C L L L H S G K P D N 
P. troglodites P D A C S T K D R C V E C L L L H S G K P D N 
F. catus P D A C S T K D R C V E C L L L H V G D P D N 
M. musculus P D A C S S K D R C V E C L L L H Q G K P D N 
G. gallus P G V C S T K D R C I E C K L F N S G R L D N 
D. rerio P D A C G T K R E C I E C R L F N T G R L D N 
X. tropicalis - - - - - - - - - - - - - - - - - - - - - - - 
 
 
Figure 4.12: ITGB5 c.146G>A and c.1929G>C identified in Family 5. (A) Protein structure of ITGB5 with 
position of the p.C49Y and p.E643D mutations marked with arrows, (B) Multiple species conservation 
alignment of the p.C49 residue of ITGB5 (shaded in blue), (C) Multiple species conservation alignment of 


























Figure 4.13: Validation of ITGB5 variants identified in Family 5. (A) Sanger sequencing to confirm the 
presence of ITGB5 c.146G>A in affected individual II:3 (indicated with an arrow), (B) Sanger sequencing 
confirms the absence of ITGB5 c.146G>A in individual I:1 (indicated with an arrow), (C) Sanger sequencing 
to confirm the presence of ITGB5 c.1929G>C in affected individual II:3 (indicated with an arrow), (D) Sanger 






4.3.3 Discussion: ITGB5 mutations as a putative cause of DCM 
 
Integrins are multifunctional transmembrane receptor proteins that are involved in cell signalling 
and cellular adhesion to the extracellular matrix (ECM). They are heterodimeric molecules, 
consisting of α and β subunits which can form up to 24 different combinations (Hynes 2002). In 
the myocardium, integrins play a role in focal adhesion, cell survival, mechanotransduction and 
remodelling of the actin cytoskeleton (Manso, Kang, and Ross 2009). They are also signal 
transducers, acting through downstream molecules such as integrin-linked kinase, extracellular-
signal related kinases and small GTPases (Hynes 2002, Wu and Dedhar 2001). Perturbation of 
myocardial integrin-actin signalling pathways has been linked to cardiac hypertrophy, fibrosis and 
the development of cardiomyopathy (Chen et al. 2016, Kubota et al. 2019, Manso et al. 2017, 
Nishimura et al. 2014, Quang et al. 2015, Valiente-Alandi et al. 2018). 
 
ITGB5 encodes the β5 subunit of integrin. The αVβ5 integrin heterodimer is expressed in the heart, 
where it binds fibronectin, osteopontin and vitronectin; expression of this dimer is reduced 
amongst heart failure patients (Manso, Kang, and Ross 2009). Although ITGB5 has not been 
associated with cardiomyopathy before, its expression in the heart, together with the documented 
role of integrins in normal cardiac function and development, means it is a plausible disease 
candidate for cardiomyopathy in Family 5. Indeed, the gene has been linked to other related 
phenotypes such as cardiomyopathy and heart failure in the context of coronary artery disease 
(Verweij et al. 2017), and cardiac fibrosis in the context of menopause (Zhang et al. 2018). 
 
The ITGB5 protein, like other integrin subunits, is composed of a large extracellular domain 
coupled to smaller transmembrane and cytoplasmic domains (Figure 4.12A) (Ross and Borg 
2001). The extracellular domain mediates contact with the ECM and other ligands; it is in this 
domain that both ITGB5 mutations in the proband were found. Because the affected protein 
residues are highly conserved (Figure 4.12B-C) and occur in known integrin β subunit signatures, 
it is possible that the mutations may affect contacts between cardiac cells and the ECM. Although 
intriguing, and no other candidate mutations in known DCM genes were identified in this family 
(Appendix Q), further research will be needed to elucidate the role of ITGB5 in the heart and the 






4.4 Chapter summary 
 
In this chapter, two families are described in which no disease-causing mutations were identified 
in known cardiomyopathy genes. Instead, variation in the putative new disease genes ITGB5 and 
POLG was found. These genes have never been associated with heritable cardiomyopathy in 
humans before. The ACMG guidelines used in the previous chapter, or any derivations from them, 
grade mutations according to their position within known disease-causing genes or observation 
in several unrelated patients (Richards et al. 2015). Therefore, these criteria cannot be used to 
judge potential novel disease genes in single families, as is the case here, although the in silico 
prediction of deleteriousness and high degree of evolutionary conservation seen for all variants 
is supportive of their pathogenic potential. 
 
The variants in ITGB5 and POLG should therefore be considered VUSs until further proof 
supporting or refuting their pathogenicity becomes available. Similarly, the modifying impact of 
the SORBS2 variant in ACM remains unclear at this stage. The utility of modelling cardiomyopathy 
in cell culture or animal models was discussed earlier (Chapter 1). These techniques may be 
particularly useful when variants have limited observations in small family settings where 
segregation analysis alone is not entirely informative. The functional exploration of POLG forms 
the basis of the next chapter, in which this gene and others are investigated using the in vivo 
zebrafish model (Chapter 5). Unfortunately, ITGB5 and SORBS2 were identified as possible 
















When examining the genetics of familial cardiomyopathy using exome sequencing, interpreting 
the pathogenicity of variants can be challenging. The identification of known disease-causing 
mutations in patients requires little clarification; however, as demonstrated in Chapters 3 and 4, 
known cardiomyopathy-causing mutations may not be found in patients, even when disease is 
ostensibly heritable. In some instances, novel mutations or unique genotype-phenotype 
relationships may be uncovered (Chapter 3), while the absence of mutations in any of the 
cardiomyopathy genes may lead to the identification of candidate genes (Chapter 4). In these 
cases, variants should ideally be validated in functional assays. 
 
As NGS becomes more available, it is likely that the need for functional assays will increase. This 
is particularly true in African patient populations, where the genetics of cardiomyopathy is largely 
unexplored. The Cardiovascular Genetics laboratory (HICRA, UCT) proposes to address the 
problem of variant validation using the zebrafish model. The zebrafish is an increasingly popular 
tool in cardiomyopathy research, offering the convenience of in vitro modelling but in a whole-
organism environment (Asnani and Peterson 2014). Although physiologically a much simpler 
animal than mice, zebrafish have been used to study numerous forms of cardiomyopathy to date, 
offering unique insights into the genetics of DCM, HCM and LVNC (Bainbridge et al. 2015, 
Dhandapany et al. 2014, Sasagawa et al. 2016, Zou et al. 2015). Due to the high-throughput 
potential of the zebrafish model, it looks to be a powerful tool in cardiomyopathy research when 
combined with NGS unbiased screening of the patient genome. 
 
5.2 Zebrafish CRISPR/Cas9 model 
 
5.2.1 Guide RNA synthesis 
 
SgRNAs were designed to target and disrupt the genes myh7, pkp2 and polg. All sgRNAs 
disrupted genes within the first exon; however, all disrupted at least 75% of the target genes 

















myh7 ENSDART00000192445 1 (37) 5,817 88.5% 97.4% 
pkp2 ENSDART00000035899 1 (13) 2,448 91.0% 91.0% 
polg ENSDART00000150129 1 (23) 3,621 87.0% 87.1% 
bp, base pairs; CDS, coding sequence; no., number 
 
 
The sgRNAs were determined to be of sufficient quality and quantity for use in injection 
experiments (Table 5.2). 
 
 
Table 5.2: Single guide RNA concentration and purity  
Gene target Concentration (ng/µl) 260/280 ratio* 
myh7 (8:16543250-16543273) 600.9 2.33 
pkp2 (4:17057073-17057096) 304.5 2.34 
polg (25:9339993-9340016) 2076.0 2.32 
* The 260/280 ratio was determined by spectrophotometry and was used to determine the RNA purity. 
µl, microlitre; ng, nanogram 
 
 
5.2.2 Characterisation of uninjected control zebrafish 
 
Controls in this experiment were uninjected zebrafish larvae from the same clutch as the embryos 
used for injection. The cmlc2:mCherry line was used, in which all cardiomyocytes express red 
fluorescence protein. Two-photon fluorescence image analysis of control zebrafish hearts at 3 dpf 
showed that the zebrafish ventricle is oval in shape, with prominent fluorescence along the 
ventricle walls (Figure 5.1). The atrium is not as visible due to the chosen plane of the microscope 







Figure 5.1: Multiphoton image of 3 dpf zebrafish uninjected control ventricle at end-diastole. Pictured 
is a cmlc2:mCherry transgenic zebrafish embryo at 32x magnification. Cardiomyocytes fluoresce red and 
were visualised at a laser wavelength of 720 nm.  
 
 
The uninjected cmlc2:mCherry ventricles were morphologically similar and used as a basis of 
comparison for the myh7, pkp2 and polg knockouts (Figure 5.2). There were overall significant 
differences in ventricle area (ANOVA, p < 0.001), length (ANOVA, p = 0.004) and thickness 
(ANOVA, p = 0.009) between the experimental groups (Figure 5.3), although only the area 
comparison was sufficiently powered (>80%) to detect significant differences as determined by 
post-hoc power calculations in which the observed effect size was assumed to reflect true 
variability (Appendix R). The ventricular area was directly correlated with chamber length for each 
group apart from the polg knockout larvae, but all groups displayed similar trends of association 
(Figure 5.4). Other numerical variables did not correlate (Appendix S). Each gene knockout will 
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Figure 5.2: Multiphoton images of 3 dpf zebrafish knockout and control ventricles at end-diastole. Fish 2 to 5 are represented for each group; 
the image for Fish 1 is included in each gene knockout subsection. Pictured are cmlc2:mCherry transgenic zebrafish embryos in control and gene 










Figure 5.3: Comparison of ventricular length, area and thickness amongst the experimental groups. 
The length (A), area (B) and thickness (C) are represented on each y-axis, while experimental groups are 
on the x-axis. Error bars indicate the standard error in each group (n = 5). Significance bars show the p-




Figure 5.4: Correlation of ventricular length and area amongst the experimental groups. The length 
is represented on the x-axis, while area is on the y-axis (n = 5 per group). The Pearson’s correlation 
coefficient is represented for each group (R), as is the significance of the relationship. 
 
 
5.2.3 Phenotyping and genotyping of myh7 knockout larvae 
 
The myh7 sgRNA achieved an average CRISPR activity of 48.4%, the lowest efficiency of the 
sgRNAs synthesised in this study (Appendix T). In addition, the majority of induced mutations at 
the cut site were non-frameshift mutations (Figure 5.5), meaning that these mutations were less 
likely to impair protein function. 
 
The knockout zebrafish hearts were largely structurally intact by 5 dpf, closely resembling those 
of uninjected control larvae (Figures 5.2 and 5.6). Although the effects of the mutations were mild, 
there was a slight increase in overall ventricular size amongst myh7 knockouts (Figure 5.3B). 
Human MYH7 is typically associated with HCM, and these findings may be consistent with this 
although there was no significant change in ventricle wall thickness (Figure 5.3C). In fact, only 
one outlier was identified when compared to uninjected controls, with marginally (26.1%) thinner 





Figure 5.5: Genotyping of zebrafish larvae injected with myh7 guide RNAs. The number of NGS reads 
with frameshift mutations (purple bars), non-frameshift mutations (grey bars) and no mutation (black bars) 
are depicted (y-axis) per larva (x-axis). Mutation rates are taken at the site of greatest insertion or deletion 








Figure 5.6: Multiphoton image of 3 dpf myh7 knockout Fish 1 ventricle at end-diastole. Pictured is a 
cmlc2:mCherry transgenic zebrafish embryo at 32x magnification, after treatment with myh7 knockout 







5.2.4 Phenotyping and genotyping of pkp2 knockout larvae 
 
A high CRISPR activity level was achieved with the pkp2 knockout sgRNA, with a mean efficiency 
of 78.6% across the larvae (Appendix T). However, similar to the myh7 knockout, a low level of 
frameshift mutations was observed, with non-frameshift insertions and deletions detected in the 
majority of genotyped calls (Figure 5.7). The most frequent genotype was a 9 bp non-frameshift 
deletion (Appendix T). 
 
Despite the low frameshift mutation rate, the pkp2 mutations had observable effects on the 
cardiac structure (Figures 5.2 and 5.8). The knockout led to a significant increase in ventricular 
thickness combined with a moderate, but significant, reduction in ventricle size (Figure 5.3). In 
the most extreme example of this (Figure 5.8), the ventricle was 62.2% smaller and 44.7% shorter, 





Figure 5.7: Genotyping of zebrafish larvae injected with pkp2 guide RNAs. The number of NGS reads 
with frameshift mutations (purple bars), non-frameshift mutations (grey bars) and no mutation (black bars) 
are depicted (y-axis) per larva (x-axis). Mutation rates are taken at the site of greatest insertion or deletion 








Figure 5.8: Multiphoton image of 3 dpf pkp2 knockout Fish 1 ventricle at end-diastole. Pictured is a 
cmlc2:mCherry transgenic zebrafish embryo at 32x magnification, after treatment with pkp2 knockout 






5.2.5 Phenotyping and genotyping of polg knockout larvae 
 
A mean CRISPR efficiency of 73.2% was achieved using the polg sgRNA (Appendix T). Very few 
non-frameshift mutations were detected; the majority of genotypes corresponded to frameshift 
insertions and deletions (Figure 5.9). The genotype that was most frequently observed was a    7 
bp deletion in the gene (Appendix T). 
 
The phenotypic effects of polg knockout were more consistent than in the other knockouts 
(Figures 5.2 and 5.10). The ventricles were significantly larger, longer and had thinner walls 
compared to uninjected control larvae (Figure 5.3). All the imaged larvae had ventricles that were 
outside the normal range for ventricle size, ranging from 100.3% to 192.5% greater than the mean 
uninjected control ventricle. In the most extreme case (Figure 5.10), in which the ventricle was 
192.5% larger than the control values, the ventricle was also 63.9% longer than expected, with 






Figure 5.9: Genotyping of zebrafish larvae injected with polg guide RNAs. The number of NGS reads 
with frameshift mutations (purple bars), non-frameshift mutations (grey bars) and no mutation (black bars) 
are depicted (y-axis) per larva (x-axis). Mutation rates are taken at the site of greatest insertion or deletion 







Figure 5.10: Multiphoton image of 3 dpf polg knockout Fish 1 ventricle at end-diastole. Pictured is a 
cmlc2:mCherry transgenic zebrafish embryo at 32x magnification, after treatment with polg knockout 








5.3 mRNA overexpression model 
  
5.3.1 Cloning and mutagenesis of POLG 
 
The entire protein-coding region of POLG was amplified by high-fidelity PCR (Figure 5.11). A 
band size of > 3 kb was obtained, as expected (POLG amplicon: 3.7 kb). Although non-specific 
PCR products < 1.5 kb and > 10 kb were observed, the PCR was not optimised as gel purification 




Figure 5.11: Image of PCR amplification of POLG cDNA. PCR products electrophoresed on a 1% (w/v) 
agarose gel. Lane 1 contains Quick-Load® 1 kb DNA ladder (NEB), and lanes 2-5, 7-9 and 11-13 contain 
PCR products. Lanes 6 and 10 are empty. The arrowheads denote the size of the DNA in the molecular 
ladder and of the POLG cDNA, in kilobases.  
 
 
The POLG coding sequence was successfully cloned into two out of ten plasmids (Figure 5.12), 
indicating a ligation efficiency of 20%. This was determined by the presence of a band of the 
expected POLG cDNA size (3.7 kb) as well as a band the size of the insert and PCS2+ vector, 
undigested (7.8 kb), occurring on the gel (Figure 5.12, lanes A3 and B2). The absence of the 
vector (4.1 kb) on the gel in lanes A3 and B2 could be due to partial digestion. However, the 
presence of the vector and insert in the colonies was confirmed by Sanger sequencing. The other 
eight colonies were transformed with PCS2+ vector without the insert, as indicated by single 
bands the size of PCS2+ (4.1 kb) on the gel (Figure 5.12, lanes A1, A2, A4, A5, B1, B3-5). 
 
3.0 kb       3.7 kb       





Figure 5.12: Image of restriction enzyme digestion of ligated plasmids. Digested products 
electrophoresed on a 1% (w/v) agarose gel. Lane 1 contains Quick-Load® 1 kb DNA ladder (NEB), and 
lanes A1-5 and B1-5 contain digested products. A and B refer to different plates from which colonies were 
picked. Lane 2 is empty. The arrowheads denote the size of the DNA in the molecular ladder and of the 
POLG cDNA, in kilobases.  
 
 
Plasmid A3 (Figure 5.12) was used as a template for site-directed mutagenesis and plasmid B2 
was kept as wild type POLG. The mutagenised plasmid A3 and wild type plasmid B2 were in vitro 
transcribed to produce mRNA for injection into zebrafish embryos (Figure 5.13). The site-directed 
mutagenesis reaction was confirmed to introduce the c.2492A>G single nucleotide change to the 






Figure 5.13: Image of mRNA for injection experiments. The in vitro transcription reaction products 
electrophoresed on a 1% (w/v) agarose gel. Lane 1 contains Quick-Load® 1 kb DNA ladder (NEB), lane 2 
contains mRNA from mutagenised plasmid A3 and lane 3 contains mRNA from unmutated plasmid B2. 
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Figure 5.14: Sequencing of the POLG region of site-directed mutagenesis. The electropherograms 
show (A) plasmid B2 in which POLG was not mutated (the wild type control plasmid) and (B) plasmid A3 in 




5.3.2 Injection optimisation 
 
In order to determine the optimal dose for comparing wild type POLG to mutated POLG, zebrafish 
embryos were first injected with wild type POLG at doses ranging from 25 pg to 200 pg. Although 
fish at all doses were developmentally normal within the first 5 dpf, a slight but significant reduction 
in heart rate was observed in larvae injected with 200 pg wild type POLG (Figure 5.15). No 




Figure 5.15: Wild type POLG mRNA dose analysis. Average heart rates in uninjected controls and 
injected larvae (at doses of 25 pg, 50 pg, 100 pg or 200 pg) are displayed. Experimental groups are on the 
x-axis while heart rate is on the y-axis. The distributions of heart rate in each group are represented by box-
and-whisker plots, in which the boxes delineate the upper and lower quartiles, and the whiskers indicate 
the minimum and maximum values. Lines within the boxes are the median values. Significance bars show 




5.3.3 Injection of mutant POLG 
 
A total of 135 zebrafish embryos were injected with mRNA carrying the POLG c.2492A>G variant. 
By 3 dpf, a proportion (16.3%) of the mutant POLG-expressing zebrafish had developmental 
deformities including cardiac oedema (14.8%), dorsalisation (5.9%) and/or body curvature 
(11.1%) (Figures 5.16 and 5.17). These were not observed in the injected or uninjected control 
zebrafish. The presence of developmental abnormalities was not the focus of this investigation, 
and cardiac oedema and dorsalisation may indicate non-specific effects of the injection itself on 
normal developmental processes, so the deformed fish were removed from subsequent analyses. 
 
A significant reduction in heart rate and function in POLG mutant zebrafish was observed 
compared to all controls (Figure 5.18). The distributions of heart rate did not differ amongst the 
control larvae (Kruskal-Wallis test, p = 0.940), but the heart rate was significantly lower amongst 
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the mutant RNA-injected zebrafish (Figure 5.18). This was observed over five separate replicates 
(Appendix U). Overall, the median heart rate was reduced by 22.2% in fish expressing mutant 
POLG compared to control zebrafish (p < 0.001). 
 
A            B       
     
 
Figure 5.16: Close-up view of zebrafish following injection experiments. Shown are bright-field images 
of POLG mutant zebrafish larvae at 4 dpf following injection of (A) 10 pg wild type POLG mRNA and (B) 10 
pg mutant POLG mRNA with resulting cardiac oedema (indicated with an arrowhead). Images were taken 
at 10X magnification. 
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Figure 5.17: Whole-body view of zebrafish following injection experiments. Shown are bright-field 
images of zebrafish larvae at 4 dpf after injection with POLG mutant mRNA. Larvae were exhibiting (A) 
cardiac oedema (indicated with an arrowhead), (B) dorsalisation (indicated with an arrowhead) and (C) 












Figure 5.18: Average heart rates in each experimental group. Experimental groups are on the x-axis 
while heart rate is on the y-axis. The distributions of heart rate are represented by (A) box-and-whisker 
plots and (B) violin plots. In A, the boxes delineate the upper and lower quartiles, and the whiskers indicate 
the minimum and maximum values. Lines within the boxes are the median values. Dots are used to show 
the distribution of variables in each group. In B, the area of the plot indicates the kernel probabliity denisity. 
Significance bars show the p-value the mutant mRNA injected group (n = 135) to each control group (n = 





In most of the experimental groups, the ventricle length and overall area were directly correlated, 
as may have been expected (Figure 5.19). Ventricular area also correlated with the width 
(Appendix V). Mutant zebrafish ventricles were significantly smaller compared to the controls 
(Figure 5.20A-C; Appendix W) (area: p = 0.002; length: p < 0.001), and the average blood flow 
activity was decreased in the mutant fish (p = 0.023) (Figure 5.20D). There were no significant 
differences in heart morphology or function in the water- or wild type mRNA-injected zebrafish 





Figure 5.19: Correlation of ventricular length and area amongst the mRNA experimental groups. The 
length is represented on the x-axis, while area is on the y-axis. The Pearson’s correlation coefficient is 




















Figure 5.20: Morphological measurements of mRNA-injected zebrafish larvae at 4 dpf. (A) Mean 
ventricle area, (B) mean ventricle width, (C) mean ventricle length, (D) mean flow rate in both POLG mutant 
(n = 20) and control (n = 16) zebrafish. Only larvae with clear images of the heart were included in these 
analyses; one statistical outlier was removed from the control group in the analysis of blood flow (n = 15). 
Controls were embryos injected with wild-type POLG mRNA. The injection groups are on the x-axes while 
the morphological measurements are on each y-axis. Significance bars show the p-value when comparing 




5.4 Discussion: zebrafish models of cardiomyopathy 
 
In this chapter, CRISPR was used to target and disrupt the zebrafish orthologues of two known 
cardiomyopathy genes (myh7 and pkp2), as well as the candidate ACM gene polg. Due to lengthy 
image acquisition times, a total of five larvae were imaged per experimental group. As a result, 
this study was mostly underpowered to perform intergroup comparisons (Appendix R). However, 
despite the small sample sizes, cardiomyopathy phenotypes could be distinguished in some 
cases. It should be noted that correction for multiple statistical testing was not performed in this 
investigation, and that the CRISPR results still require replication in an independent experiment.  
 
POLG was identified as a putative cardiomyopathy gene in a South African family with ACM 
(Chapter 4). The clinical significance of the gene is unknown, and although mutations in POLG 
have been associated with a wide variety of disorders including Parkinson’s disease and skeletal 
myopathy (Cohen, Chinnery, and Copeland 2018), POLG genetic variation has not been 
associated with cardiomyopathy to date. All polg mutant larvae in this investigation had 
significantly larger ventricles compared to control zebrafish, with significantly thinner walls. The 
reduction in wall size may indicate myocyte cell death in the region, a hallmark feature of ACM; it 
may alternatively indicate developmental problems in the larval heart. Regardless of the cause, 
these deviations from normal in the mutant larvae indicate that polg may play a role in the 
morphological development of the zebrafish heart. Disruption of polg by TALENs has been 
described, although the cardiovascular effects were not investigated or reported on (Rahn et al. 
2015). What is noteworthy is that these homozygous polg mutants survived up to three weeks, 
meaning that stable mutations could perhaps be studied for longer periods if desired. 
 
Because of the uncertainty surrounding the interpretation of zebrafish phenotypes of 
cardiomyopathy, knockouts of the well-established cardiomyopathy genes myh7 and pkp2 were 
included. Human MYH7 is traditionally an HCM gene, although can be associated with DCM in 
human patients, as demonstrated in Chapter 3. There were no drastic effects of myh7 knockout 
in zebrafish, although the ventricular area was increased in all larvae, and one larva had thinner 
ventricular walls than expected; these are DCM characteristics. In a study by Auman et al, the 
described zebrafish mutant haf carries a stable, recessive truncating myh7 mutation: the lack of 
myh7 in this line was shown to cause ventricular distension and enlargement, as well as 
contractility defects (Auman et al. 2007). The relatively mild phenotypic effects in the present 
study are possibly due to the large number of non-frameshift insertions and deletions that this 
123 
 
CRISPR reaction produced (Appendix T), or may be due to other MYH7 orthologues such as 
myh7l present in zebrafish that may compensate for the gene disruption (Shih et al. 2015). 
Similarly in mice, predominant expression of myh6 in the ventricles means that it is not an 
appropriate model for studying myh7-related cardiomyopathies (Duncker et al. 2015, Lompré, 
Nadal-Ginard, and Mahdavi 1984); it may be that both myh7 and myh7l need to be targeted in 
zebrafish to induce a myocardial phenotype, although the results of prior myh7 disruption in 
zebrafish do not support this (Auman et al. 2007). Indeed, the pkp2 CRISPR reaction also resulted 
in largely non-frameshift insertions and deletions generated in embryos; the phenotypic 
consequences, however, were more severe. PKP2 only has one zebrafish orthologue and is a 
desmosomal gene associated with ACM in humans. Targeting the gene in this study led to thicker 
ventricle walls and smaller, misshapen ventricle chambers. In previous reports, morpholino 
knockdown of pkp2 in zebrafish led to, in the severest case, cardiac oedema, blood pooling and 
small, abnormally developed ventricles (Moriarty et al. 2012). Because a fluorescent transgenic 
line was used in this experiment, blood flow and oedema were not measured in the mutant 
zebrafish; however, the finding of smaller, deformed ventricles is in keeping with the pkp2 
knockdown study (Moriarty et al. 2012). 
 
There are two important limitations of the CRISPR technique used here. Firstly, the use of an 
uninjected control is not preferable as it does not eliminate the potential non-specific effects of 
the injection itself on embryonic development. Rather, an injection control would allow delineation 
that the observed effects may be due to the gene knockout itself. Although there is no gold 
standard for CRISPR injection controls as yet, examples that may be suitable include sgRNA 
without Cas9 (or vice versa), a scrambled sgRNA which is composed of the same nucleotides but 
in a different order, or sgRNAs that target different regions of the gene (Masselink 2021). A second 
limitation is that different genotypes were generated in the F0 generation. Ideally, mutant 
zebrafish should be bred over two or three generations to produce stable knockouts with no off-
target effects. The benefit of this approach is that single mutations can be compared. However, 
this was not possible due to high embryonic lethality of the mutations, especially amongst the 
polg knockout group. Therefore, while some of the embryos were observed to develop signs of 
cardiomyopathy phenotypes in this pilot investigation, it cannot be said with certainty that these 
are not non-specific effects of the microinjection. As discussed above, conditional knockouts may 
be more suitable; other techniques that may remedy this are ‘knock-in’ CRISPR reactions or 
mRNA overexpression. CRISPR knock-in utilises homology-directed repair mechanisms to 
incorporate a repair template carrying a desired mutation into the zebrafish genome, as opposed 
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to the nonhomologous end-joining approach used in this study. The knock-in approach is currently 
limited by extremely low efficiency, although factors such as the donor template length and type 
of donor DNA may be optimised (Collery and Link 2019, Eschstruth, Schneider-Maunoury, and 
Giudicelli 2019); successful approaches may still require hundreds to thousands of zebrafish bred 
over several generations (Zhang, Zhang, and Ge 2018). The overexpression of mRNA is a 
comparatively simple technique and was explored in more detail in analysis of POLG c.2492A>G. 
 
The POLG c.2492A>G variant was found in a South African family with ACM, after exome 
sequencing and the identification of no variants in known cardiomyopathy genes (Chapter 4). The 
variant was found in four affected individuals with a variable disease phenotype. Due to ambiguity 
in the literature regarding the role of POLG in cardiomyopathy, and the lack of any other genetic 
candidate in this family, this variant was selected for functional investigation to determine if the 
disease seen in Family 4 could be recapitulated variant in zebrafish. 
 
The previous CRISPR/Cas9 knockout model was suggestive that zebrafish polg may play a role 
in heart development and/or functioning (Section 5.2.5). However, the model was restricted to five 
larvae due to the imaging technique used and was also limited due to genotypic heterogeneity 
between mutant zebrafish. In the mRNA overexpression model, however, light microscopy was 
used to visualise the hearts of the larvae, meaning that substantially more zebrafish could be 
analysed, reaching statistically significant numbers (Appendix R). Because mutagenised mRNA 
was used instead of CRISPR/Cas9-mediated gene disruption, the genotypic heterogeneity within 
experimental groups was reduced. Potential limitations of this technique are that gene 
overexpression may not mimic physiologically relevant levels of mRNA, and the endogenous 
expression of zebrafish polg is not abolished. In addition, when injecting human mRNA into 
zebrafish embryos, the stability and function of the resulting protein may be compromised (Becker 
et al. 2003), for example due to differing physiological conditions between the species. For these 
reasons, several control groups were established, and a dose-response analysis was performed 
to identify the dose at which wild type POLG will not induce significant cardiac dysfunction in 
zebrafish. Due to the reduction in mRNA concentrations over time, the model is limited to the first 
few days of development and therefore cannot be used to model adult zebrafish; however, other 
successful recapitulations of ACM phenotypes have been achieved within 2-4 dpf (Giuliodori et 
al. 2018, Heuser et al. 2006, Martin et al. 2009, Moriarty et al. 2012), so the analysis of larvae at 




Expression of the mutation in zebrafish larvae induced several cardiac effects suggestive of 
arrhythmia and cardiomyopathy. Extracardiac phenotypes such as dorsalisation and body 
curvature were also observed, but these were not the focus of this investigation. In comparison 
to siblings expressing the wild type form of the gene, larvae expressing mutant POLG developed 
smaller hearts with a slower heartbeat and reduced cardiac output, suggesting an overall 
reduction in heart function. Similar results have been described following mutation of other ACM 
genes in zebrafish. A reduced heart rate and size were reported in jup mutant zebrafish (Martin 
et al. 2009), while dsc2, dspa and dspb null fish had lower heart rates (Heuser et al. 2006, 
Giuliodori et al. 2018), and morpholino knockdown of pkp2 in zebrafish resulted in smaller 
ventricles, reduced blood flow as well as body curvature (Moriarty et al. 2012). Unfortunately, the 
ventricular thickness could not be measured because of the strain of zebrafish used. 
 
In Chapter 4, the results of prior animal model studies of POLG were discussed. Two prominent 
phenotypes observed in the affected family members in this study (cardiomyopathy and diffuse 
ventricular fibrosis) were also present in transgenic mice expressing Polg point mutations (Koczor 
et al. 2013, Lewis et al. 2007). However, arrhythmias have never been reported in Polg mutant 
animal models. To our knowledge, this may be the first evidence that POLG could play a role in 
arrhythmia phenotypes in both humans and zebrafish. Zebrafish hearts are capable of 
regeneration following cardiac injury, and therefore undergo limited, transient fibrosis (Sánchez-
Iranzo et al. 2018). The fact that expression of POLG p.Y831C in zebrafish could recapitulate, at 
least in part, the disease phenotype seen in Family 4 suggests that, although additional genetic 
factors may play a role in disease expression, POLG p.Y831C is a likely disease-contributing 




Chapter 6 Conclusion and future perspectives 
 
6.1 Principal findings 
 
Cardiomyopathies are rare disorders of the myocardium that constitute an important cause of 
heart failure, arrhythmias and sudden death. They frequently present as heritable disease, but 
many causative genes are yet to be identified. The aims of this study were to investigate the 
genetics of familial cardiomyopathy using exome sequencing, and to establish methods of 
functional validation. Using these techniques, pathogenic or likely pathogenic mutations were 
identified in two out of five families studied, while three VUSs with moderate or strong pathogenic 
potential were identified in two other families (Figure 6.1). This study illustrates the benefits and 





Figure 6.1: Summary of the genetic findings in this investigation. Pie chart in which red slices indicate 
pathogenic variants (P), orange slices indicate likely pathogenic variants (LP) and blue slices indicate VUSs 
with strong or moderate evidence of pathogenicity. Grey slices indicate VUSs. Pathogenicity as described 
by ACMG criteria (Richards et al. 2015). ACMG, American College of Medical Genetics and Genomics; 
LOF, loss-of-function; VUS, variant of uncertain significance 
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The pathogenic and likely pathogenic mutations, GLA c.774_775delAC (Family 2) and MYH7 
c.4394C>T (Family 1), were both novel mutations in known disease-causing genes. The 
identification of these variants as causative of HCM phenocopy and DCM, respectively, indicates 
an allelic heterogeneity of cardiomyopathy that has not been described in South African patients 
to date. In addition, two desmosomal gene VUSs were found in a family with DCM (Family 3): 
although desmosomal gene mutations have been reported in DCM patients before, their 
contribution to DCM is unclear at this stage, and neither variant segregated entirely with disease 
despite fulfilling many other pathogenicity criteria (absence in population databases, evolutionary 
conservation and in silico prediction of pathogenicity). Oligogenic or more complex inheritance 
patterns may underly the phenotypic manifestations in Family 3, and more research is needed to 
resolve the roles of the VUSs identified in these individuals. 
 
Exome sequencing is well suited for the identification of candidate disease genes, which was 
necessary in Families 4 and 5 where no mutations were identified in known cardiomyopathy 
genes. Variants of interest were found in the candidate genes ITGB5 and POLG; however, 
proving the disease-causing potential of candidate genes is challenging based on literature 
searches alone, especially in the absence of additional reported mutation carriers (as was the 
case for ITGB5), or conflicting reports of variant pathogenicity (as was the case for POLG). While 
ITGB5 was identified as a candidate too late for functional investigation, POLG variation was 
modelled using CRISPR/Cas9 knockout and mRNA overexpression in zebrafish larvae. The 
results of CRISPR knockout suggested that polg may play a role in cardiac development, while 
overexpressing mutant POLG mRNA in zebrafish larvae led to signs of arrhythmia. As the 
cardiomyopathy seen in Family 4 was characterised by arrhythmia and left ventricular fibrosis, 
these results suggest that POLG variation could well contribute to the disease phenotype 
observed in this family. 
 
This study also identified two potential genetic modifiers, SORBS2 c.322T>C and KCNK10 
c.1052A>G, in ACM and DCM families respectively. Genetic modifiers are variants that, when 
inherited with a disease-causing mutation, can affect the expressivity or penetrance of the 
mutation, and may account for phenotypic variability that is observed in some families or between 
unrelated mutation carriers. As with candidate disease genes, proving their modifying potential 
may require functional investigation even though both SORBS2 and KCNK10 have documented 
roles in cardiac function. Genetic modifiers have been documented in heritable cardiomyopathies, 
particularly HCM and DCM, where they can comprise rare, deleterious variants that are co-
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inherited with known disease-causing mutations (Long et al. 2015, Lopes et al. 2015) or common 
polymorphisms in cardiovascular genes that associate with disease severity or outcomes in 
mutation carriers (Kumar et al. 2018). Similar modifiers have been demonstrated in South African 
HCM patients, in which AGTR1 and MYBPH polymorphisms were shown to associate with the 
degree of cardiac hypertrophy (Carstens et al. 2011, Mouton et al. 2016). Therefore, the role of 
modifying variants such as those in SORBS2 and KCNK10 could be further explored, as more 
evidence will be needed to determine the true role of these variants in disease. It should also be 
noted that in these families, only rare mutations were considered as modifiers due to the current 
bioinformatic challenges in analysing variants of low impact. 
 
6.2 Practical implications 
 
Current guidelines for the diagnosis and management of DCM, HCM and ACM from the ESC, 
American Heart Association and Heart Rhythm Society recommend the construction of a detailed 
family history (usually at least three generations), periodic clinical screening of first-degree 
relatives by echocardiography and ECG, and genetic testing in the case of familial disease 
(Bozkurt et al. 2016, Elliott et al. 2014, Gersh et al. 2011, Pinto et al. 2016, Towbin et al. 2019). 
This approach allows at-risk family members to be identified and, when disease-causing 
mutations are found, cardiac follow-up can be guided by the presence of the mutation in family 
members. While such international guidelines are typically subscribed to amongst African 
cardiology societies, limited resources as well as incomplete knowledge of the genetics of 
cardiomyopathy in Africa means that genetic testing is unlikely to be routinely applied in these 
settings. However, given the familial implications of cardiomyopathies, it may be advisable to 
obtain a family history from index cases and consider genetic testing in the instance of a family 
history of CVD. 
 
Because targeted sequencing can be used to accurately screen numerous cardiomyopathy genes 
in a single experiment, NGS panels are becoming routinely incorporated into the diagnosis of 
heritable cardiomyopathy in some countries (Martin et al. 2019), although there is a degree of 
uncertainty about the disclosure of VUSs to patients (Vears, Sénécal, and Borry 2017). 
Nevertheless, the increasing availability of NGS panels means that it now may be considered 
more cost-effective to conduct genetic testing on asymptomatic family members than to 
phenotypically screen them (Catchpool et al. 2019, Ingles et al. 2012). This means that, if a patient 
is found to carry a disease-causing mutation, this could allow clinical follow-up to be limited to 
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relatives who also carry the mutation and thus release asymptomatic non-carriers from regular 
screening. However, in order to realise these benefits of genetic testing, a better understanding 
of the genetics of cardiomyopathy in Africa is crucial. 
 
An objective of the IMHOTEP project is to test the applicability of an international 48-gene 
cardiomyopathy panel in South African and Mozambiquan cardiomyopathy patients (Kraus 2019). 
No large-scale genetic analysis of African cardiomyopathy patients has been conducted to date, 
and this ongoing research will be essential in determining, firstly, whether genetic testing should 
be routinely performed in South African cardiomyopathy patients and, secondly, if panel 
sequencing or exome sequencing should be the primary testing platform used in African 
cardiomyopathy. Both NGS platforms, while carrying increasingly similar costs (Mazzarotto, 
Olivotto, and Walsh 2020), have advantages and limitations (Chapter 1). If panel testing of the 
IMHOTEP cohort yields a mutation rate that is similar to the populations on which the panels were 
based, this will indicate that panel testing of African cardiomyopathy patients may be warranted 
in the clinical setting, especially when familial disease is observed. Two sequencing studies of 
African cohorts have been conducted using sarcomere gene panels, comprising a total of 80 HCM 
patients from South Africa and Tunisia; both studies reported mutation yields less than 30% 
(Jaafar et al. 2016, Ntusi et al. 2016). These figures are considerably lower than the yield of 
approximately 50% for HCM reported internationally (Marian and Braunwald 2017), although the 
larger patient cohort in IMHOTEP (target recruitment of 750 patients) and larger gene panel used 
may lead to greater mutation rates. 
 
Previous research conducted in African patients suggests that the genetic basis of 
cardiomyopathy, while underexplored (Shaboodien et al. 2020), may differ slightly compared to 
other populations, with a high proportion of founder mutations as well as many novel, previously 
unreported variants occurring in established cardiomyopathy genes (Moolman-Smook et al. 1999, 
Moolman-Smook et al. 1998, Mouton et al. 2015, Ntusi et al. 2016, Watkins et al. 2009). Given 
the lower yield of genetic testing reported so far, it is likely, too, that additional disease-causing 
genes are yet to be discovered in the African patient population. This is reflected by the results of 
this study, in which novel mutations were found in three out of five families, and candidate genes 
identified in the other two families. There is therefore much scope for future research into the 





6.3 Future perspectives 
 
6.3.1 Genetic studies of African cardiomyopathy 
 
Although the field of genetic research into cardiomyopathy has been considerably broadened 
through the advent of NGS technologies such as exome sequencing (Chapter 1), NGS has had 
limited utility in Africa so far. To our knowledge, there have only been six reports of NGS in African 
cardiomyopathy patients or families: four studies used targeted sequencing (Adadi et al. 2018, 
Choung et al. 2017, Jaafar et al. 2016, Ntusi et al. 2016), and two used exome sequencing 
(Lahrouchi, Behr, and Bezzina 2016, Mayosi et al. 2017), one of which reported the novel ACM 
gene CDH2 (Mayosi et al. 2017). Aside from NGS, few candidate gene investigations have been 
described in Africa (Shaboodien et al. 2020). It is perhaps unsurprising then that little is known 
about the genetics of inherited cardiac diseases in African patients. This may be remedied through 
NGS studies, as discussed above, although variant interpretation is a matter for some 
consideration. 
 
Internationally accepted pathogenicity criteria emphasise loss-of-function or de novo mutations in 
known disease-causing genes when previously established pathogenic variants are not identified 
(Richards et al. 2015). Given the genetically unique African population, one may expect that many 
cardiomyopathy patients will not harbour reported pathogenic mutations; the results of this 
investigation support this notion. The next levels of evidence for pathogenicity, according to 
ACMG guidelines, are functional studies and segregation in multiple (preferably more than seven) 
family members (Kelly et al. 2018, Richards et al. 2015). This stresses the need for large family 
studies and/or well-established functional models of cardiomyopathy, which may be challenging 
to perform in Africa. In this study, the families were relatively small, ranging in size from one to 
four affected individuals. It may be that different pathogenicity criteria are needed in Africa, 
although the stringency of international guidelines reflects the recent finding that previously 
published mutations may not be disease-causing in light of modern, large-scale NGS population 
databases such as gnomAD in which these variants can now be interrogated (Tayal et al. 2017). 
 
Using the ACMG guidelines as a framework and taking disease prevalence and penetrance into 
account, a MAF of < 0.01 was used in this investigation. We evaluated variants using evidence 
from population and gene/disease-specific databases, in silico prediction tools, our in-house 
variant database, and the relevant scientific literature. To this end, established criteria were used 
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to evaluate variants for potential pathogenicity, with evidence from the relevant databases and 
literature as the foundation for classification. While it is recognised that other studies are using 
MAFs that are more stringent (for example, a maximum MAF of 0.00004 has been advocated for 
pathogenic HCM variants (Whiffin et al. 2017)), the choice of a relatively low MAF for filtering in 
this study was motivated by the unique African population and the need to strike a balance 
between retaining variants of potential interest compared to excluding potentially causative ones.  
Our robust filtering approach led to identification of the POLG variant c.2492A>G, which initial 
functional work indicates may indeed play a role in disease presentation, as well as pathogenic 
and likely pathogenic mutations in known cardiomyopathy genes. That said, combining all of these 
factors along with comprehensive patient clinical information and history with recent powerful 
advances in bioinformatics (afforded by large population sequencing databases such as gnomAD 
and ExAC) (Karczewski et al. 2020)), may be key in identifying rare African mutations in genes 
otherwise unknown to cause disease. 
 
To ascertain the role of common variation in cardiomyopathy in Africa, genome-wide association 
studies (GWASs) may be considered. Two recent GWASs have demonstrated the association of 
single-nucleotide polymorphisms with cardiac parameters and the risks of DCM and HCM in 
largely European populations (Harper et al. 2021, Pirruccello et al. 2020). Both studies used the 
genetic results to reliably predict the presence of DCM and HCM in validation cohorts, implying 
an additive effect in which accumulation of common variants with subtle phenotypic impacts can 
ultimately influence disease risk. These studies indicate the valuable insights that can be gleaned 
by genotyping large cohorts of cardiomyopathy patients and controls, and point to potential future 
avenues for research into cardiomyopathy in Africa, providing the logistical challenges can be 
overcome. 
 
The utility of exome sequencing in identifying new genotype-phenotype correlations, as well as 
potential new disease genes for cardiomyopathy, means that it should be considered for 
researching the genetics of cardiac disease in Africa. Implications of genotype-phenotype 
correlations have been realised in international cohorts, where mutations can have consequences 
on individual prognosis and treatment depending on the affected gene (Paldino et al. 2018). 
Whether these or similar prognostic mutations exist in African patients remains to be determined. 
The zebrafish model system may also be of use when conducting future genetic studies of this 
population, as there is a need to validate variants with unclear clinical consequences (discussed 
below). It may well be that NGS coupled with zebrafish modelling could be used to close the gap 
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in our knowledge of the genetics of cardiomyopathy and, most importantly, provide answers to 
the families that are affected by heritable cardiac conditions. 
 
6.3.2 Further investigation of POLG 
 
Exome sequencing of Family 4 led to the identification of POLG c.2492A>G as a candidate 
variant, and functional investigation demonstrated that the variant could induce signs of 
arrhythmia when introduced to zebrafish larvae. The potential role of POLG in human 
cardiomyopathy and arrhythmic phenotypes is a finding that should be explored further. Although 
39 ACM patients were screened for additional POLG mutations in this study, with the identification 
of the VUS c.3077G>A (p.R1026H) as a result, continued screening of the gene in an extended 
cardiomyopathy cohort may yield more variants of interest. Future functional work should be 
considered, including validation of the zebrafish as a model of POLG variation, for example by 
modelling additional POLG variants, and determination of the mechanism whereby mutations in 
POLG may lead to features of cardiomyopathy. 
 
The mRNA overexpression approach used in this investigation has much scope for further 
refinement. One chief concern is the need to confirm that POLG mRNA is taken up and expressed 
in the heart during development. The incorporation of a fused fluorescent tag in the vector is an 
experiment that may address this, and would allow quantification of the POLG protein, 
determination of its expression patterns, and the ability to perform direct comparisons of embryos 
expressing equal amounts of the mutant POLG. An experimental protocol of this nature may be 
of interest, as this would serve to confirm (or refute) the cardiovascular effects of POLG mutation 
at the protein level. Confirmation of pathogenicity at this level would be strong evidence for the 
role of POLG in human cardiomyopathy; indeed, any other genes that are identified through future 
NGS studies may be examined in this way. 
 
6.3.3 Functional modelling of variants in zebrafish 
 
One of the greatest challenges to arise from exome sequencing is the identification of VUSs. In 
the literature review (Chapter 1), it was suggested that by screening more genes, NGS 
experiments may simply give rise to more unclear genetic findings. The results here certainly 
seem to support this notion, as VUSs were detected in three out of five families. When studying 
the genetic material of living participants, there is a profound need to resolve the uncertainty 
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surrounding these variants, as the results will have consequences on patients and their relatives. 
Sometimes, genetic results can also improve their treatment, as seen in Family 2 where the 
identification of a pathogenic GLA mutation indicates that the participants have Fabry disease, 
not HCM as originally indicated (Chapter 3). VUSs may be resolved through large family studies 
but when these are not possible, in vivo functional assays can be used to support or prove their 
disease-causing potential. An example of this is the POLG variant identified in Family 4, where 
exome sequencing combined with analysis in zebrafish demonstrated that mutations in POLG 
may contribute to ACM in that family. 
 
The zebrafish is an emerging model for heart disease and heart development, due to numerous 
advantages which include the ease of genetic manipulation, large clutch sizes and larval 
transparency. In this investigation, two genetic models were used in zebrafish: CRISPR-mediated 
gene knockout, and mRNA overexpression. While CRISPR was used to successfully knock out 
three genes, the technique was limited due to small sample sizes and inconsistent genotypes. 
What is clear from this research is that future CRISPR projects will need to focus on the generation 
of stable gene knockout or ‘knock-in’ lines, propagated over at least two generations; this. An 
alternative model, mRNA overexpression, was explored. This model allowed investigation of a 
stable genotype expressed over the first five days of zebrafish development. It also enabled the 
analysis of substantially more larvae than were possible in the CRISPR investigation, and 
statistically significant numbers could be reached (Chapter 5). Although this model is limited to 
the first few days of development, this approach may prove useful in the first-line investigation of 
VUSs and other variants that are detected using NGS studies of cardiomyopathy, especially when 
modified to allow fluorescent protein production as described above (Section 6.3.2) or combined 
with mRNA rescue experiments (Badrock et al. 2020).  
 
Alternatively, CRISPR genome editing can be used in some instances to create stable zebrafish 
mutants to recapitulate cardiovascular disease to great effect (Farr et al. 2018). In particular, the 
mutations PKP2 c.2540T>C, DSC2 c.2642T>A, ITGB5 c.146G>A, and ITGB5 c.1929G>C, which 
were identified during the course of this investigation, may be explored in this manner. Similar 
zebrafish models may also be used to resolve the role of genetic modifiers in cardiomyopathy, an 
underexplored research area that may warrant further investigation. This study identified two 
potential genetic modifiers, SORBS2 c.322T>C and KCNK10 c.1052A>G, and the expression of 
these variants in zebrafish, both alone and in combination with other disease-causing mutations, 
may be useful in delineating their contributions to disease phenotypes. Functional data of this 
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nature, supplemented with bioinformatic analysis and familial segregation, may provide clarity 
regarding the true disease-causing potential of these variants, as well as other variants that will 
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Appendix A New HCM genes and variants identified through next-generation sequencing 
 
Table A.1: Expanded list of HCM disease genes identified through NGS 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
FLNC 
c.19del (p.Y7Tfs*51) 0 Heterozygous AD DCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.115C>T (p.Q39*) 0 Heterozygous AD DCM 




Janin et al. 
(2017) 
c.230_234del (p.L77Pfs*73) 0 Heterozygous AD DCM 




Janin et al. 
(2017) 


















Ashkenazi Jewish family 
WES 
Reinstein et al. 
(2016) 





















c.601+1G>T 0 Heterozygous Sporadic DCM French patient 
Targeted 
sequencing 










c.711del (p.E238Rfs*14) 0 Heterozygous AD DCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 





c.1322G>T (p.R441I) 0 Heterozygous Sporadic DCM Chinese patient 
Exome 
sequencing 
Xiao et al. 
(2020) 
c.1412‐1G>A 0.000001 Heterozygous Sporadic DCM French patient 
Targeted 
sequencing 
Ader et al. 
(2019) 
Continued on next page 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
ACM, arrhythmogenic cardiomyopathy; AD, autosomal dominant; AR, autosomal recessive; DCM, dilated cardiomyopathy; gnomAD, Genome Aggregation 




Table A.1 continued 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
FLNC 
c.1444C>T (p.R482*) 0 




Hall et al. 
(2020) 
c.1890C>A (p.Y630*) 0 Heterozygous AD DCM 




Janin et al. 
(2017) 
c.2041_2047dup (p.I683Rfs*9) 0 Heterozygous AD DCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 





c.2265+4del 0 Heterozygous Sporadic DCM Chinese patient 
Exome 
sequencing 
Xiao et al. 
(2020) 
c.2375G>T (p.S792I) 0.000007 Not specified Sporadic HCM Tunisian patients 
Targeted 
sequencing 
Jaafar et al. 
(2016) 







Hall et al. 
(2020) 
c.2784C>G (p.Y928*) 0 Heterozygous AD DCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 





c.3592dup (p.V1198Gfs*64) 0 Heterozygous Sporadic DCM French patient 
Targeted 
sequencing 









c.3547GC>CT (p.A1183L) 0 Heterozygous Sporadic RCM Swedish patient 
Exome 
sequencing 
Kiselev et al. 
(2018) 
c.3557C>T (p.A1186V) 0 De novo Sporadic RCM Swedish patients 
Exome 
sequencing 
Kiselev et al. 
(2018) 
c.3557C>T (p.A1186V) 0 De novo Sporadic RCM Chinese patient 
Exome 
sequencing 
Xiao et al. 
(2020) 
c.3581C>T (p.S1194L) 0.000001 Heterozygous Sporadic HCM French patient 
Targeted 
sequencing 
Ader et al. 
(2019) 





c.4271G>T (p.G1424V) 0 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
Continued on next page 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
ACM, arrhythmogenic cardiomyopathy; AD, autosomal dominant; AR, autosomal recessive; DCM, dilated cardiomyopathy; gnomAD, Genome Aggregation 





Table A.1 continued 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
FLNC 












c.4651G>A (p.A1551T) 0.000112 Not specified Sporadic HCM Tunisian patients 
Targeted 
sequencing 
Jaafar et al. 
(2016) 
c.4718T>A (p.L1573*) 0 




Hall et al. 
(2020) 
c.4871C>T (p.S1624L) 0 Heterozygous AD RCM 




Brodehl et al. 
(2016) 
c.4871C>T (p.S1624L) 0 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.4916G>A (p.C1639Y) 0 De novo Sporadic RCM Chinese patient 
Exome 
sequencing 
Xiao et al. 
(2020) 





c.5836_5841dup (p.I1946_T1947dup) 0 Heterozygous AD RCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.5996G>A (p.R1999Q) 0.000016 Not specified Sporadic HCM Tunisian patients 
Targeted 
sequencing 
Jaafar et al. 
(2016) 
c.6032G>A (p.G2011E) 0 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.6115G>A (p.G2039R) 0.000001 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 























et al. (2019) 







Continued on next page 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
ACM, arrhythmogenic cardiomyopathy; AD, autosomal dominant; AR, autosomal recessive; DCM, dilated cardiomyopathy; gnomAD, Genome Aggregation 





Table A.1 continued 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
FLNC 





Gómez et al. 
(2017) 
c.6419G>A (p.R2140Q) 0.000016 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 





c.6478A>T (p.I2160F) 0 Heterozygous AD RCM 




Brodehl et al. 
(2016) 
c.6565G>T (p.E2189*) 0 Not specified ACM Caucasian patient 
Targeted 
sequencing 
Brun et al. 
(2020) 





Tucker et al. 
(2017) 
c.6889G>A (p.V2297M) 0 Heterozygous AD RCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 





Gómez et al. 
(2017) 
c.6893C>T (p.P2298L) 0 Heterozygous AD RCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.6895G>A (p.G2299S) 0 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 







c.6952C>T (p.R2318W) 0 Heterozygous Sporadic HCM French patient 
Targeted 
sequencing 
Ader et al. 
(2019) 





c.6989dupG (p.V2331Rfs*25) 0 Heterozygous AD DCM 




Janin et al. 
(2017) 
c.7076T>C (p.I2359T) 0 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.7118_7119del (p.Y2373Cfs*7) 0 Heterozygous AD DCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.7123G>C (p.V2375L) 0 Heterozygous Sporadic HCM French patient 
Targeted 
sequencing 
Ader et al. 
(2019) 
Continued on next page 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
ACM, arrhythmogenic cardiomyopathy; AD, autosomal dominant; AR, autosomal recessive; DCM, dilated cardiomyopathy; gnomAD, Genome Aggregation 





Table A.1 continued 
Gene Mutation gnomAD MAF Inheritance  Disease Cohort Technology* Reference 
FLNC 
c.7228C>T (p.R2410C) 0.000002 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.7250A>C (p.Q2417P) 0 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.7252-1G>A 0 Not specified 




Hall et al. 
(2020) 







c.7484G>A (p.R2495H) 0.000002 Heterozygous AD HCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.7645C>T (p.Q2549*) 0 Heterozygous Sporadic DCM French patient 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.7665T>A (p.C2555*) 0 Heterozygous AD DCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 
c.7927_7935del (p.P2643_L2645del) 0 Heterozygous AD RCM French family 
Targeted 
sequencing 
Ader et al. 
(2019) 





c.8107delG (p.D2703Tfs*69) 0 Possible digenic LVNC Chinese patient 
Exome 
sequencing 
Liu et al. 
(2019) 
c.8107delG (p.D2703Tfs*69) 0 Not specified Sporadic ACM Caucasian patient 
Targeted 
sequencing 

































HCM Croatian patient 
Exome 
sequencing 
Taylor et al. 
(2014) 




O'Byrne et al. 
(2018) 





Baruffini et al. 
(2013) 
c.1232C>T (p.T411I) 0.000024 Homozygous HCM 




Taylor et al. 
(2014) 
Continued on next page 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
ACM, arrhythmogenic cardiomyopathy; AD, autosomal dominant; AR, autosomal recessive; DCM, dilated cardiomyopathy; gnomAD, Genome Aggregation 





Table A.1 continued 
























O'Byrne et al. 
(2018) 






AR HCM Italian family 
Exome 
sequencing 
Ghezzi et al. 
(2012) 
c.1282G>A (p.A428T) 0.000051 Homozygous Sporadic HCM Not specified 
Candidate gene 
screen 













Baruffini et al. 
(2013) 
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(2018) 




O'Byrne et al. 
(2018) 
SMYD1 
c.675delA (p.K225Nfs*8) 0 Not specified LVNC Chinese patient 
Exome 
sequencing 
Liu et al. 
(2019) 
c.814T>C (p.F272L) 0.000004 De novo HCM Chinese patient 
Exome 
sequencing 
Fan et al. 
(2019) 
* Technology used for the original discovery is indicated in bold print, and subsequent screens are indicated in italics 
ACM, arrhythmogenic cardiomyopathy; AD, autosomal dominant; AR, autosomal recessive; DCM, dilated cardiomyopathy; gnomAD, Genome Aggregation 



















Appendix D DNA extraction protocols 
 
Note: exceptions to the protocols are written in bold 
 
Gentra Puregene Blood Kit protocol – DNA purification from buffy coat 
 
1. If the buffy coat preparation contains red blood cells, continue with step 2. Otherwise, 
pipet 3 ml Cell Lysis Solution into a 15 ml centrifuge tube, add 150–250 μl sample, and 
continue with step 8. 
2. Dispense 3 volumes RBC Lysis Solution into a 15 ml centrifuge tube (e.g., if processing 
250 μl buffy coat, dispense 750 μl RBC Lysis Solution). Add 150–250 μl buffy coat 
preparation. 
3. Invert to mix and incubate for 10 min at room temperature (15–25°C). Invert again at 
least once during the incubation. 
4. Centrifuge for 5 min at 2000 x g. (Samples were centrifuged for 10 min) 
5. Carefully discard the supernatant by pipetting or pouring, leaving approximately        
100–200 μl of the residual liquid and the pellet. 
6. Vortex the tube vigorously to resuspend the pellet in the residual liquid. 
7. Add 3 ml Cell Lysis Solution and pipet up and down or vortex vigorously to lyse the cells. 
Usually no incubation is required; however, if cell clumps are visible, incubate at 37°C 
until the solution is homogeneous. Samples are stable in Cell Lysis Solution for at least 2 
years at room temperature. 
8. Optional: If RNA-free DNA is required, add 15 μl RNase A Solution and mix by inverting 
25 times. Incubate for 15 min at 37°C. Then incubate for 3 min on ice to quickly cool the 
sample. (not done) 
9. Add 1 ml Protein Precipitation Solution and vortex vigorously for 20 s at high speed. (1.5 
ml Protein Precipitation Solution was added) 
10. Centrifuge for 5 min at 2000 x g. (Samples were centrifuged for 10 min) 
11. Pipet 3 ml isopropanol into a clean 15 ml centrifuge tube and add the supernatant from 
the previous step by pouring carefully. (6 ml isopropanol was used) 
12. Mix by inverting gently 50 times. (samples were inverted until DNA was visible) 
13. Centrifuge for 3 min at 2000 x g. (the visible DNA was removed by pipette and 
centrifuged for 1 min in a new 2 ml microcentrifuge tube) 
14. Carefully discard the supernatant and drain the tube by inverting on a clean piece of 
absorbent paper, taking care that the pellet remains in the tube. 
15. Add 3 ml of 70% ethanol and invert several times to wash the DNA pellet. (1 ml of 70% 
ethanol was added) 
16. Centrifuge for 1 min at 2000 x g. 
17. Carefully discard the supernatant. Drain the tube on a clean piece of absorbent paper, 
taking care that the pellet remains in the tube. Allow to air dry for 5–10 min. 
18. Add 300 μl DNA Hydration Solution and vortex for 5 s at medium speed to mix. (200 µl 
DNA Hydration Solution was added) 
19. Incubate at 65°C for 1h to dissolve the DNA. (not done) 
20. Incubate at room temperature overnight.  
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PAXgene® Blood DNA Kit protocol 
 
Before starting: 
• Thaw frozen PAXgene Blood DNA Tubes in a wire rack at ambient temperature (18–
25°C) for approximately 2 hr or at 37°C in a water bath for approximately 15 minutes. 
Carefully invert the thawed PAXgene Blood DNA Tubes 10 times before beginning the 
procedure. 
• Heat a heating block or water bath to 65°C for use in steps 8 and 17. 
• Add 1.4 ml Buffer BG4 (resuspension buffer) to lyophilised PreAnalytiX Protease. 
Dissolved PreAnalytiX Protease should be stored at 2–8°C or in aliquots at –20°C. 
• For every sample, mix 5 ml Buffer BG3 (digestion buffer) and 50 μl reconstituted 
PreAnalytiX Protease. For example, to process 10 samples, mix 50 ml Buffer BG3 with 
500 μl PreAnalytiX Protease. The Buffer BG3–PreAnalytiX Protease mixture should be 
prepared immediately before the start of the procedure. 
 
Procedure: 
1. Pour all the blood from one PAXgene Blood DNA Tube into a Processing Tube 
containing 25 ml Buffer BG1. Close the tube. To avoid cracking the blue lids of the 
Processing Tubes, do not overtighten them. Tighten the lid only until the first sign of 
resistance is felt. Mix by inverting the tube 5 times. 
2. Centrifuge for 5 min at 2500 x g in a swing-out rotor. 
3. Carefully discard the supernatant and place the tube in a rack. 
4. Add 5 ml Buffer BG2, close the tube and wash the pellet by vortexing vigorously for 5 s. 
5. Centrifuge for 3 min at 2500 x g in a swing-out rotor. 
6. Carefully discard the supernatant and place the tube back in the rack. 
7. Add 5 ml Buffer BG3/PreAnalytiX Protease, close the tube and vortex for 20 s at high 
speed. 
8. Place the tube in a heating block or water bath and incubate at 65°C for 10 min. 
9. Vortex again for 5 s at high speed. 
10. Add 5 ml isopropanol (100%) and mix by inverting the tube at least 20 times until the 
white DNA strands clump visibly together. 
11. Centrifuge for 3 min at 2500 x g. 
12. Discard the supernatant and leave the tube inverted on a clean piece of absorbent paper 
for 1 min. 
13. Add 5 ml 70% (v/v) ethanol and vortex for 1 s at high speed. 
14. Centrifuge for 3 min at 2500 x g. 
15. Discard the supernatant and leave the tube inverted on a clean piece of absorbent paper 
for at least 5 min. 
16. Carefully dab the tube onto absorbent paper to remove ethanol from the rim and leave it 
inverted for a further 5 min to allow the DNA pellet to dry. 
17. Add 1 ml Buffer BG4 and dissolve the DNA by incubating for 1 h at 65°C in a heating 








1 M Tris-HCl (pH 8.0): 
• 121.1 g Tris base (Glentham Life Sciences, Corsham, UK) in 800 ml distilled water 
• Adjust the pH to 8.0 with concentrated HCl 
• Make to a total volume of 1 L with sterile distilled water 
 
0.5 M EDTA (pH 8.0): 
• 186.1 g EDTA (Glentham Life Sciences) in 800 ml distilled water 
• Adjust the pH to 8.0 with NaOH 
• Make to a total volume of 1 L with sterile distilled water 
 
1X Tris/EDTA (TE) buffer: 
• 1 ml 1 M Tris-HCl (final concentration: 10 mM) 
• 0.2 ml 0.5 M EDTA (final concentration: 1 mM) 
• 98.8 ml sterile distilled water 
 
Agarose gel electrophoresis 
 
Tris/Borate/EDTA (TBE) buffers 
 
10X TBE (stock): 
• 121.1 g Tris (Glentham Life Sciences) (final concentration: 1 M) 
• 61.8 g Boric acid (AMRESCO, Solon, OH USA) (final concentration: 1 M) 
• 7.4 g EDTA (Glentham Life Sciences) (final concentration: 0.02 M) 
• Made to a total volume of 1 L with sterile distilled water 
 
1X TBE (working): 









• 1 ml 5X Green GoTaq® Flexi buffer (Promega) 
• 5 µl GelRed® nucleic acid gel stain (Biotium) 
• Mixed with DNA samples at a ratio of 3:5 (dye:sample) before loading 
 
1% agarose gel: 
• 1 g SeaKem® LE agarose (Lonza, Basel, Switzerland) 
• 100 ml 1X TBE 
 
2% agarose gel: 
• 2 g SeaKem® LE agarose (Lonza) 
• 100 ml 1X TBE 
 
DNA molecular weight markers 
 
A       B 
      
 
Figure E.1: DNA molecular weight markers. Shown are (A) the 100 bp ladder (NEB) and (B) the Quick-
load® 1kb DNA ladder (NEB). Adapted from New England BioLabs product listing (New England Biolabs , 









E3 60X stock solution: 
• 17.5 g NaCl (Sigma-Aldrich, St Louis, MO USA) 
• 0.76 g KCl (Sigma-Aldrich) 
• 2.9 g CaCl2 (Sigma-Aldrich) 
• 4.88 g MgSO4 (Sigma-Aldrich) 
• Made to a total volume of 1 L with distilled water 
 
Methylene blue E3 water: 
• 1 g methylene blue (Sigma-Aldrich) 




Tricaine 0.4% stock solution: 
• 400 mg tricaine powder (Sigma-Aldrich) 
• 97.9 ml double-distilled water 
• 2.1 ml 1 M Tris (pH 9) 
• Adjust pH to 7 
• Store at -20°C 
 
Cloning and site-directed mutagenesis 
 
LB broth: 
• 10 g tryptone 
• 5 g yeast extract 
• 10 g NaCl (Sigma-Aldrich) 






• Add 37 g LB-agar powder per L of sterile water and swirl to form a colloid 
• Autoclave 
• Submerge the molten gel mix in a 60°C water bath and add ampicillin while swirling 
• Pour agar into petri dishes next to an open flame 
• Leave on the bench to cool and solidify 
 
3% methylcellulose: 
• 3 g methylcellulose 
• 100 ml E3 water or distilled water 







Appendix F Variant annotation and analysis pipeline 
 
Note: Protocol courtesy of Dr Simon Williams (University of Manchester, UK) 
 
This protocol describes how to go from GRCh37 VCF files to annotated files containing variants 
that can be merged samples and/or filtered on gene candidate lists. These instructions are for 






Figure F.1: Schematic representation of the annotation and filtering pipeline. Image courtesy of            






1. Run VEP to annotate the VCF file: 
a. Get the VCF files for each individual. These should be in gzipped format with the 
suffix ‘.vcf.gz’ 
b. The script to run VEP on the UCT cluster is /opt/exp_soft/vep/run_VEP.sh. Copy 
this script to your own directory 
c. Once copied to your local directory, to run this on a single VCF file:  
sbatch run_VEP.sh file1.vcf.gz 
d. This will produce ‘file1.annotated.vcf’ 
e. To check the progress of your job type squeue –u <username>   
2. Convert this VCF formatted output file into a file that can be read by excel:  
perl /opt/exp_soft/vep/scripts/parse_vep_output.pl file.annotated.vcf 
3. (optional) Combine selected samples: 
a. Make a list of all the files to be combined: 
ls file1.annotated.txt file 2.annotated.txt file3.annotated.txt > input_list 
b. Run the script: 
perl /opt/exp_soft/vep/scripts/combine_samples/pl -sample_list input_list > 
combined_samples.annotated.txt 
4. (optional) Filter variants against a list of candidate genes: 
a. Compile a list of candidate genes of interest (cardiomyopathy_panel; Appendix G) 
b. Run the script: 
perl /opt/exp_soft/vep/scripts/filter_variants.pl -sample file1.annotated.txt -gene_list 
cardiomyopathy_panel.txt 
c. To return results all variants in genes not on the list (i.e. previously unknown 
genes), add the -exclude flag to the command 
5. (optional) Create a gene-based summary of variants: 








This is an optional step if you have trio files and you want to look for de novo or homozygous 
recessive variants. It should be run after stage 2 has been run for each of the trio samples and 
you have annotated.txt files for each. 
 
perl /opt/exp_soft/vep/scripts/trio_analysis.pl –proband file_proband.annotated.txt –parent1 
file_parent1.annotated.txt –parent2 file_parent2.annotated.vcf > file_proband_trio_analysis_annotated.txt  
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Appendix G Cardiomyopathy gene panel 
 
A cardiomyopathy gene panel was compiled, consisting of 250 known and putative 
cardiomyopathy genes according to two sources: 
 
1. The cardiomyopathy panel by Blueprint Genetics (n = 155) (Blue Print Genetics 2019) 
2. A custom panel of known or predicted cardiac disease genes (n = 160) (Zou et al. 2015) 
 
Table G.1: Cardiomyopathy gene panel used in NGS data analysis 
Gene name Associated heart disease(s) Source* 
AARS2 Mitochondrial cardiomyopathy 1,2 
ABCC6 None (candidate) 1 
ABCC9 DCM, atrial fibrillation 1,2 
ACAD9 ACAD9 deficiency 1 
ACADVL Acyl-CoA dehydrogenase, very long chain, deficiency 1,2 
ACTA1 None (candidate gene) 1,2 
ACTC1 DCM, HCM, RCM, LVNC 1,2 
ACTN2 DCM, HCM 1,2 
AGK Mitochondrial cardiomyopathy 1,2 
AGL Glycogen storage disease 1,2 
AKAP1 None (candidate gene) 2 
AKAP10 None (candidate gene) 2 
AKAP12 None (candidate gene) 2 
AKAP13 None (candidate gene) 2 
AKAP5 None (candidate gene) 2 
AKAP6 None (candidate gene) 2 
AKAP7 None (candidate gene) 2 
AKAP9 Long QT syndrome 2 
ALMS1 Alström syndrome 1 
ALPK3 Paediatric cardiomyopathy 1 
ANK2 Long QT syndrome 2 
ANKRD1 DCM, HCM 2 
ANO5 None (candidate gene) 1 
APOA1 Amyloidosis 1 
ASPH None (candidate gene) 2 
BAG3 DCM 1,2 
BRAF Noonan syndrome, Cardiofaciocutaneous syndrome 1,2 
Continued on next page 
* 1: Blueprint Genetics cardiomyopathy gene panel; 2: known and predicted cardiomyopathy genes 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left 




Table G.1 continued 
Gene name Associated heart disease(s) Source* 
CACNA1C Long QT syndrome, Brugada syndrome 2 
CACNA2D1 Brugada syndrome 2 
CACNA2D2 None (candidate gene) 2 
CACNA2D3 None (candidate gene) 2 
CACNB2 Brugada syndrome 2 
CALM1 Catecholaminergic polymorphic ventricular tachycardia 2 
CALR3 HCM 1,2 
CAPN3 None (candidate gene) 1 
CASQ2 Catecholaminergic polymorphic ventricular tachycardia 1,2 
CAV3 HCM, Long QT syndrome 2 
CBL Noonan syndrome-like disorder 1 
CDH2 ACM 1 
CMYA5 None (candidate gene) 2 
COX15 Leigh syndrome, Cardioencephalomyopathy 1,2 
CPT2 Carnitine palmitoyltransferase II deficiency 1 
CRYAB DCM, HCM 1,2 
CSRP3 DCM, HCM 1,2 
CTF1 DCM 2 
CTNNA3 ACM 1,2 
DBH None (candidate gene) 1 
DES DCM, RCM 1,2 
DMD DCM 1,2 
DNAJC19 DCM 1,2 
DOLK None (candidate gene) 1 
DPP6 Ventricular fibrillation 2 
DSC2 ACM 1,2 
DSG2 DCM, ACM 1,2 
DSP DCM, ACM 1,2 
DTNA LVNC 1,2 
DYSF None (candidate gene) 1 
EEF1A2 None (candidate gene) 1 
ELAC2 Combined oxidative phosphorylation deficiency 17 1 
EMD DCM 1,2 
EPG5 Vici syndrome 1 
ETFA None (candidate gene) 1 
ETFB None (candidate gene) 1 
Continued on next page 
* 1: Blueprint Genetics cardiomyopathy gene panel; 2: known and predicted cardiomyopathy genes 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left 




Table G.1 continued 
Gene name Associated heart disease(s) Source* 
ETFDH None (candidate gene) 1 
EYA4 DCM 2 
FBXO32 DCM 1 
FHL1 HCM 1,2 
FHL2 DCM 2 
FKRP None (candidate gene) 1 
FKTN DCM 1,2 
FLNC DCM, HCM, ACM, RCM 1,2 
FOXD4 DCM 1,2 
FOXRED1 Mitochondrial cardiomyopathy, Leigh syndrome 1,2 
FXN None (candidate gene) 1,2 
GAA Glycogen storage disease 1,2 
GATA6 Congenital heart defects 1 
GATAD1 DCM 1 
GBE1 Glycogen storage disease 1 
GFM1 Combined oxidative phosphorylation deficiency 1 
GJA1 None (candidate gene) 2 
GJA5 None (candidate gene) 2 
GLA Fabry disease 1,2 
GLB1 GM1-gangliosidosis 1 
GMPPB None (candidate gene) 1 
GPD1L Brugada syndrome 2 
GTPBP3 Combined oxidative phosphorylation deficiency 23 1 
GUSB None (candidate gene) 1 
HADHA Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, Trifunctional protein 
deficiency 
1 
HAND1 DCM, Congenital heart defects 1 
HCN4 LVNC, Brugada syndrome 1,2 
HFE None (candidate gene) 1 
HRAS None (candidate gene) 1 
HRC None (candidate gene) 2 
HSPB2 None (candidate gene) 2 
HSPB6 None (candidate gene) 2 
HSPB7 None (candidate gene) 2 
HSPB8 None (candidate gene) 2 
ILK DCM 1,2 
ISPD None (candidate gene) 1 
Continued on next page 
* 1: Blueprint Genetics cardiomyopathy gene panel; 2: known and predicted cardiomyopathy genes 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left 




Table G.1 continued 
Gene name Associated heart disease(s) Source* 
JPH2 HCM 1,2 
JUP DCM, ACM 1,2 
KCNA5 None (candidate gene) 2 
KCND3 None (candidate gene) 2 
KCNE1 Long QT syndrome 2 
KCNE1L None (candidate gene) 2 
KCNE2 Long QT syndrome 2 
KCNE3 Brugada syndrome 2 
KCNE4 None (candidate gene) 2 
KCNH2 Long QT syndrome 2 
KCNIP2 None (candidate gene) 2 
KCNJ11 None (candidate gene) 2 
KCNJ2 Long QT syndrome 2 
KCNJ4 None (candidate gene) 2 
KCNJ8 None (candidate gene) 2 
KCNK1 None (candidate gene) 2 
KCNN2 None (candidate gene) 2 
KCNN3 None (candidate gene) 2 
KCNQ1 Long QT syndrome 2 
KLF10 HCM 2 
KRAS Noonan syndrome, Cardiofaciocutaneous syndrome 1 
LAMA2 None (candidate gene) 1 
LAMA4 DCM 2 
LAMP2 Danon disease 1,2 
LARGE None (candidate gene) 1 
LDB3 DCM, LVNC 1,2 
LMNA DCM 1,2 
LMOD2 None (candidate gene) 2 
LRRC10 DCM 1 
LZTR1 Noonan syndrome 1 
MAP2K1 Cardiofaciocutaneous syndrome 1 
MAP2K2 Cardiofaciocutaneous syndrome 1 
MIB1 LVNC 2 
MLYCD Malonyl-CoA decarboxylase deficiency 1 
MRPL3 Mitochondrial cardiomyopathy 2 
MTO1 HCM, Combined oxidative phosphorylation deficiency 1 
Continued on next page 
* 1: Blueprint Genetics cardiomyopathy gene panel; 2: known and predicted cardiomyopathy genes 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left 




Table G.1 continued 
Gene name Associated heart disease(s) Source* 
MURC HCM 2 
MYBPC3 DCM, HCM, LVNC 1,2 
MYH6 DCM, HCM 1,2 
MYH7 DCM, HCM, LVNC 1,2 
MYL2 HCM 1,2 
MYL3 HCM 1,2 
MYL4 Atrial fibrillation 1 
MYLK2 None (candidate gene) 2 
MYOM1 None (candidate gene) 2 
MYOT None (candidate gene) 1,2 
MYOZ2 HCM 2 
MYPN DCM, HCM, RCM 1,2 
NDUFAF1 Mitochondrial cardiomyopathy 2 
NDUFAF2 Mitochondrial cardiomyopathy, Leigh syndrome 1 
NDUFS2 Mitochondrial cardiomyopathy 2 
NEBL DCM 2 
NEXN DCM, HCM 1,2 
NF1 Neurofibromatosis-Noonan syndrome 1 
NOS1AP None (candidate gene) 2 
NPPA Atrial fibrillation 2 
NRAS Noonan syndrome 1 
OBSCN HCM 2 
PCCA None (candidate gene) 1 
PCCB None (candidate gene) 1 
PDE3A None (candidate gene) 2 
PDE4A None (candidate gene) 2 
PDE4B None (candidate gene) 2 
PDE4D None (candidate gene) 2 
PDE4DIP None (candidate gene) 2 
PDLIM3 DCM 2 
PKP2 ACM 1,2 
PLEC None (candidate gene) 1 
PLEKHM2 DCM, LVNC 1 
PLN DCM, HCM 1,2 
PNPLA2 Neutral lipid storage disease with myopathy 1 
PPA2 Sudden cardiac failure 1 
Continued on next page 
* 1: Blueprint Genetics cardiomyopathy gene panel; 2: known and predicted cardiomyopathy genes 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left 




Table G.1 continued 
Gene name Associated heart disease(s) Source* 
PPP1CB Noonan syndrome-like disorder with loose anagen hair 2 1 
PRDM16 DCM, LVNC 1 
PRKAG2 HCM 1,2 
PSEN1 DCM 2 
PSEN2 DCM, PPCM 2 
PTPN11 None (candidate gene) 1 
RAF1 DCM 1 
RANGRF Brugada syndrome 2 
RASA2 Noonan syndrome 1 
RBCK1 None (candidate gene) 1 
RBM20 DCM 1,2 
RBM24 None (candidate gene) 2 
RIT1 Noonan syndrome 1 
RMND1 Combined oxidative phosphorylation deficiency 1 
RRAS Noonan-syndrome like phenotype 1 
RYR2 ACM, Catecholaminergic polymorphic ventricular tachycardia 1,2 
SCN10A None (candidate gene) 2 
SCN1B Brugada syndrome 2 
SCN2B None (candidate gene) 2 
SCN3B Brugada syndrome 2 
SCN4B Long QT syndrome 2 
SCN5A DCM, atrial/ventricular fibrillation, Long QT syndrome, Brugada syndrome 1,2 
SCN7A None (candidate gene) 2 
SCNN1B None (candidate gene) 1 
SCNN1G None (candidate gene) 1 
SCO2 HCM, Mitochondrial cardiomyopathy 1,2 
SDHA DCM, Mitochondrial cardiomyopathy, Leigh syndrome 1,2 
SELENON None (candidate gene) 1 
SGCA None (candidate gene) 1 
SGCB None (candidate gene) 1 
SGCD DCM 1,2 
SGCG None (candidate gene) 1 
SHOC2 Noonan-like syndrome with loose anagen hair 1 
SLC22A5 Carnitine deficiency 1 
SLC25A20 Carnitine-acylcarnitine translocase deficiency 1 
SLC25A3 Mitochondrial cardiomyopathy 2 
Continued on next page 
* 1: Blueprint Genetics cardiomyopathy gene panel; 2: known and predicted cardiomyopathy genes 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left 




Table G.1 continued 
Gene name Associated heart disease(s) Source* 
SLC25A4 Mitochondrial cardiomyopathy 1,2 
SLMAP Brugada syndrome 2 
SMCHD1 None (candidate gene) 1 
SNTA1 Long QT syndrome 2 
SOS1 Noonan syndrome 1 
SOS2 Noonan syndrome 1 
SPRED1 None (candidate gene) 1 
SVIL None (candidate gene) 2 
SYNE1 DCM 2 
SYNE2 DCM 2 
SYNM DCM 2 
TAB2 Congenital heart defects 1 
TAZ DCM, Mitochondrial cardiomyopathy, LVNC 1,2 
TBX20 Atrial septal defect 1 
TBX5 Holt-Oram syndrome 1 
TCAP DCM, HCM 1,2 
TGFB3 ACM 1,2 
TLN1 None (candidate gene) 2 
TMEM43 ACM 1,2 
TMEM70 Mitochondrial cardiomyopathy 1,2 
TMOD1 None (candidate gene) 2 
TMPO DCM 2 
TNNC1 DCM, HCM 1,2 
TNNI3 DCM, HCM, RCM 1,2 
TNNI3K Cardiac conduction disease with or without DCM 1 
TNNT2 DCM, HCM, RCM, LVNC 1,2 
TOR1AIP1 None (candidate gene) 1 
TPM1 DCM, HCM 1,2 
TRDN Catecholaminergic polymorphic ventricular tachycardia 2 
TRIM32 None (candidate gene) 1 
TRIM63 None (candidate gene) 2 
TSFM Combined oxidative phosphorylation deficiency 1 
TTN DCM, HCM, ACM 1,2 
TTR HCM 1,2 
USP13 None (candidate gene) 2 
UTRN None (candidate gene) 2 
Continued on next page 
* 1: Blueprint Genetics cardiomyopathy gene panel; 2: known and predicted cardiomyopathy genes 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left 




Table G.1 continued 
Gene name Associated heart disease(s) Source* 
VCL DCM, HCM 1,2 
VCP None (candidate gene) 1 
VIM None (candidate gene) 2 
VPS13A None (candidate gene) 1 
XIRP1 None (candidate gene) 2 
XK McLeod syndrome 1 
ZYX None (candidate gene) 2 
* 1: Blueprint Genetics cardiomyopathy gene panel; 2: known and predicted cardiomyopathy genes 
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left 





Appendix H CRISPR guide RNA synthesis and purification protocols 
 
Note: exceptions to the protocols are written in bold 
 
QIAquick PCR purification kit protocol 
 
Before starting:  
• Add ethanol (96–100%) to Buffer PE before use (see bottle label for volume). 
• All centrifugation steps are carried out at 17,900 x g (13,000 rpm) in a conventional 
tabletop microcentrifuge at room temperature. 
• Add 1:250 volume pH indicator I to Buffer PB (i.e., add 120 µl pH indicator I to 30 ml 
Buffer PB or add 600 µl pH indicator I to 150 ml Buffer PB). The yellow colour of Buffer 
PB with pH indicator I indicates a pH of ≤ 7.5. (not done) 
• Add pH indicator I to entire buffer contents. Do not add pH indicator I to buffer aliquots. 
(not done) 
• If the purified PCR product is to be used in sensitive microarray applications, it may be 
beneficial to use Buffer PB without the addition of pH indicator I. 
 
Procedure: 
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix. It is not necessary 
to remove mineral oil or kerosene. (6 volumes of Buffer PB were added) 
2. If pH indicator I has been added to Buffer PB, check that the colour of the mixture is 
yellow. (not done) 
3. Place a QIAquick spin column in a provided 2 ml collection tube. 
4. To bind DNA, apply the sample to the QIAquick column and centrifuge for 30–60 s. 
5. Discard flow-through. Place the QIAquick column back into the same tube. 
6. To wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge for 30–60 s. 
7. Discard flow-through and place the QIAquick column back in the same tube. Centrifuge 
the column for an additional 1 min. 
8. Place QIAquick column in a clean 1.5 ml microcentrifuge tube. 
9. To elute DNA, add 50 µl Buffer EB (10 mM Tris·Cl, pH 8.5) or water (pH 7.0–8.5) to the 
centre of the QIAquick membrane and centrifuge the column for 1 min. Alternatively, for 
increased DNA concentration, add 30 µl elution buffer to the centre of the QIAquick 
membrane, let the column stand for 1 min and then centrifuge. (elutions were 
performed using 30 µl of nuclease-free water) 
10. If the purified DNA is to be analysed on a gel, add 1 volume of Loading Dye to 5 
volumes of purified DNA. Mix the solution by pipetting up and down before loading the 






MEGAclearTM Transcription Clean-Up kit protocol 
 
Before starting and other notes:  
• Add 20 ml of ACS grade 100% ethanol to the bottle labelled Wash Solution Concentrate. 
Mix well. Place a check in the box on the label to indicate that the ethanol was added. 
With the ethanol, this solution will be referred to as Wash Solution. 
• Before working with RNA, it is always a good idea to clean the lab bench and pipettors 
with an RNase decontamination solution (e.g. Ambion® RNaseZap® Solution). 
• Wear laboratory gloves at all times during this procedure and change them frequently. 
They will protect you from the reagents, and they will protect the RNA from nucleases 
that are present on skin. 
• Use RNase-free pipette tips to handle the Wash Solution and the Elution Solution and 
avoid putting used tips into the reagent containers. 
• Use the Collection and Elution Tubes supplied with the kit; they have been tested for 
RNase contamination and are certified RNase-free. 
 
Procedure: 
1. Bring the RNA sample to 100 µL with Elution Solution. Mix gently but thoroughly. 
2. Add 350 µL of Binding Solution Concentrate to the sample. Mix gently by pipetting. 
3. Add 250 µL of 100% ethanol to the sample. Mix gently by pipetting. 
4. Apply the sample to the filter: 
a. Insert a Filter Cartridge into 1 of the Collection and Elution Tubes supplied. 
b. Pipet the RNA mixture onto the Filter Cartridge. 
c. Centrifuge for ~15 sec to 1 min, or until the mixture has passed through the filter. 
Centrifuge at RCF 10,000–15,000 × g (typically 10,000–14,000 rpm). Spinning 
harder than this may damage the filters. 
d. Discard the flow-through and reuse the Collection and Elution Tube for the 
washing steps. 
5. Wash with 2 × 500 µL Wash Solution: 
a. Apply 500 µL Wash Solution. Draw the Wash Solution through the filter as in the 
previous step. 
b. Repeat with a second 500 µL aliquot of Wash Solution. 
c. After discarding the Wash Solution, continue centrifugation for 10–30 sec to 
remove the last traces of Wash Solution. 
6. Elute RNA from the filter with 50 µL Elution Solution:  
a. Place the Filter Cartridge into a new Collection/Elution Tube. 
b. Apply 50 µL of Elution Solution to the centre of the Filter Cartridge. Close the cap 
of the tube and incubate in a heat block set to 65–70°C for 5–10 min. (50 µl 
nuclease-free water was used instead of Elution Solution) 
c. Recover eluted RNA by centrifuging for 1 min at RT (RCF 10,000–15,000 × g). 
d. To maximise RNA recovery, repeat this elution procedure with a second 50 µL 
aliquot of Elution Solution. Collect the eluate into the same tube. (to maximise 
the concentration, the flow-through was used instead of a second aliquot)  
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Appendix I Bioline Isolate II purification protocols 
 
Note: exceptions to the protocols are written in bold 
 
Isolate II PCR and gel kit – gel purification protocol 
 
1. Excise and dissolve gel slice: 
a. Using a clean scalpel, excise DNA fragment from gel. 
b. Remove excess agarose, determine weight of gel slice and transfer into a clean 
tube. 
c. Add 200 µl Binding Buffer CB per 100 mg of 2% agarose gel* 
* For gels containing > 2% agarose, double the volume of Binding Buffer CB. 
d. Incubate sample at 50°C for 5-10 min, vortexing sample briefly every 2-3 min until 
gel slice is completely dissolved. 
2. Bind DNA: 
a. Place ISOLATE II PCR and Gel Column in a 2 ml Collection Tube and load sample. 
b. Centrifuge 30 s at 11,000 x g and discard flow-through. 
c. Reuse collection tube for step 3. 
3. Wash silica membrane: 
a. Add 700 µl Wash Buffer CW to ISOLATE II PCR and Gel Column.  
b. Centrifuge 30 s at 11,000 x g. 
c. Discard flow-through and place column back into collection tube. 
Recommended: Repeat washing step to minimise chaotropic salt carry-over. (done) 
4. Dry silica membrane: 
a. Centrifuge 1 min at 11,000 x g, to remove residual ethanol. 
b. Place ISOLATE II PCR and Gel Column in a 1.5 ml microcentrifuge tube (not 
supplied). 
5. Elute DNA: 
a. Add 15-30 µl Elution Buffer C directly onto silica membrane. (20 µl was used) 
b. Incubate at room temperature for 1 min. 






Isolate II PCR and gel kit – PCR purification protocol 
 
1. Sample preparation: 
a. For volumes < 30 µl, adjust volume to 50-100 µl with water.  
b. Mix 1 volume of sample with 2 volumes of Binding Buffer CB. 
2. Bind DNA: 
a. Place ISOLATE II PCR and Gel Column in a 2 ml Collection Tube and load sample. 
b. Centrifuge 30 s at 11,000 x g and discard flow-through. 
c. Reuse collection tube for step 3. 
3. Wash silica membrane: 
a. Add 700 µl Wash Buffer CW to ISOLATE II PCR and Gel Column.  
b. Centrifuge 30 s at 11,000 x g. 
c. Discard flow-through and place column back into collection tube. 
Recommended: Repeat washing step to minimise chaotropic salt carry-over. (done) 
4. Dry silica membrane: 
a. Centrifuge 1 min at 11,000 x g, to remove residual ethanol. 
b. Place ISOLATE II PCR and Gel Column in a 1.5 ml microcentrifuge tube (not 
supplied). 
5. Elute DNA: 
a. Add 15-30 µl Elution Buffer C directly onto silica membrane. (20 µl was used) 
b. Incubate at room temperature for 1 min. 






Isolate II plasmid mini kit protocol 
 
1. Harvest bacterial cells: 
a. Pellet 1-5 ml of a saturated E. coli LB culture for 30 s at 11,000 x g. (the total 
volume of E. coli in LB was centrifuged – to do this, cultures were separated 
into aliquots of 5 ml) 
b. Discard supernatant and remove as much liquid as possible. 
2. Lyse cells: 
a. Add 250 µl Resuspension Buffer P1 and resuspend cell pellet by vortexing or 
pipetting up and down. 
b. Add 250 µl Lysis Buffer P2. Mix gently by inverting tube 6-8 times. Incubate at 
room temperature for up to 5 min or until lysate appears clear. 
c. Add 300 µl Neutralisation Buffer P3. Mix thoroughly by inverting tube 6-8 times.  
3. Clarification of lysate: 
a. Centrifuge 5 min at 11,000 x g at room temperature. 
4. Bind DNA: 
a. Place ISOLATE II Plasmid Mini Spin Column in a 2 ml Collection Tube (supplied). 
b. Decant or pipette a maximum of 750 µl of clarified sample supernatant onto 
column. (750 µl of each sample was used) 
c. Centrifuge 1 min at 11,000 x g and discard flow-through. 
5. Wash silica membrane: 
a. If plasmid DNA is prepared from host strains containing high levels of nucleases, 
an extra wash with Wash Buffer PW1 is strongly recommended. 
b. (Optional) Add 500 µl Wash Buffer PW1 preheated to 50°C. Centrifuge 1 min at 
11,000 x g. (done) 
c. Add 600 µl Wash Buffer PW2 (supplemented with ethanol). Centrifuge 1 min at 
11,000 x g. 
d. Discard flow-through and reuse Collection Tube. 
6. Dry silica membrane: 
a. Centrifuge 2 min at 11,000 x g, to remove residual ethanol. 
b. Place ISOLATE II Plasmid Mini Spin Column in a 1.5 ml microcentrifuge tube (not 
supplied). 
7. Elute DNA: 
a. Add 50 µl Elution Buffer P directly onto centre of silica membrane. (50 µl nuclease-
free water was used instead of Elution Solution) 
b. Incubate at room temperature for 1 min. 





Appendix J Filtered variants in Family 1 
 
 
Table J.1: Filtered cardiomyopathy panel variants in Family 1 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
MYH7 c.4394C>T p.S1465L 0 0 0 0 D (0.581) D (0.67) D (0) B (0.322) 25.4 4514.0 Yes 7/7 
MYOM1 c.139A>G p.S47G 0.003 0.005376 0.007187 0.00201 NS D (0.76) B (0.08) B (0.079) 21.9 207.1 NA 5/7 
PDE4DIP c.5599C>T p.R1867C 0 0.500000 0.500000 0.00008 NS D (0.94) D (0.01) D (0.989) 23.3 47.7 Yes 3/7 
PDE4DIP c.824C>T p.S275L 0 0.500000 0.500000 0.00008 NS B (0.99) B (0.15) B (0.031) 21.9 47.7 Yes 3/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 
Pathogenicity; MGI, Mouse Genome Informatics; MT, MutationTaster; NS, not scored; PP-2, PolyPhen-2; SIFT, Sorting Intolerant From Tolerant 
 
 
Table J.2: Other filtered variants in Family 1 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
ACO2 c.220C>G p.L74V 0.002 0.004144 0.003738 0.00415 D (0.175) D (0.99) D (0.01) D (0.485) 22.7 252.3 NA 5/7 
ADAT1 c.433G>A p.A145T 0 0 0 0 D (0.362) D (0.99) D (0) D (1) 32.0 1.8 NA 7/7 
APMAP c.479A>G p.N160S 0.001 0.001351 0.001202 0.00162 B (0.010) D (0.99) D (0.04) B (0.02) 23.2 19.1 NA 6/7 
ARHGAP4 c.1751T>G p.V584G 0 0 0 0 D (0.252) D (0.99) D (0) D (0.987) 25.2 6.3 NA 5/7 
ASB10 c.709C>G p.R237G 0.003 0.004366 0.004653 0.00508 B (0.017) B (0.99) B (0.16) B (0.262) 22.6 12.4 No 2/7 
ATG2A c.1585_6del p.R529G*4 0 0 0 0 NS D (1) NS NS 27.2 6.8 NA NS 
ATP7B c.1518A>G p.I506M 0 0 0 0 D (0.883) D (0.99) D (0) D (0.999) 20.5 1.6 No 5/7 
BCAP31 c.584C>T p.T195M 0.001 0.001327 0.001356 0.00114 D (0.414) B (0.00) D (0.01) D (0.986) 25.9 42.9 NA 5/7 
CCDC92 c.602C>T p.T201M 0.0004 0.000231 0.000181 0.00031 D (0.075) D (0.99) B (0.09) D (0.996) 23.5 14.6 No 5/7 
CEP350 c.1270T>A p.S424T 0 0.000683 0.000354 0.00046 B (0.019) D (0.99) B (0.13) D (0.955) 23.5 3.3 NA 6/7 
CMKLR1 c.311A>G p.H104R 0 0 0 0 D (0.100) B (0.52) D (0) D (0.980) 23.6 2.4 No 4/7 
CPEB2 c.337G>T p.A113S 0 0 0 0 D (0.619) B (0.99) B (0.25) Unknown 21.4 3.7 Yes 1/7 
Continued on next page 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 





Table J.2 continued 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
CSNK1D c.1_2dup p.M1? 0 0 0 0 NS D (0.99) NS NS 23.2 23.9 No NS 
DAAM2 c.1664C>T p.P555L 0.001 0.002073 0.000950 0.00121 D (0.157) D (0.99) B (0.18) D (0.994) 22.0 8.1 No 5/7 
DMXL2 c.6046G>A p.D2016N 0.0004 0.002070 0.001769 0.00270 D (0.027) D (0.99) B (0.33) B (0.012) 20.5 1.3 No 4/7 
EIF4ENIF1 c.97G>A p.E33K 0.003 0.003778 0.003884 0.00315 B (0.016) D (0.99) B (0.08) D (0.991) 32.0 7.6 Yes 7/7 
EIF5 c.998T>C p.I333T 0 0 0 0 D (0.050) D (0.99) B (0.19) D (0.586) 23.8 30.4 NA 5/7 
ERCC4 c.1031A>T p.Y344F 0.001 0.000091 0.000117 0.00054 D (0.026) D (0.99) B (0.1) B (0.026) 22.7 1.3 No 7/7 
ESYT1 c.797G>A p.R266Q 0.0004 0.000223 0.000212 0.00046 B (0.017) D (0.99) B (0.13) B (0.14) 23.6 15.3 NA 6/7 
ETV3 c.98G>A p.R33Q 0 0 0.000032 0 B (0.024) D (0.99) D (0) D (0.991) 31.0 2.9 No 6/7 
FAM135A c.626G>A p.S209N 0.003 0.006127 0.005981 0.00423 NS D (0.99) B (0.66) D (0.977) 22.9 1.8 NA 6/7 
FGD2 c.206G>C p.S69T 0.001 0.002056 0.001832 0.00277 B (0.015) B (0.59) B (0.08) D (0.971) 23.5 2.0 NA 3/7 
FMO2 c.584_5inv p.S195K 0 0.396000 0.394900 0 NS D (0.99) D (0) B (0.366) 23.7 19.7 No 5/7 
GALNS c.499T>G p.F167V 0.0004 0.000900 0.001068 0.00115 D (0.887) D (0.99) B (0.09) D (0.529) 24.3 4.6 No 5/7 
GORASP1 c.380C>T p.A127V 0.002 0.005482 0.004923 0.00431 D (0.069) D (0.99) D (0) D (0.971) 24.2 13.2 No 6/7 
ITPR2 c.3539G>A p.R1180Q 0.003 0.004389 0.004538 0.00566 NS D (0.61) B (0.99) B (0) 21.9 1.6 No 4/7 
JAG2 c.2459C>T p.A820V 0 0.002023 0.001231 0.00117 NS D (0.99) D (0) D (0.993) 25.1 12.5 No 5/7 
KCNJ12 c.467C>T p.P156L 0 0.499700 0.499800 0 NS D (0.99) D (0.04) D (1) 29.5 3.8 No 6/7 
KIAA1217 c.1523G>A p.R508H 0.003 0.005745 0.005301 0.00423 NS D (0.99) D (0) D (0.998) 29.2 6.9 No 5/7 
KIFC2 c.466del p.D156M*54 0 0 0 0 NS D (1) NS NS 22.6 5.3 No NS 
LAMA3 c.4643A>G p.D1548G 0.0002 0.000878 0.000941 0.00138 B (0.012) D (0.99) B (0.06) D (0.795) 25.1 1.2 No 4/7 
LEPREL1 c.1694T>A p.L565Q 0 0 0.000008 0 D (0.025) D (0.99) D (0) D (0.776) 29.9 1.1 No 7/7 
LGI4 c.68C>G p.P23R 0 0 0 0 D (0.025) D (0.99) B (0.27) D (0.659) 23.5 6.8 No 4/7 
LRCH4 c.853G>C p.A285P 0.004 0.005015 0.003946 0.00023 NS B (0.99) B (0.28) B (0.027) 20.2 19.2 NA 5/7 
MAP2K3 c.286C>T p.R96W 0 0.4998 0.490700 0 NS D (0.99) D (0) D (0.992) 33.0 20.7 No 5/7 
MAST4 c.3922C>T p.R1308W 0 0.000124 0.000128 0.00033 D (0.125) D (0.68) D (0) D (1) 24.1 7.6 No 2/7 
MDN1 c.14648A>G p.D4883G 0.006 0.010190 0.009027 0.01084 NS D (0.99) D (0) D (0.494) 25.3 4.2 No 5/7 
METTL1 c.137G>C p.W46S 0 0 0 0 D (0.063) D (0.99) D (0) D (0.988) 31.0 2.9 NA 6/7 
MRI1 c.269G>T p.R90L 0.001 0.002198 0.002628 0.00191 D (0.399) D (0.99) D (0.03) D (1) 26.6 4.7 NA 5/7 
MTERF c.994A>G p.I332V 0.0002 0.000305 0.000290 0.00008 B (0.004) D (0.57) B (0.05) B (0.015) 21.4 1.5 Yes 4/7 
MTIF3 c.413A>G p.Q138R 0.004 0.008140 0.007611 0.00869 NS D (0.61) D (0) B (0.265) 22.2 61.8 No 7/7 
NDEL1 c.100C>G p.R34G 0 0 0 0 B (0.008) D (0.99) D (0) B (0.258) 25.7 8.2 No 7/7 
NDNL2 c.400C>T p.L134F 0 0 0 0 B (0.008) D (0.99) B (0.11) D (0.914) 24.0 3.3 NA 3/7 
NRP1 c.1295C>T p.S432F 0.0004 0.000348 0.000384 0.00023 D (0.826) D (0.99) D (0) D (0.997) 28.6 16.6 No 6/7 
NSL1 c.794C>T p.P265L 0 0.000734 0.000651 0.00054 B (0.017) D (0.99) D (0) B (0.251) 24.1 4.1 No 4/7 
OR51E1 c.896A>G p.K299R 0.004 0.004533 0.005033 0.00369 NS B (0.86) D (0.04) B (0.025) 23.2 1.6 NA 5/7 
PCK2 c.1679G>A p.R560Q 0.0002 0.000503 0.000446 0.00069 B (0.010) D (0.99) B (0.11) B (0.103) 24.2 1.3 NA 4/7 
PCNX c.3817G>T p.G1273C 0.0004 0.000973 0.000945 0.00092 D (0.025) D (0.99) D (0) D (0.754) 29.7 5.5 NA 5/7 
PHC3 c.1532T>C p.I511T 0 0.000066 0.000064 0.00008 B (0.005) B (0.85) D (0.03) B (0.035) 22.8 2.4 Yes 5/7 
Continued on next page 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 




Table J.2 continued 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
PITPNM1 c.2398G>A p.G800S 0.0002 0.000062 0.000028 0 B (0.021) D (0.99) B (0.36) D (0.649) 23.5 14.4 No 5/7 
PLXND1 c.2174T>C p.F725S 0 0 0 0 B (0.009) B (0.97) B (0.39) B (0.007) 21.0 18.4 Yes 4/7 
PMM1 c.588G>C p.W196C 0 0.000482 0.000439 0.00031 D (0.880) D (0.99) D (0.01) D (1) 24.5 12.8 No 5/7 
PPP1R3A c.785A>G p.K262R 0 0 0 0 B (0.009) D (0.99) D (0.02) B (0.354) 24.1 17.3 No 6/7 
RIC3 c.934G>A p.D312N 0.003 0.003748 0.003882 0.00570 B (0.013) D (0.99) B (0.05) D (0.998) 24.4 2.9 NA 6/7 
RIOK2 c.730A>G p.M244V 0.004 0.009764 0.008764 0.00754 NS D (0.99) B (0.27) B (0.088) 21.8 3.4 Yes 6/7 
RRAGD c.203T>C p.M68T 0 0 0 0 D (0.400) D (0.99) D (0) D (0.997) 26.4 24.2 NA 6/7 
SBF2 c.2938A>G p.I980V 0 0.000074 0.000060 0.00023 D (0.036) D (0.99) B (0.06) B (0.109) 21.7 4.2 No 6/7 
SEC24A c.3053C>T p.P1018L 0.001 0.003018 0.002998 0.00136 NS D (0.99) D (0) D (0.923) 27.2 2.6 No 6/7 
SEMA6C c.824G>A p.R275H 0.0004 0.000129 0.002628 0 B (0.010) D (0.99) D (0) D (0.954) 28.1 17.7 No 4/7 
SIPA1L1 c.166C>A p.P56T 0.002 0.007484 0.007982 0.00869 NS D (0.99) B (0.08) B (0.193) 20.6 1.1 No 6/7 
SLC9A9 c.991G>A p.G331S 0.0002 0.000083 0.000078 0 B (0.008) D (0.99) D (0.02) B (0.302) 23.7 1.3 NA 5/7 
SORL1 c.6194A>T p.D2065V 0.001 0.002823 0.002537 0.00423 D (0.071) D (0.99) D (0) D (0.997) 28.5 1.0 No 5/7 
SPAG4 c.5G>A p.R2Q 0.002 0.000544 0.000540 0.00178 B (0.011) B (0.62) B (0.06) B (0.003) 21.8 1.4 No 4/7 
STAB1 c.5195C>T p.A1732V 0 0 0 0 D (0.141) D (0.52) D (0.03) D (0.999) 24.0 19.8 NA 5/7 
STARD13 c.3022C>T p.P1008S 0.004 0.000840 0.000870 0.00223 NS D (0.99) D (0) D (0.996) 31.0 5.9 No 7/7 
SYTL3 c.1169G>A p.R390Q 0 0.000161 0.000196 0.00015 B (0.019) D (0.98) D (0) B (0.434) 22.7 3.9 NA 5/7 
TBC1D10A c.997G>A p.G333S 0 0 0 0 B (0.017) D (0.99) D (0) B (0.223) 26.0 4.8 No 6/7 
TJP1 c.1412A>G p.N471S 0.005 0.009164 0.009063 0.00975 NS D (0.99) D (0.02) B (0.04) 23.0 15.0 Yes 7/7 
TMED8 c.361G>A p.D121N 0.001 0.003839 0.004707 0.00269 NS D (0.99) D (0.02) D (0.996) 28.8 2.0 NA 6/7 
TMEM41A c.586T>C p.Y196H 0.002 0.005235 0.005435 0.00538 NS D (0.99) D (0.03) D (1) 32.0 5. 5 NA 7/7 
TNXB c.1307C>G p.P436R 0 0 0 0 B (0.018) B (0.80) D (0) D (0.997) 25.3 10.6 Yes 1/7 
TRIM4 c.586C>T p.R196* 0 0.000041 0.000032 0 NS D (0.99) NS NS 35.0 3.8 NA 1/7 
TTC21B c.3004C>G p.L1002V 0.001 0.005608 0.005246 0.00654 D (0.027) D (0.99) D (0) D (0.628) 24.3 3.4 No 6/7 
TTI1 c.2089T>C p.Y697H 0.001 0.000264 0.000308 0.00077 D (0.042) D (0.99) D (0) D (0.999) 28.3 4.9 NA 7/7 
UGGT2 c.3820T>C p.F1274L 0.005 0.007618 0.007852 0.00716 NS D (0.99) B (0.17) D (0.791) 25.7 2.3 NA 6/7 
VILL c.838G>C p.E280Q 0.0004 0.000369 0.000277 0.00046 B (0.012) B (0.85) B (0.07) B (0.296) 20.0 1.9 NA 3/7 
VTN c.1208C>T p.S403F 0 0.000272 0.000264 0 B (0.006) B (0.67) B (0.15) D (0.473) 20.8 5.5 No 5/7 
XRN2 c.1173G>C p.M391I 0.0002 0.000363 0.000305 0.00054 B (0.009) D (0.99) B (0.09) B (0.003) 22.7 17.4 NA 7/7 
ZNF548 c.982A>G p.K328E 0 0 0 0 B (0.004) B (0.98) D (0) D (0.964) 24.7 2.6 NA 1/7 
ZNF623 c.446A>T p.K149I 0.002 0.004336 0.004117 0.00546 D (0.054) B (0.80) D (0) D (0.887) 23.9 2.7 NA 2/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 
Pathogenicity; MGI, Mouse Genome Informatics; MT, MutationTaster; NS, not scored; PP-2, PolyPhen-2; SIFT, Sorting Intolerant From Tolerant 
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Appendix K Segregation of candidate variants in Family 1 
 
 
Figure K.1: Pedigree indicating segregation of TJP1 c.1412A>G in Family 1. Individuals marked ‘TJP1 
pos’ were heterozygous for the variant and those marked ‘TJP1 neg’ tested negative for it. DNA was not 
available for unmarked individuals. Squares represent males and circles represent females. Symbols that 
are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. Blue shading 
indicates individuals diagnosed with DCM. No shading indicates that the individual has no reported 
cardiomyopathy. Numbers in Roman numerals are the generation number while Arabic numerals denote 




Figure K.2: Pedigree indicating segregation of LAMA3 c.4643A>G in Family 1. Individuals marked 
‘LAMA3 pos’ were heterozygous for the variant and those marked ‘LAMA3 neg’ tested negative for it. DNA 
was not available for unmarked individuals. Squares represent males and circles represent females. 
Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. 
Blue shading indicates individuals diagnosed with DCM. No shading indicates that the individual has no 
reported cardiomyopathy. Numbers in Roman numerals are the generation number while Arabic numerals 
denote individuals. The index case is indicated with an arrow. 
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Figure K.3: Pedigree indicating segregation of ABCB4 c.523A>G in Family 1. Individuals marked 
‘ABCB4 pos’ were heterozygous for the variant and those marked ‘ABCB4 neg’ tested negative for it. DNA 
was not available for unmarked individuals. Squares represent males and circles represent females. 
Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. 
Blue shading indicates individuals diagnosed with DCM. No shading indicates that the individual has no 
reported cardiomyopathy. Numbers in Roman numerals are the generation number while Arabic numerals 
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Appendix L Filtered variants in Family 2 
 
 
Table L.1: Filtered cardiomyopathy panel variants in Family 2 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
GBE1 c.664A>G p.N222D 0 0 0 0 D (0.040) D (0.99) B (0.37) B (0.021) 22.4 24.5 Yes 3/7 
GLA c.774_775delAC p.P259R*5 0 0 0 0 NS D (1) NS NS 35.0 4.0 Yes NS 
LAMA2 c.7040G>T p.G2347V 0.004 0.000157 0.0001156 0 D (0.148) D (0.99) D (0) D (0.952) 32.0 33.1 No 5/7 
MYBPC3 c.3392T>C p.I1131T 0 0.001064 0.0008403 0.00057 D (0.184) D (0.99) D (0.04) B (0.400) 24.3 1369.0 Yes 7/7 
PDE4DIP c.1864C>T p.R622* 0 0.500000 0.500000 0 NS D (1) NS NS 35.0 47.7 Yes NS 
PKP2 c.1592T>G p.I531S 0.001 0.004722 0.004722 0.00323 NS D (0.80) D (0) D (0.974) 24.8 84.1 Yes 6/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 
Pathogenicity; MGI, Mouse Genome Informatics; MT, MutationTaster; NS, not scored; PP-2, PolyPhen-2; SIFT, Sorting Intolerant From Tolerant 
 
 
Table L.2: Other filtered variants in Family 2 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
ADAM17 c.148A>G p.I50V 0.002 0.003696 0.003778 0.00300 B (0.004) D (0.77) B (0.25) B (0.354) 20.8 3.5 Yes 5/7 
ADCK1 c.386A>G p.E129G 0 0.000008 0.000048 0 D (0.066) D (0.99) D (0.01) B (0.127) 24.0 5.6 No 6/7 
AGRN c.1660G>A p.V554M 0.011 0.008835 0.008361 0.00300 NS D (0.99) D (0) D (0.997) 24.9 6.8 No 6/7 
ANK3 c.4400A>G p.K1467R 0.0002 0.000675 0.000587 0.00100 B (0.022) D (0.99) D (0.01) D (0.824) 26.7 5.7 No 5/7 
BLOC1S2 c.11C>T p.A4V 0 0.000228 0.000206 0.00025 B (0.020) B (0.99) D (0.03) B (0) 20.9 6.4 Yes 2/7 
C21orf91 c.16C>A p.Q6K 0 0 0 0 B (0.006) D (0.99) D (0.02) B (0.19) 23.7 1.7 NA 5/7 
C2CD3 c.2659G>A p.V887M 0.003 0.004750 0.004726 0.00524 NS B (0.74) B (0.35) D (0.565) 23.2 2.1 Yes 3/7 
CAD c.1433G>C p.G478A 0 0 0 0 D (0.620) D (0.99) D (0) D (0.962) 25.2 2.8 No 5/7 
CCDC85B c.451C>G p.R151G 0 0 0 0 D (0.114) D (0.99) B (0.23) B (0.434) 23.0 33.7 NA 5/7 
CELSR1 c.4447G>A p.G1483S 0 0 0.000004 0 D (0.258) D (0.99) D (0) D (0.998) 28.4 1.2 No 1/7 
Continued on next page 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 





Table L.2 continued 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
CENPO c.583G>C p.D195H 0.0004 0.000066 0.000120 0.00015 B (0.013) D (0.98) D (0) D (1) 28.0 1.6 No 4/7 
CEP68 c.1882A>G p.K628E 0 0 0 0 D (0.041) D (0.80) D (0.02) D (0.453) 24.4 4.9 No 5/7 
CES1 c.148A>G p.I50V 0 0.316800 0.185300 0 NS B (0.99) B (1) B (0) 22.7 32.1 No 5/7 
CHST3 c.277C>G p.R93G 0 0 0 0 D (0.061) D (0.92) D (0.02) B (0.182) 23.7 8.1 No 5/7 
CREB3L1 c.599A>T p.D200V 0.0002 0.003861 0.003617 0.00413 B (0.010) D (0.99) D (0) B (0.091) 23.7 14.1 No 4/7 
CREBBP c.5837del p.P1946H*30 0 0 0 0 NS D (1) NS NS 33.0 7.3 Yes NS 
CTNNAL1 c.2041A>G p.K681E 0 0 0 0 D (0.025) B (0.91) D (0.01) B (0.189) 23.8 21.8 No 3/7 
DDRGK1 c.916C>T p.R306W 0 0.000025 0.000028 0.00008 B (0.007) B (0.99) D (0.02) B (0.001) 24.1 18.9 No 4/7 
DDX24 c.1805G>A p.R602H 0.0002 0.001458 0.001280 0.00138 B (0.011) D (0.99) D (0) D (0.997) 34.0 44.4 No 3/7 
DDX31 c.1061G>A p.R354H 0.001 0.002503 0.002378 0.00208 D (0.036) D (0.99) D (0) D (1) 33.0 1.5 No 5/7 
DST c.7678G>A p.D2560N 0 0.000017 0.000016 0 B (0.003) D (0.54) D (0.02) B (0.236) 24.9 18.8 No 5/7 
ERC1 c.659A>C p.E220A 0 0.000042 0.000080 0.00023 B (0.017) D (0.99) B (0.14) D (0.84) 25.0 5.6 No 5/7 
FAM13A c.1793C>T p.P598L 0.0002 0.000058 0.000085 0.00008 D (0.069) D (0.99) D (0.01) B (0.397) 23.2 1.9 No 7/7 
FAT1 c.7700G>A p.R2567H 0.004 0.008599 0.008242 0.00996 NS D (0.73) B (0.56) D (0.888) 23.2 5.1 No 3/7 
FGD6 c.2255G>T p.R752L 0.005 0.007959 0.008498 0.00792 NS B (0.99) D (0.04) B (0.103) 22.9 1.6 NA 3/7 
GAK c.2359G>T p.D787Y 0.004 0.013170 0.008759 0.01054 NS B (0.99) D (0) D (0.73) 21.9 9.5 No 5/7 
ICAM1 c.1432C>T p.R478W 0.003 0.004105 0.003812 0.00461 B (0.010) B (0.99) D (0.04) D (0.797) 21.2 5.5 Yes 1/7 
KAT6B c.5749A>G p.I1917V 0 0.000190 0.000199 0.00015 D (0.016) D (0.99) D (0) B (0.045) 23.6 3.1 No 5/7 
KIAA0100 c.3263C>T p.S1088L 0 0.000034 0.000024 0.00008 B (0.021) D (0.99) B (0.14) D (0.997) 25.3 17.4 NA 5/7 
KIF7 c.2552G>A p.R851H 0 0.000044 0.000028 0 D (0.084) D (0.99) D (0.04) D (0.974) 31.0 2.2 Yes 6/7 
KMT2D c.2243insC p.E748D*10 0 0 0 0 NS D (1) NS NS 23.6 6.0 Yes NS 
LGI4 c.68C>G p.P23R 0 0 0 0 D (0.025) D (0.99) B (0.27) D (0.659) 23.5 6.8 No 4/7 
LRP5L c.118G>C p.A40P 0.001 0.000948 0.001185 0.00162 D (0.035) D (0.99) D (0) D (0.999) 22.9 1.7 NA 5/7 
LUM c.596T>C p.L199P 0.001 0.002397 0.002246 0.00331 D (0.153) D (0.99) D (0) D (0.971) 28.9 33.9 Yes 7/7 
MKL1 c.1322T>G p.V441G 0.004 0.003795 0.001992 0 NS D (0.99) D (0.01) B (0.399) 23.8 7.0 Yes 5/7 
MOXD1 c.1267G>T p.E423* 0 0 0.000011 0 NS D (1) NS NS 44.0 1.1 No 5/7 
MROH7 c.3091C>G p.R1031G 0 0.000251 0.000202 0.00024 B (0.011) B (0.99) B (0.15) B (0.43) 22.0 5.8 NA 3/7 
MYBBP1A c.358G>C p.D120H 0.002 0.007821 0.007401 0.00761 NS B (0.99) D (0.01) D (0.682) 22.4 9.7 No 3/7 
MYO1C c.2574A>C p.K858N 0.004 0.007805 0.006439 0.00715 NS D (0.91) D (0.04) B (0.024) 21.8 46.8 No 4/7 
NAPEPLD c.718G>A p.G240R 0 0.000008 0.000014 0 D (0.039) D (0.99) B (0.06) B (0.04) 22.8 2.4 No 6/7 
NOC3L c.971del p.L324R*6 0 0.000824 0.000962 0 NS D (1) NS NS 35.0 2.5 No NS 
NRDE2 c.89G>A p.S30N 0.0002 0.001895 0.001960 0.00338 D (0.032) D (0.99) D (0) D (0.979) 25.1 1.8 No 6/7 
NSA2 c.767C>T p.A256V 0 0.000050 0.000046 0 B (0.008) D (0.99) B (0.05) D (0.996) 27.1 27.0 No 7/7 
NUP133 c.2561G>A p.G854D 0.002 0.004386 0.004562 0.004466 B (0.022) D (0.99) D (0.03) D (0.966) 27.9 9.1 Yes 6/7 
NUP210 c.5504G>T p.R1835L 0 0 0 0 D (0.052) D (0.97) D (0.04) B (0.103) 22.3 1.3 No 6/7 
ODF2L c.1689dup p.K564* 0.001 0.000479 0.000474 0 NS D (0.99) NS NS 35.0 1.9 NA 4/7 
OLFML1 c.158C>T p.T53M 0.001 0.003292 0.003179 0.00354 D (0.074) D (0.91) B (0.13) D (0.893) 23.8 3.0 NA 4/7 
PCNX c.6067A>G p.R2023G 0 0.000091 0.000078 0.00008 B (0.020) D (0.99) B (0.06) B (0.021) 22.7 5.5 NA 6/7 
Continued on next page 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 




Table L.2 continued 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
PDE4C c.430G>A p.D144N 0.001 0.000389 0.000432 0.00038 D (0.051) D (0.99) D (0.05) B (0.265) 24.4 1.1 No 2/7 
PFKP c.1577A>G p.E526G 0.003 0.005307 0.004841 0.00577 D (0.032) D (0.81) B (0.06) B (0.02) 23.3 44.8 NA 6/7 
PIP4K2B c.553G>A p.G185S 0.001 0.002867 0.002966 0.00292 D (0.065) D (0.99) D (0.01) D (0.956) 29.5 16.0 No 5/7 
PIP5K1C c.1648A>G p.R550G 0 0.000125 0.000110 0.00031 D (0.069) D (0.98) D (0) B (0.231) 23.3 13.8 No 4/7 
PPM1F c.136G>T p.G46W 0.0002 0.000025 0.000012 0 D (0.076) B (0.99) D (0) D (0.963) 22.3 6.6 No 5/7 
PPP1R21 c.1253C>G p.T418R 0 0.000017 0.000008 0 B (0.004) D (0.55) B (0.2) B (0.023) 22.3 4.4 No 5/7 
PPP6R1 c.1988G>A p.R663Q 0.003 0.014040 0.005753 0.00401 NS D (0.70) D (0.05) D (0.953) 26.9 19.5 NA 3/7 
PRKDC c.8689C>T p.L2897F 0 0.000047 0.000054 0 B (0.008) D (0.86) D (0.01) D (0.807) 23.2 7.1 No 6/7 
PROS1 c.939A>T p.L313F 0 0 0 0 D (0.049) D (0.99) D (0) D (0.996) 24.0 16.7 Yes 5/7 
PTPN13 c.2258C>T p.T753I 0 0 0 0 D (0.045) D (0.99) D (0) D (0.988) 26.3 1.4 No 6/7 
PTPN2 c.244A>C p.S82R 0 0 0.000008 0 B (0.014) B (0.52) B (0.11) B (0.072) 22.9 2.6 No 3/7 
RAD23B c.464C>T p.T155I 0 0.000008 0.000008 0.00008 B (0.009) D (0.93) D (0.05) B (0.034) 23.8 31.7 Yes 3/7 
RC3H2 c.2030C>T p.P677L 0 0.0000911 0.000093 0 B (0.018) D (0.99) D (0.02) D (0.982) 28.2 4.8 No 5/7 
REPS1 c.1967C>T p.P656L 0.003 0.0006591 0.000721 0.00169 NS D (0.99) B (0.17) B (0.023) 23.9 5.3 NA 3/7 
RIC3 c.362G>C p.G121A 0.003 0.007348 0.007448 0.00970 NS D (0.99) D (0.04) D (0.999) 26.1 2.9 NA 6/7 
SASH1 c.2459G>A p.R820Q 0.002 0.001606 0.001584 0.00131 B (0.017) D (0.99) D (0) D (0.994) 32.0 6.7 Yes 4/7 
SEC24C c.2483C>T p.A828V 0 0.000692 0.000598 0.00062 D (0.089) D (0.99) D (0) D (0.683) 28.0 15.3 No 7/7 
SLC20A2 c.295G>A p.A99T 0 0.000059 0.000054 0.00008 D (0.238) D (0.99) D (0) D (0.844) 24.6 19.5 No 7/7 
SLC25A25 c.1456A>G p.I486V 0 0.000018 0.000019 0 D (0.055) D (0.99) B (0.05) B (0.365) 23.1 2.9 No 7/7 
SLC9A8 c.26A>C p.E9A 0.004 0.008874 0.008854 0.01136 D (0.125) B (0.92) B (0.38) B (0) 23.8 3.9 No 3/7 
SMARCD1 c.1444G>A p.G482R 0 0.000008 0.000004 0 D (0.050) D (0.99) B (0.09) B (0.031) 23.0 3.6 Yes 5/7 
SNRPA c.208C>T p.R70C 0 0 0.000004 0 D (0.078) D (0.99) D (0) B (0.001) 23.1 19.2 NA 5/7 
SORBS2 c.322T>C p.F108L 0.004 0.008899 0.009501 0.00754 NS D (0.99) B (0.15) D (0.995) 24.7 67.1 Yes 7/7 
SPATA13 c.594C>A p.H198Q 0 0 0 0 D (0.187) P (0.95) D (0.01) D (0.996) 23.8 3.3 No 2/7 
STARD3 c.1055G>A p.R352H 0.0002 0.001709 0.001536 0.00138 D (0.112) D (0.99) B (0.34) D (0.626) 24.0 10.5 No 6/7 
TDRD7 c.1760A>G p.D587G 0 0 0 0 B (0.014) D (0.99) D (0.03) D (0.734) 26.1 3.3 No 6/7 
TGS1 c.344C>T p.S115F 0.003 0.025590 0.009407 0.00808 NS B (0.97) D (0) D (0.936) 24.0 3.3 No 4/7 
TNXB c.1307C>G p.P436R 0 0 0 0 B (0.018) P (0.80) D (0) D (0.997) 25.3 10.6 Yes 1/7 
TRAP1 c.776delinsAC p.S259L 0 0 0 0 NS D (0.97) B (0.28) B (0.015) 20.9 22.1 No 3/7 
TRPM4 c.2674C>T p.R892C 0 0.000511 0.000577 0.00077 D (0.283) D (0.99) D (0) D (0.993) 26.9 12.1 Yes 5/7 
UAP1 c.989A>G p.N330S 0.001 0.002489 0.002554 0.00238 D (0.032) D (0.99) D (0.01) D (0.994) 26.0 14.3 NA 7/7 
VPS13D c.7294C>T p.R2432C 0.002 0.002117 0.002288 0.00315 B (0.003) D (0.99) D (0.02) B (0.062) 23.2 9.7 No 3/7 
ZNF3 c.679C>T p.P227S 0 0 0 0 B (0.017) D (0.99) D (0.01) D (0.725) 26.1 5.4 NA 4/7 
ZNF35 c.752A>T p.E251V 0 0 0 0 B (0.006) B (0.99) D (0.02) D (0.475) 24.5 2.5 No 4/7 
ZNF527 c.1396G>A p.G466R 0 0.000008 0.000021 0 B (0.007) D (0.98) D (0) D (0.884) 25.2 1.1 NA 3/7 
ZNF580 c.75G>C p.K25N 0 0 0 0 D (0.041) B (0.95) D (0.04) B (0.234) 23.9 11.2 NA 2/7 
ZNF638 c.4856T>C p.V1619A 0 0 0 0 B (0.018) D (0.92) B (0.19) D (0.675) 24.2 12.0 NA 5/7 
ZZEF1 c.764A>G p.Y255C 0.002 0.007044 0.005582 0.00469 B (0.022) B (0.87) B (0.15) D (0.806) 23.6 7.4 No 5/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 
Pathogenicity; MGI, Mouse Genome Informatics; MT, MutationTaster; NS, not scored; PP-2, PolyPhen-2; SIFT, Sorting Intolerant From Tolerant 
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Appendix M Filtered variants in Family 3 
 
 
Table M.1: Filtered cardiomyopathy panel variants in Family 3 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
TTN c.16529A>G p.Y5510C 0.007 0.002240 0.002213 0.00025 NS D (0.99) NS D (0.715) 21.0 67.7 Yes 3/7 
TTN c.76739C>T p.T25580M 0.005 0.001661 0.001618 0.00917 NS D (0.99) NS B (0.191) 22.2 67.7 Yes 5/7 
SYNE2 c.12001_12002inv p.W4001Q 0 0 0 0 NS B (0.99) NS B (0) 23.7 9.1 No 0/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 




Table M.2: Other filtered variants in Family 3 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
ADCK1 c.1456G>A p.E486K 0 0.000025 0.000014 0.00008 D (0.044) D (0.99) B (0.22) B (0.163) 22.5 5.6 No 7/7 
ARFGAP3 c.1210C>T p.R404C 0.0002 0.000140 0.000135 0.00031 D (0.095) D (0.99) D (0.01) D (0.912) 32.0 12.1 NA 5/7 
ARRDC2 c.40G>C p.D14H 0.001 0.000281 0.000256 0.00131 D (0.091) D (0.99) D (0) D (0.9) 24.9 12.5 No 6/7 
C22orf23 c.323G>A p.R108Q 0 0.000008 0.000012 0 D (0.062) D (0.99) D (0) D (0.999) 31.0 1.9 NA 6/7 
DIAPH1 c.2525A>C p.Q842P 0.005 0.003277 0.002593 0 NS D (0.99) B (0.36) D (0.966) 24.4 17.6 No 3/7 
DNAJC28 c.472A>G p.R158G 0 0 0 0 D (0.032) D (0.99) D (0) D (0.997) 25.0 1.4 No 4/7 
FAM104B c.331C>T p.R111* 0 0.000461 0.000034 0 NS B (0.98) NS NS 34.0 3.8 NA NS 
FN3KRP c.259G>T p.V87L 0 0 0 0 B (0.009) D (0.99) D (0.02) B (0.443) 23.0 7.5 NA 6/7 
FN3KRP c.468+1G>A - 0 0.000025 0.000008 0 NS D (1) NS NS 34.0 7.5 NA NS 
GADD45GIP1 c.281C>G p.P94R 0.004 0.000972 0.000951 0.00300 NS D (0.99) D (0) D (0.993) 23.1 47.5 No 4/7 
MANBA c.2356A>G p.N786D 0 0 0.000004 0 D (0.048) D (0.99) D (0.02) B (0.26) 23.2 5.0 Yes 6/7 
Continued on next page 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 





Table M.2 continued 
VARIANT IDENTIFIERS POPULATION FREQUENCIES PATHOGENICITY PREDICTION OTHER DATABASES 
Gene Variant Protein 1000G ExAC  gnomAD  EVS  M-CAP MT SIFT PP-2 CADD GTex MGI* Cons. 
TIPARP c.569A>G p.Q190R 0 0 0 0 B (0.011) D (0.99) D (0.03) D (0.549) 24.3 6.7 Yes 6/7 
TMEM184B c.1048G>A p.V350M 0 0.000017 0.000025 0 B (0.016) D (0.99) B (0.37) B (0.324) 22.7 21.5 Yes 6/7 
TRPV1 c.860C>T p.T287M 0.001 0.000504 0.000223 0.00086 D (0.035) D (0.99) D (0.03) D (0.943) 24.4 4.0 Yes 5/7 
XRN1 c.5006A>G p.E1669G 0 0.000008 0.000004 0 B (0.006) D (0.50) B (0.2) B (0.007) 21.9 2.5 NA 4/7 
ZNF3 c.679C>T p.P227S 0 0 0 0 B (0.017) D (0.99) D (0.01) D (0.725) 26.1 5.4 No 4/7 
ZNF548 c.980G>A p.G327E 0 0 0 0 B (0.018) B (0.52) D (0) D (0.991) 24.7 2.6 NA 1/7 
ZNF548 c.982A>G p.K328E 0 0 0 0 B (0.004) B (0.98) D (0) D (0.964) 24.7 2.6 NA 1/7 
* Yes indicates mice with cardiovascular phenotypes have been recorded in the MGI database, while No indicates that no cardiovascular phenotype was found for 
these mice. NA indicates no phenotypes are recorded for the gene, or no mouse orthologue for the gene exists. 
1000G, 1000 Genomes Project; B, benign; CADD, Combined Annotation Dependent Depletion; Cons.: conservation; D, deleterious; ExAC, Exome Aggregation 
Consortium; EVS, Exome Variant Server; gnomAD, Genome Aggregation Database; GTex, Genotype-Tissue Expression; M-CAP, Mendelian Clinically Applicable 








Figure N.1: Pedigree indicating segregation of KCNK10 c.1052A>G in Family 3. Individuals marked ‘KCNK10 pos’ were heterozygous for the 
variant and those marked ‘KCNK10 neg’ tested negative for it. DNA was not available for unmarked individuals. Squares represent males and circles 
represent females. Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. Blue shading indicates 
DCM, green shading indicates diabetes mellitus and brown shading indicates obesity. No shading indicates that the individual has no reported 
conditions. Numbers in Roman numerals are the generation number while Arabic numerals denote individuals. The index case is indicated with an 
arrow. 
KCNK10 pos KCNK10 
pos KCNK10 
neg 
KCNK10 neg KCNK10 neg 
KCNK10 neg KCNK10 neg 
KCNK10 neg KCNK10 neg 













H. sapiens E I K A H A A E W K A N V T A E F R E T R R R 
M. mulatta E I K A H A A E W K A N V T A E F R E T R R R 
P. troglodites E I K A H A A E W K A N V T A E F R E T R R R 
F. catus E I K A H A A E W K A N V T A E F R E T R R R 
M. musculus E I K A H A A E W K A N V T A E F R E T R R R 
G. gallus E I K A H A A E W K A N V T A E F R E T R R R 
D. rerio E I K A H A A E W K A N V R A E L R E T R R R 
X. tropicalis E I K A H A A E W K A N V T A E F R E T R R R 
 
Figure N.2: KCNK10 c.1052A>G identified in Family 3. (A) Protein structure of KCNK10 with position of 
the p.N351S mutation marked with an arrow, (B) Multiple species conservation alignment of the p.N351 
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Figure O.1: Pedigree indicating segregation of HEXB c.1250C>T in Family 4. Individuals marked 
‘HEXB pos’ were heterozygous for the variant and those marked ‘HEXB neg’ tested negative for it. DNA was 
not available for unmarked individuals. Squares represent males and circles represent females. Symbols 
that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. Purple 
shading indicates individuals diagnosed with ACM, while grey shading indicates sudden cardiac death. No 
shading indicates that the individual has no reported cardiomyopathy. Numbers in Roman numerals are the 
generation number while Arabic numerals denote individuals. The index case is indicated with an arrow. 
HEXB pos HEXB pos HEXB pos HEXB pos 
HEXB pos HEXB 




Figure O.2: Pedigree indicating segregation of NDUFB1 c.257G>C in Family 4. Individuals marked 
‘NDUFB1 pos’ were heterozygous for the variant and those marked ‘NDUFB1 neg’ (B) tested negative for it. 
DNA was not available for unmarked individuals. Squares represent males and circles represent females. 
Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. 
Purple shading indicates individuals diagnosed with ACM, while grey shading indicates sudden cardiac 
death. No shading indicates that the individual has no reported cardiomyopathy. Numbers in Roman 
numerals are the generation number while Arabic numerals denote individuals. The index case is indicated 
with an arrow. 
  
NDUFB1 pos NDUFB1 pos NDUFB1 pos NDUFB1 
pos 
NDUFB1 neg NDUFB1 pos NDUFB1 
pos NDUFB1 





Figure O.3: Pedigree indicating segregation of PXDNL c.2218C>T in Family 4. Individuals marked 
‘PXDNL pos’ were heterozygous for the variant and those marked ‘PXDNL neg’ tested negative for it. DNA 
was not available for unmarked individuals. Squares represent males and circles represent females. 
Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. 
Purple shading indicates individuals diagnosed with ACM, while grey shading indicates sudden cardiac 
death. No shading indicates that the individual has no reported cardiomyopathy. Numbers in Roman 
numerals are the generation number while Arabic numerals denote individuals. The index case is indicated 






PXDNL neg PXDNL neg PXDNL neg 
PXDNL neg PXDNL neg PXDNL pos 





Figure O.4: pedigree indicating segregation of TTN c.3899A>G in Family 4. Individuals marked 
‘c.3899A>G pos’ were heterozygous for the variant and those marked ‘c.3899A>G neg’ tested negative for it. 
DNA was not available for unmarked individuals. Squares represent males and circles represent females. 
Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. 
Purple shading indicates individuals diagnosed with ACM, while grey shading indicates sudden cardiac 
death. No shading indicates that the individual has no reported cardiomyopathy. Numbers in Roman 
numerals are the generation number while Arabic numerals denote individuals. The index case is indicated 
with an arrow. 
 
 
Figure O.5: Pedigree indicating segregation of TTN c.24083G>C in Family 4. Individuals marked 
‘c.24083G>C pos’ were heterozygous for the variant and those marked ‘c.24083G>C neg’ tested negative for 
it. DNA was not available for unmarked individuals. Squares represent males and circles represent females. 
Symbols that are crossed out indicate deceased individuals. Shaded symbols indicate affected individuals. 
Purple shading indicates individuals diagnosed with ACM, while grey shading indicates sudden cardiac 
death. No shading indicates that the individual has no reported cardiomyopathy. Numbers in Roman 
numerals are the generation number while Arabic numerals denote individuals. The index case is indicated 
with an arrow. 
 
c.3899A>G neg c.3899A>G 
neg c.3899A>G pos c.3899A>G pos 
c.3899A>G pos c.3899A>G pos 
c.3899A>G pos c.3899A>G pos c.3899A>G 
neg 
c.24083G>C pos c.24083G>C pos c.24083G>C neg c.24083G>C neg 
c.24083G>C neg c.24083G>C pos c.24083G>C pos 
















H. sapiens A V S P M S Y Y Q R P F S P S A Y S L P A S L 
M. mulatta A V S P M S Y Y Q R P F S P S A Y S L P A S L 
P. troglodites A V S P M S Y Y Q R P F S P S A Y S L P A S L 
F. catus A V S P M S Y Y Q R P F S P S A Y S L P G S L 
M. musculus A V S P V S Y Y Q R P F S P S A Y S L P A S L 
G. gallus A A S P V S H F Q R P F S P SS A Y S P P A S L 
D. rerio P A S P R S H I Q R P F S P S T Y P P P P S L 
X. tropicalis P A S P M S H Y Q R T F S P SP T Y P S S R S L 
 
Figure P.1: SORBS2 c.322T>C identified in Family 4. (A) Protein structure of SORBS2 with position of 
the p.F108L mutation marked with an arrow, (B) Multiple species conservation alignment of the p.F108 
residue of SORBS2 (shaded in blue). SH3, Src Homology-3; SoHo, Sorbin-homology domain; ZNF, zinc 
finger C2H2-type domain 
 
  




Appendix Q Coding region variation in well-characterised DCM genes in Family 5 
 
 
Table Q.1: Coding region variation in well-characterised DCM genes in the proband of Family 5 
Gene* Variant Protein change Carriers gnomAD MAF  MT CADD 
Sarcomeric genes      
ACTN2 c.351T>C p.I117= I:1, I:2, II:3 0.997800 B (1.4-21) 10.1 
ACTN2 c.378C>T p.N126= I:1, II:3 0.958800 B (1.5-17) 8.3 
ACTN2 c.1296G>A p.A432= I:1, II:3 0.018660 B (5.2-8) 0.1 
LDB3 c.302C>T p.P101L I:1, II:3 0.003162 D (0.99)† 24.8 
LDB3 c.609G>A p.S203= I:2, II:3 0.004768 D (1)† 9.0 
MYBPC3 c.833G>A p.G278E I:2, II:3 0.001332 D (0.97)† 21.3 
MYH7 c.1128C>T p.D376= I:1, II:3 0.096820 B (1.6-17) 8.1 
MYH7 c.1605A>G p.E535= I:1, I:2, II:3 0.010740 B (7.7-22) 10.1 
TNNT2 c.207G>A p.S69= I;1, II:3 0.063130 B (0.02) 5.4 
TNNT2 c.318C>T p.I106= I:1, II:3 0.719400 B (1.2-22) 10.4 
TTN c.1002C>T p.T334= I:2, II:3 0.000407 B (0.99) 0.3 
TTN c.2432A>T p.T811I I:1, II:3 0.168700 B (0.90) 22.4 
TTN c.2949C>T p.I983= I:1, II:3 0.004338 D (1)† 16.2 
TTN c.3601A>G p.K1201E I:1, II:3 0.688700 B (0.99) 22.4 
TTN c.3884C>T p.S1295L I:1, I:2, II:3 0.960100 B (0.99) 22.3 
TTN c.4177A>G p.I1393V I:2, II:3 0.012490 B (0.99) 19.1 
TTN c.9781G>A p.V3261M I:2, II:3 0.844500 B (0.99) 19.9 
TTN c.9879A>G p.E3293= I:2, II:3 0.991700 B (4.8-13) 17.9 
TTN c.10104T>G p.V3368= I:2, II:3 0.000403 D (1)† 14.0 
TTN c.10256G>A p.S3419N I:1, I:2, II:3 0.845900 B (0.99) 11.6 
TTN c.10726G>A p.A3576T I:1, I:2, II:3 0.999700 B (0.99) 20.1 
TTN c.11252G>A p.G3751D I:2, II:3 0.843400 B (0.72) 21.9 
TTN c.11422C>T p.P3808S I:1, I:2, II:3 0.182900 B (0.99) 21.9 
TTN c.14525G>A p.R4842K I:2, II:3 0.100500 B (0.99) 13.4 
TTN c.14610C>T p.S4870= I:1, I:2, II:3 0.994400 B (2.6-22) 14.5 
TTN c.21106G>A p.D7036N I:2, II:3 0.005536 D (0.99)† 22.8 
TTN c.23223G>A p.Q7741= I:1, I:2, II:3 0.994500 B (1.7-18) 15.9 
TTN c.25064C>A p.A8355E II:3 0.306300 B (0.99) 22.7 
TTN c.25398T>A p.D8466E I:2, II:3 0.011050 B (0.99) 19.9 
TTN c.26091A>T p.L8697= II:3 0.306800 B (0.18) 11.6 
TTN c.26289A>G p.E8763= I:1, II:3 0.318800 B (1.3-26) 18.1 
TTN c.26655C>T p.S8885= II:3 0.306000 B (3.4-16) 14.9 
TTN c.26818G>A p.G8940S I:2, II:3 0.000311 D (0.97)† 22.2 
TTN c.28662G>A p.R9554= I:2, II:3 0.047670 B (1.6-29) 15.5 
TTN c.29763T>C p.I9921= I:2, II:3 0.054550 B (1.6-27) 18.7 
TTN c.29799G>A p.S9933= I:2, II:3 0.049550 B (7.2-23) 15.7 
TTN c.31564A>G p.I10522V I:1, II:3 0.337300 B (0.99) 21.4 
TTN c.32593G>C p.V10865L I:2, II:3 0.000421 B (0.99) 18.1 
TTN c.33834G>A p.E11278= I:2, II:3 0.186000 B (1.2-9) 14.9 
TTN c.56101A>G p.N18701D I:1, II:3 0.354700 B (0.94) 23.3 
TTN c.58436G>A p.R19479H I:2, II:3 0.174300 B (4.8-10) 24.7 
TTN c.59585C>T p.P19862L I:2, II:3 0.173400 B (0.0001) 23.0 
TTN c.61029T>C p.F20343= I:2, II:3 0.000440 D (1)† 17.6 
TTN c.61245A>G p.T20415= I:1, II:3 0.345100 B (0.99) 8.8 
TTN c.62058T>C p.Y20686= I:1, II:3 0.354400 B (1.4-16) 16.1 
TTN c.64208C>T p.T21403I I:1, II:3 0.350400 B (0.99) 23.2 
TTN c.65682A>G p.T21894= I:1, II:3 0.354500 B (0.88) 11.2 
TTN c.67075G>A p.V22359I II:3 0.240200 B (0.01) 16.9 
TTN c.67246G>C p.A22416P I:1, I:2, II:3 0.998500 B (0.99) 12.5 
TTN c.74839C>T p.R24947C I:2, II:3 0.171500 B (3.0-6) 23.8 
TTN c.79862C>T p.T26621M II:3 0.233200 B (0.04) 22.5 
Continued on next page 
* List of paediatric DCM genes adapted from Lee TM et al. 2017. Circ Res, 121(7):33-35.  
† Although predicted deleterious by MT, this variant was benign by other pathogenicity prediction tools and/or ClinVar 
B, benign; CADD, Combined Annotation Dependent Depletion; D, deleterious; gnomAD, Genome Aggregation 





Table Q.1 continued 
Gene* Variant Protein change Carriers gnomAD MAF  MT CADD 
TTN c.83323A>G p.I27775V I:1, II:3 0.352000 B (0.99) 22.0 
TTN c.83673T>C p.G27891= I:1, II:3 0.351000 B (3.4-23) 16.3 
TTN c.88187T>C p.I29396T I:1, II:3 0.350500 B (0.99) 12.6 
TTN c.93243C>T p.A31081= I:2, II:3 0.180900 B (0.0003) 10.9 
TTN c.97613G>A p.R32538H I:2, II:3 0.171900 B (1.1-8) 25.5 
TTN c.98267C>T p.T32756I I:2, II:3 0.000453 D (0.98)† 23.6 
TTN c.102519C>T p.G34173= I:2, II:3 0.179700 B (2.0-14) 4.8 
TTN c.103781G>A p.R34594H I:2, II:3 0.172100 B (1.2-7) 25.2 
TTN c.104988C>T p.V34996= I:2, II:3 0.179600 B (8.2-12) 12.8 
TTN c.105384A>G p.A35128= I:1, II:3 0.352000 B (1.3-15) 11.2 
       
Nuclear membrane genes      
LMNA c.861T>C p.A287= I:1, I:2, II:3 0.109600 B (3.7-14) 9.4 
LMNA c.1338T>C p.D446= I:1, I:2, II:3 0.128500 B (2.5-17) 10.7 
SYNE1 c.1794A>C p.S598= I:1, II:3 0.001240 D (0.99)† 0.6 
SYNE1 c.2653T>G p.L885V I:2, II:3 0.055500 B (0.99) 14.7 
SYNE1 c.3104T>C p.V1035A I:1, I:2, II:3 0.475400 B (0.91) 20.1 
SYNE1 c.3306C>T p.H1102= I:2, II:3 0.057260 B (0.53) 0.1 
SYNE1 c.5190T>A p.D1730E I:2, II:3 0.043340 B (0.99) 10.9 
SYNE1 c.6470A>G p.K2157R I:1, II:3 0.007910 B (0.76) 21.3 
SYNE1 c.8737G>T p.A2913S I:2, II:3 0.000054 B (0.61) 22.9 
SYNE1 c.9495A>G p.E3165= I:1, II:3 0.504100 B (1.6-12) 8.5 
SYNE1 c.10191C>A p.G3397= I:1, II:3 0.658200 B (3.9-20) 0.1 
SYNE1 c.10866T>C p.S3622= I:1, II:3 0.584700 B (0.99) 0.3 
SYNE1 c.12180G>T p.E4060D I:1, I:2, II:3 0.580500 B (0.99) 6.4 
SYNE1 c.12362A>G p.K4121R I:1, I:2, II:3 0.757200 B (0.99) 20.4 
SYNE1 c.13786T>A p.S4596T I:1, I:2, II:3 0.784200 B (0.99) 0.001 
SYNE1 c.15043T>A p.L5015M I:1, I:2, II:3 0.787900 B (0.99) 21.0 
SYNE1 c.21904T>G p.F7302V I:1, I:2, II:3 0.991900 B (0.99) 16.8 
SYNE1 c.25038T>C p.R8346= I:1, II:3 0.611200 B (5.5-8) 1.1 
SYNE2 c.399G>C p.L133= I:1, II:3 0.087370 B (7.6-25) 11.8 
SYNE2 c.8404A>G p.S2802G I:1, II:3 0.909400 B (0.99) 0.8 
SYNE2 c.8597C>T p.T2866M I:1, II:3 0.004167 B (0.99) 23.4 
SYNE2 c.9023T>C p.I3008T I:1, II:3 0.003793 B (0.99) 12.4 
SYNE2 c.9389A>G p.N3130S I:2, II:3 0.043650 B (0.99) 11.7 
SYNE2 c.9757G>C p.D3253H II:3 0.803800 B (0.99) 21.0 
SYNE2 c.9926A>G p.H3309R II:3 0.804400 B (0.99) 14.3 
SYNE2 c.10567A>C p.K3523Q I:1, II:3 0.025200 B (0.99) 8.8 
SYNE2 c.11385G>A p.K3795= I:1, II:3 0.006816 B (2.1-17) 18.2 
SYNE2 c.11613A>G p.V3871= I:2, II:3 0.085970 B (0.29) 11.5 
SYNE2 c.11944A>C p.N3982H I:2, II:3 0.066610 B (0.98) 22.6 
SYNE2 c.14734C>G p.P4912A I:2, II:3 0.033450 B (0.23) 22.9 
SYNE2 c.15543C>T p.I5181= I:2, II:3 0.371300 B (0.0001) 13.3 
SYNE2 c.15556C>A p.L5186M I:1, I:2, II:3 0.504900 B (0.99) 12.1 
SYNE2 c.16722A>G p.Q5574= I:2, II:3 0.036290 B (2.8-13) 15.5 
SYNE2 c.17202C>A p.L5734= I:2, II:3 0.331300 B (0.006) 15.9 
       
Other genes      
DES c.669T>C p.I223= I:2, II:3 0.009637 B (2.9-22) 19.9 
DES c.1026C>T p.N342= I:1, II:3 0.006725 B (4.5-18) 12.3 
RBM20 c.90G>A p.R30= I:1, II:3 0.155100 B (0.99) 14.7 
RBM20 c.2303G>C p.W768S I:1, I:2, II:3 0.997100 B (0.99) 0.02 
VCL c.945C>A p.G315= I:1, I:2, II:3 0.008791 B (7.1-21) 12.5 
VCL c.2814C>G p.G938= I:1, I:2, II:3 0.676000 B (3.1-20) 11.4 
* List of paediatric DCM genes adapted from Lee TM et al. 2017. Circ Res, 121(7):33-35.  
† Although predicted deleterious by MT, this variant was benign by other pathogenicity prediction tools and/or ClinVar 
B, benign; CADD, Combined Annotation Dependent Depletion; D, deleterious; gnomAD, Genome Aggregation 





Appendix R Power analyses of zebrafish experiments 
 
 
Table R.1: Power analysis of ANOVA tests of CRISPR zebrafish ventricle measurements 
CRISPR knockout group Mean measurement Standard deviation Calculated power* 
Comparison of ventricle length    
myh7 41.128 9.400 0.753 
pkp2 28.140   
polg 46.848   
Uninjected 33.976   
Comparison of ventricle thickness    
myh7 5.254 1.262 0.784 
pkp2 7.374   
polg 4.574   
Uninjected 5.910   
Comparison of ventricle area    
myh7 731.324 330.782 0.850 
pkp2 273.560   
polg 1054.222   
Uninjected 462.428   
* Sufficiently powered tests (> 0.80) are indicated in bold print 
ANOVA, analysis of variance; CRISPR, clustered regularly-interspaced short palindromic repeats 
 
Table R.2: Power analysis of pairwise comparisons of CRISPR zebrafish ventricle measurements 
CRISPR knockout group Mean measurement Standard deviation Calculated power* 
Comparison of ventricle length    
Uninjected (control) 33.976 7.625 NA 
myh7 41.128 6.667 0.243 
pkp2 28.140 6.164 0.187 
polg 46.848 5.328 0.687 
Comparison of ventricle thickness    
Uninjected (control) 5.910 0.409 NA 
myh7 5.254 0.810 0.252 
pkp2 7.374 0.891 0.751 
polg 4.574 0.768 0.774 
Comparison of ventricle area    
Uninjected (control) 462.428 136.014 NA 
myh7 731.324 162.078 0.615 
pkp2 273.560 108.032 0.489 
polg 1054.222 177.820 0.999 
* Sufficiently powered tests (> 0.80) are indicated in bold print 




Table R.3: Power analysis of pairwise comparisons of zebrafish heart rates 
mRNA injection group Mean measurement Standard deviation Calculated power* 
Mutant POLG (experimental) 142.332 34.132 NA 
Uninjected (control) 183.000 33.028 > 0.999 
Water (control) 182.647 32.213 > 0.999 
Wild type POLG (control) 180.400 26.582 > 0.999 
* Sufficiently powered tests (> 0.80) are indicated in bold print 
mRNA, messenger ribonucleic acid; NA, not applicable 
 
 
Table R.4: Power analysis of pairwise comparisons of POLG zebrafish ventricle measurements 
mRNA injection group Mean measurement Standard deviation Calculated power* 
Comparison of ventricle length    
Wild type POLG 50.456 5.997 0.987 
Mutant POLG 42.538 4.870  
Comparison of ventricle width    
Wild type POLG 28.598 3.418 0.400 
Mutant POLG 26.185 4.681  
Comparison of ventricle area    
Wild type POLG 1236.714 232.319 0.896 
Mutant POLG 957.796 268.057  
Comparison of blood flow    
Wild type POLG 9.603 4.227 0.889 
Mutant POLG 4.485 3.600  
* Sufficiently powered tests (> 0.80) are indicated in bold print 




Appendix S Additional correlation analyses of CRISPR knockout zebrafish 
 
 
Figure S.1: Correlation of ventricular thickness and area amongst the experimental groups. The 
thickness is represented on the x-axis, while area is on the y-axis. The Pearson’s correlation coefficient is 
represented for each group (R), as is the significance of the relationship. 
 
Figure S.2: Correlation of ventricular thickness and length amongst the experimental groups. The 
thickness is represented on the x-axis, while length is on the y-axis. The Pearson’s correlation coefficient 
is represented for each group (R), as is the significance of the relationship.
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Appendix T Genotyping of CRISPR mutant zebrafish larvae 
 
 
Table T.1: Mutation detection rates in CRISPR gene edited zebrafish larvae 
Target gene Fish no. Site of greatest indel rate Proportion of frameshift reads* Proportion of non-frameshift reads* Mean indel rate* 
myh7 1 584-594 16.77% 39.77% 48.43% 
 2 583-593 11.89% 39.88%  
 3 584-594 4.97% 50.45%  
 4 584-594 15.25% 38.17%  
 5 584-594 6.81% 18.16%  
pkp2 1 302-312 34.52% 61.30% 78.59% 
 2 302-312 18.72% 42.79%  
 3 299-309 7.91% 72.41%  
 4 299-309 7.57% 66.27%  
 5 299-309 0.82% 80.65%  
polg 1 430-440 75.97% 0.65% 73.19% 
 2 430-440 64.69% 5.67%  
 3 430-440 72.95% 2.73%  
 4 430-440 71.97% 1.27%  
 5 430-440 62.85% 7.23%  
* Calculated at site of greatest indel rate 









Table T.2: Genotyping results of myh7 knockout zebrafish larvae 
Fish no. Sequence position Genotype (reference/alternate allele) Indel size (bp)* Indel count Total read count 
1 589 ATGAAG/- -6 1217 6502 
 588 GAT/- -3 717 6590 
 589 ATGA/- -4 (frameshift) 590 6541 
 589 ATGAAGAG/- -8 (frameshift) 326 6500 
 591 CCA/- 3 256 6604 
 583 ATCCAGATGAAG/- -12 247 6469 
 587 AGATG/- -5 183 6561 
 591 GAA/- -3 159 6580 
 591 GAAGAG/- -6 132 6539 
 582 GATCCAGAT/- -9 125 6559 
2 588 GAT/- -3 1101 5602 
 589 ATGAAG/- -6 667 5478 
 592; 603 AA/-; -/A -2 ; 1 (frameshift) 402 5399 
 591 GAAGAGTAT/- -9 269 5468 
 591 -/CCA 3 197 5620 
 590 -/TGCC 4 (frameshift) 159 5629 
 590 TGAAGAGTA/- -9 101 5432 
 592 AA/- -2 (frameshift) 97 5664 
 582 GATCCAGAT/- -9 71 5549 
 591 GAAGAG/- -6 70 5532 
3 589 ATGAAG/- -6 599 4389 
 588 GAT/- -3 556 4515 
 591 -/CCA 3 349 4505 
 591 GAA/- -3 283 4428 
 591 GAAGAGTAT/- -9 212 4386 
Continued on next page 
* Entries marked ‘frameshift’ were frameshift mutations 




Table T.2 continued 
Fish no. Sequence position Genotype (reference/alternate allele) Indel size (bp)* Indel count Total read count 
3 591 G/- -1 (frameshift) 150 4505 
 589 ATGAAGAGTATGTGA/- -15 126 4282 
 592 -/TGA 3 97 4486 
 583 ATCCAGATGA/- -10 (frameshift) 77 4377 
 591 GAAGAGTATGTGAAAGCGTC/- -20 (frameshift) 69 4142 
4 589 ATGAAG/- -6 1144 4827 
 590 TGAAGAG/- -7 (frameshift) 436 4816 
 588 GAT/- -3 394 4958 
 591 GA/- -2 (frameshift) 139 4915 
 591 -/CCA 3 127 4975 
 591 GAAGAG/- -6 113 4830 
 589 ATGAAGAG/- -8 (frameshift) 90 4794 
 591 GAAGAGTAT/- -9 75 4659 
 591 GAA/- -3 (frameshift) 75 4911 
5 589 ATGAAG/- -6 528 6785 
 588 GAT/- -3 491 7318 
 591 GAAGAGTAT/- -9 234 6279 
 590 -/TTATG 5 (frameshift) 182 7396 
 582 GATCCAGAT/- -9 131 6899 
 591 GAAGAGTATGTG/- -12 (frameshift) 69 6116 
 591 G/- -1 (frameshift) 83 7366 
 589 ATGAAGAG/- -8 (frameshift) 71 6653 
 576 GTGCCTGATCCAGAT/- -15 68 6616 
 587 AGATG/- -5 (frameshift) 65 7269 
* Entries marked ‘frameshift’ were frameshift mutations 





Table T.3: Genotyping results of pkp2 knockout zebrafish larvae 
Fish no. Sequence position Genotype (reference/alternate allele) Indel size (bp)* Indel count Total read count 
1 307 CTGAACCGA/- -9 1324 4181 
 309 -/A 1 (frameshift) 1338 4261 
 304 CGGCTGAAC/- -9 1274 4252 
 309 GAACC/- -5 (frameshift) 105 4202 
 300 GCACCGGCT/- -9 41 4146 
 308 T/- -1 (frameshift) 21 4293 
 349 A/- -1 (frameshift) 21 4563 
 294 CGACGCGCACCGGCTGAAC/- -19 (frameshift) 18 4080 
2 307 CTGAACCGA/- -9 1227 6772 
 287 CGCTCGCCGACGCGCACCGGCTGAAC/- -26 (frameshift) 1205 6660 
 300 GCACCGGCT/- -9 1227 6807 
 308 T/- -1 (frameshift) 1150 6819 
 304 CGGCTGAAC/- -9 915 6785 
 309 GAA/- -3 538 6805 
 309 G/- -1 230 6805 
 309 -/C 1 (frameshift) 69 6805 
 308 -/G 1 (frameshift) 54 6819 
3 304 CGGCTGAAC/- -9 2464 9083 
 307 CTGAACCGA/- -9 2088 9063 
 302 ACCGGCTG/- -8 (frameshift) 719 9072 
 309 -/ACA 3 536 9121 
 308 T/- -1 477 9164 
 300 GCACCGGCT/- -9 455 9111 
 292 GCCGACGCGCACCGGCTGA/- -19 (frameshift) 423 8995 
 307 CTGAAC/- -6 237 9089 
Continued on next page 
* Entries marked ‘frameshift’ were frameshift mutations 




Table T.3 continued 
Fish no. Sequence position Genotype (reference/alternate allele) Indel size (bp)* Indel count Total read count 
3 309 -/ACAGCAACAAGTCAA 15 200 9121 
 301 CACCGGCTGAACCGACTACAG/- -21 125 8987 
4 304 CGGCTGAAC/- -9 3421 8811 
 307 CTGAACCGA/- -9 1408 8824 
 300 GCACCGGCT/- -9 1027 8814 
 302 ACCGGCTG/- -8 (frameshift) 196 8799 
 291 CGCCGACGCGCACCGGCTGAACCG/- -24 182 8661 
 306 GCTGAA/- -6 (frameshift) 167 8856 
 294 CGACGCGCACCGGCTG/- -16 (frameshift) 116 8748 
 309 GAACC/- -5 (frameshift) 112 8859 
 308 TG/- -2 (frameshift) 109 8863 
 309 G/- -1 (frameshift) 85 8868 
5 304 CGGCTGAAC/- -9 2641 4805 
 307 CTGAACCGA/- -9 632 4805 
 300 GCACCGGCT/- -9 370 4791 
 304; 349 CGGCTGAAC/-; A/- -9; -1 (frameshift, latter) 16 3528 
 297; 309 -/CGCGCACCGG; GA/- 10; -2 (frameshift) 21 4754 
* Entries marked ‘frameshift’ were frameshift mutations 




Table T.4: Genotyping results of polg knockout zebrafish larvae 
Fish no. Sequence position Genotype (reference/alternate allele) Indel size (bp)* Indel count Total read count 
1 435 GCCAAAA/- -7 (frameshift) 2652 5290 
 436 C/- -1 (frameshift) 1066 5410 
 436 -/C 1 (frameshift) 207 5410 
 436 C/- -1 (frameshift) 21 1165 
 417 ATGGGGCGGATGGAGAGAGCCAAA/- -24 56 5093 
 436 CC/- -2 (frameshift) 41 5409 
 437 CAAAAG/- -6 35 5295 
 431 GAGAGCCAAAA/- -11 (frameshift) 34 5218 
 434 AGCCA/- -5 (frameshift) 34 5393 
 437 C/- -1 (frameshift) 34 5417 
2 435 GCCAAAA/- -7 (frameshift) 2563 5758 
 436 CC/- -2 (frameshift) 388 5850 
 435 GCCAAA/- -6 330 5778 
 436 C/- -1 (frameshift) 289 5858 
 417 ATGGGGCGGATGGAGAGAGCCAA/- -23 (frameshift) 147 5518 
 434 AGCC/- -4 (frameshift) 147 5847 
 436 -/C 1 (frameshift) 147 5858 
 437 C/- -1 (frameshift) 85 5851 
 436 CC/- -2 (frameshift) 77 5850 
 435 GCCAA/- -5 (frameshift) 72 5779 
3 435 GCCAAAA/- -7 (frameshift) 3892 8020 
 436 CC/- -2 (frameshift) 1341 7968 
 437 CAAAAG/- -6 214 7654 
 436 -/C 1 (frameshift) 214 7812 
 437 C/- -1 (frameshift) 137 7796 
Continued on next page 
* Entries marked ‘frameshift’ were frameshift mutations 




Table T.4 continued 
Fish no. Sequence position Genotype (reference/alternate allele) Indel size (bp)* Indel count Total read count 
3 417 ATGGGGCGGATGGAGAGAGCCAAA/- -24 45 7883 
 437 C/- -1 (frameshift) 36 7409 
 436 CC/- -2 (frameshift) 35 8123 
 434 AGCC/- -4 (frameshift) 34 7894 
 436 -/C 1 (frameshift) 34 7895 
 435 GCCAAAA/- -7 (frameshift) 3892 8020 
4 435 GCCAAAA/- -7 (frameshift) 2794 5768 
 436 C/- -1 (frameshift) 894 5412 
 436 -/C 1 (frameshift) 235 5909 
 436 C/- -1 (frameshift) 102 5904 
 417 ATGGGGCGGATGGAGAGAGCCAAA/- -24 74 6058 
 436 CC/- -2 (frameshift) 74 5872 
 435 GCCAAA/- -6 74 5825 
 437 C/- -1 (frameshift) 43 5778 
 431 GAGAGCCAAAA/- -11 (frameshift) 34 6032 
 434 AGCCA/- -5 (frameshift) 21 5762 
 435 GCCAAAA/- -7 (frameshift) 2794 5768 
5 435 GCCAAAA/- -7 (frameshift) 1892 5840 
 436 C/- -1 (frameshift) 838 5902 
 436 -/C 1 (frameshift) 401 5722 
 437 CAAAAG/- -6 405 5662 
 431 GAGAGCCAAAA/- -11 (frameshift) 224 4928 
 417 ATGGGGCGGATGGAGAGAGCCAA/- -23 (frameshift) 122 5421 
 437 C/- -1 (frameshift) 87 5620 
 431 GAGAGCCAAAA/- -11 (frameshift) 55 5872 
 434 AGCCA/- -5 (frameshift) 23 5444 
* Entries marked ‘frameshift’ were frameshift mutations 
Bp, base pairs; indel, insertion/deletion mutation 
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Figure U.1: Average heart rates in POLG overexpression experiment 1. Experimental groups are on 
the x-axis while heart rate is on the y-axis. The distributions of heart rate are represented by box-and-
whisker plots in which the boxes delineate the upper and lower quartiles, and the whiskers indicate the 
minimum and maximum values. Lines within the boxes are the median values. Dots are used to show the 
distribution of variables in each group. Significance bars show the p-value when comparing each dose 
group to the uninjected control group (two-sided Mann-Whitney U test). Note that no data for wild type 





Figure U.2: Average heart rates in POLG overexpression experiment 2. Experimental groups are on 
the x-axis while heart rate is on the y-axis. The distributions of heart rate are represented by box-and-
whisker plots in which the boxes delineate the upper and lower quartiles, and the whiskers indicate the 
minimum and maximum values. Lines within the boxes are the median values. Dots are used to show the 
distribution of variables in each group. Significance bars show the p-value when comparing each dose 




Figure U.3: Average heart rates in POLG overexpression experiment 3. Experimental groups are on 
the x-axis while heart rate is on the y-axis. The distributions of heart rate are represented by box-and-
whisker plots in which the boxes delineate the upper and lower quartiles, and the whiskers indicate the 
minimum and maximum values. Lines within the boxes are the median values. Dots are used to show the 
distribution of variables in each group. Significance bars show the p-value when comparing each dose 




Figure U.4: Average heart rates in POLG overexpression experiment 4. Experimental groups are on 
the x-axis while heart rate is on the y-axis. The distributions of heart rate are represented by box-and-
whisker plots in which the boxes delineate the upper and lower quartiles, and the whiskers indicate the 
minimum and maximum values. Lines within the boxes are the median values. Dots are used to show the 
distribution of variables in each group. Significance bars show the p-value when comparing each dose 




Figure U.5: Average heart rates in POLG overexpression experiment 5. Experimental groups are on 
the x-axis while heart rate is on the y-axis. The distributions of heart rate are represented by box-and-
whisker plots in which the boxes delineate the upper and lower quartiles, and the whiskers indicate the 
minimum and maximum values. Lines within the boxes are the median values. Dots are used to show the 
distribution of variables in each group. Significance bars show the p-value when comparing each dose 
group to the uninjected control group (two-sided Mann-Whitney U test).  
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Appendix V Additional correlation analyses of mRNA injected zebrafish 
 
 
Figure V.1: Correlation of ventricular width and area amongst the mRNA experimental groups. The 
length is represented on the x-axis, while area is on the y-axis. The Pearson’s correlation coefficient is 
represented for each group (R), as is the significance of the relationship. 
 
Figure V.2: Correlation of ventricular width and length amongst the mRNA experimental groups. 
The length is represented on the x-axis, while area is on the y-axis. The Pearson’s correlation coefficient is 
represented for each group (R), as is the significance of the relationship. 
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Figure W.1: Comparison of ventricular length amongst the experimental groups. The length is 
represented on the y-axis, while experimental groups are on the x-axis. Error bars indicate the standard 
error in each group. Significance bars show the p-value when comparing each experimental group to the 




Figure W.2: Comparison of ventricular area amongst the experimental groups. The area is 
represented on the y-axis, while experimental groups are on the x-axis. Error bars indicate the standard 
error in each group. Significance bars show the p-value when comparing each experimental group to the 






Figure W.3: Comparison of ventricular width amongst the experimental groups. The width is 
represented on the y-axis, while experimental groups are on the x-axis. Error bars indicate the standard 
error in each group. Significance bars show the p-value when comparing each experimental group to the 
uninjected control group (two-sided t-test).  
 
